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HAL Id: tel-02337194
https://tel.archives-ouvertes.fr/tel-02337194
Submitted on 29 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
The involvement of the three main inflammatory bowel
disease pathways and the secretion of trypsin proteolytic
activity on intestinal epithelial cells
Nuria Solà Tapias
To cite this version:
Nuria Solà Tapias. The involvement of the three main inflammatory bowel disease pathways and the
secretion of trypsin proteolytic activity on intestinal epithelial cells. Tissues and Organs [q-bio.TO].
Université Paul Sabatier - Toulouse III, 2018. English. ￿NNT : 2018TOU30049￿. ￿tel-02337194￿
?????????????????????????
????????? ??????????????? ???????????
?????????????
 
??????????????????????????? 
???????
????? ?????????? et discipline ou spécialité ??
????????????????????
?????????????????????? ?????
                                             Jury  :
?
?????
le
Université Toulouse 3 Paul Sabatier (UT3 Paul Sabatier)
Núria Solà Tapias
vendredi 13 avril 2018
The involvement of the three main Inflammatory Bowel Disease pathways and
the secretion of trypsin proteolytic activity on intestinal epithelial cells
ED BSB : Physiopathologie
Institut de Recherche en Santé Digestive (IRSD-INSERM U1220)
Dr. Alain Couvineau, Directeur de Recherche. Rapporteur
Pr. Sophie Thenet, Professeur à l'Ecole Pratique des Hautes Etudes. Rapporteur
Pr. Vincent Lagente, Professeur Université Rennes 1. Président du Jury
Dr. Nathalie Vergnolle, Directrice de Recherche. Directrice de thèse
Dr. Frédérick Barreau, Chargé de Recherche. Directeur de thèse
Dr. Nathalie Vergnolle
Dr. Frédérick Barreau
  
 
Abstract 
 
1 | 
 
Abstract  
 
Crohn's disease (CD) and Ulcerative colitis (UC) are two forms of Inflammatory Bowel Disease 
(IBD), a chronic inflammatory pathology affecting the digestive tract. Patients suffer from 
relapsing flares, diarrhea, abdominal pain and bleeding. Although the molecular mechanisms of 
IBD are poorly understood, recent data suggest that IBD occurs in genetically predisposed 
individuals developing an abnormal immune response to intestinal microbes after, being 
exposed to specific environmental triggers. Genetic studies have reported more than 170 
polymorphisms susceptible to be involved in IBD pathogenesis. The strongest associations have 
highlighted three main pathways altered in IBD including bacterial sensing (NOD2, CD), 
autophagy (ATG16L1 and IRGM, CD) and endoplasmic reticulum stress (ER-Stress) (XBP1, UC). 
The role of intestinal barrier function is also strongly implicated in IBD pathogenesis, and is 
modulated by factors present in the lumen derived from microbiota, food or at a molecular level, 
by factors such as proteases. In IBD pathophysiology, the inflammatory process is characterized 
by impaired intestinal biology including disruption of tight junctions and leaky gut, decreased 
amount of Paneth and Goblet cells, and translocation of luminal antigens triggering 
inflammation. Previous studies have demonstrated an increased level of active serine proteases 
in the stools and tissues of IBD patients, supposing that proteases originate from infiltrated 
immune cells, pancreatic secretion or microbiota. However, our team has reported that intestinal 
epithelial cells are a major source of serine proteases, in particular trypsin-like enzymes, are 
released by a stressed epithelium in pathogenic context such as irritable bowel syndrome. 
In this project, we aimed at better understanding whether the three main pathways involved in 
IBD (Nod2, autophagy, ER-stress) could be linked to an epithelial release of trypsin and 
reciprocally, if epithelial trypsin is able to induce or modulate these three IBD pathways.  
We confirmed that trypsin-like activity was significantly higher in biopsies from UC and CD 
patients compared to healthy controls. In Caco-2 monolayers cultured in transwells, secreted 
trypsin-like proteolytic activity remained stable upon NOD2 stimulation but decreased under 
autophagy induction. Thapsigargin (Tg) stimulation a well-known ER-stress inducer, enhanced 
the apical release of trypsin-like activity in Caco2 cells. Activity-based probe assay identified a 
unique band at 33-KDa in ER-Stress-induced Caco-2 supernatants. This band showed specificity 
for Trypsin-3 in western blot. In UC patients, immunochemistry of colonic biopsies showed that 
Trypsin-3 was detectable mainly in epithelial cells, and up-regulated compared to biopsies from 
healthy controls and CD. Similarly, only UC patients displayed altered ER-stress with increased 
XBP1s mRNA levels.  In Caco-2 cells, ER-Stress induction provoked increased paracellular 
permeability, CXCL8 release, antimicrobial peptides (AMP) (TFF-3 and HBD2), and mucins 
(MUC2) dysregulation. Serine protease inhibitor AEBSF inhibited Tg-induced increased 
permeability and AMP dysregulation, while CXCL8 increase was aggravated. In Caco-2, Tg-induced 
ER-Stress increased PAR2 and -4 mRNA expression, PAR4 control levels were restored in the 
presence of AEBSF. ER-Stress-associated increased paracellular permeability was suppressed by 
PAR2 and/or -4 antagonist treatment, while CXCL8 was aggravated. Trypsin-3 didn’t induce ER 
stress in Caco2. 
Our data showed that in intestinal epithelial cells, ER-Stress increased trypsin-3 expression 
and trypsin proteolytic activity, which is responsible for altered barrier function and 
dysregulated AMP and mucin expressions. We identified PAR2 and -4 activation as possible 
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mechanisms by which ER-Stress contributed to epithelial pathophysiology. Trypsin-3 appears as 
a candidate protease overexpressed upon ER-Stress and in UC patients epithelium. 
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Résumé 
 
Les maladies inflammatoires chroniques de l’intestin (MICI) se caractérisent par une 
inflammation sévère de l’intestin grêle et du côlon et comprennent la maladie de Crohn (MC) et la 
rectocolite hémorragique (RCH). Les MICI sont des maladies complexes faisant intervenir des 
facteurs génétiques : certains senseurs bactériens, l’autophagie et le stress du réticulum 
endoplasmique. Un défaut de barrière de l’épithélium digestif est également fortement impliqué 
dans la physiopathologie du processus inflammatoire. La fonction barrière de l’épithélium digestif 
est assurée par plusieurs types cellulaires, synthétisant entre autres, des peptides antimicrobiens 
(PAM) et des mucines. Dans les MICI, une augmentation de la perméabilité intestinale et une perte 
de muco-sécrétion ont été décrites. 
Les protéases jouent un rôle fondamental dans la digestion du bol alimentaire mais également 
dans le maintien de l’homéostasie intestinale en activant ou dégradant divers motifs moléculaires, 
ou in induisant des signaux spécifiques aux cellules par l’activation de quatre récepteurs : les PARs 
(Protease-Activated Receptor). Dans les MICI, un excès d’activité protéolytique de type trypsine est 
observé. L’origine de cette activité est théoriquement attribuée aux cellules immunitaires, à une 
surproduction pancréatique ou au microbiote, mais les cellules épithéliales intestinales semblent 
également être une source majeure de protéases.  
L’objectif de mon projet de thèse visait à étudier l’impact des principales voies impliquées dans 
les MICI sur l’homéostasie des protéases épithéliales et le rôle de celles-ci dans la déstabilisation 
de la fonction de barrière. 
Nos résultats ont confirmé un excès de protéases à sérine dans les cellules épithéliales de patients 
atteint de MC ou de RCH. In vitro, sur des monocouches de cellules Caco-2, l’induction de 
l’autophagie diminuait la libération apicale de protéase de type trypsine, alors que le senseur 
bactériens NOD2 n’avait aucun effet. A l’inverse, une stimulation du Stress du réticulum 
endoplasmique (SRE) par la Thapsigargin, induisait une libération accrue de protéases actives de 
type trypsine au pôle apical des cellules. L’utilisation d’ABP (Activity-based probe), emprisonnant 
les protéases actives de type trypsine dans des surnageants apicaux de Caco-2 stimulées par la 
Thapsigargin, a montré une importante sécrétion d’une protéase unique au poids moléculaire de 
33-KDa. Par western blot, la présence augmentée de Trypsine-3 était identifiée dans ces 
surnageants, de même que dans les colonocytes de patients atteints de RCH comparé à des 
échantillons contrôles ou CD. Seul les colonocytes de patients RCH présentaient également une 
induction du SRE. Sur les monocouches de Caco-2, l'induction du SRE augmentait la perméabilité 
paracellulaire, la sécrétion de CXCL88 et l’expression de PAM, de mucine et des récepteurs PAR2 
et -4. Les inhibiteurs de protéases de type trypsine supprimaient l’augmentation de la 
perméabilité et l’expression des PAM, de la mucine 2 et des récepteurs PAR2 et -4 induite par le 
SRE, et aggravaient la sécrétion de CXCL8. Les antagonistes sélectifs des récepteurs PAR2 et/ou 
PAR4 inhibaient l’augmentation de la perméabilité et l’expression des PAM, de la mucine 2 et des 
récepteurs PAR2 et -4 induite par le SRE, mais aggravaient la sécrétion de CXCL8. Enfin, la 
Trypsine-3 ne modifiait pas les marqueurs de SRE. 
En conclusion, l’induction d’un SRE dans les cellules épithéliales déclenche une libération apicale 
de Trypsine-3 et d’activité trypsine, responsable de l’altération de la fonction de barrière de la 
monocouche cellulaire. Nous avons identifié l’implication des récepteurs PAR2 et -4 (tous deux 
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activables par la Trypsine-3) dans la rupture de l’homéostasie de l’épithélium intestinal. La 
Trypsine-3 semble être spécifiquement surexprimée dans les colonocytes de patients RCH, cette 
surexpression pourrait être liée à une induction anormale du SRE. 
Acknowledgment 
 
5 | 
 
 
Acknowledgment 
 
First and foremost I wish to thank my advisors Dr. Nathalie Vergnolle and Dr. Frédérick 
Barreau. Thank you, Nathalie Vergnolle, for giving me unique advice and guiding me through my 
PhD. Similar, profound gratitude goes to Frédérick Barreau for your understanding and guidance. 
I appreciate your contributions and ideas to make my PhD productive and interesting.  
My thesis Jury members: Dr. Alain Couvineau, Pr. Sophie Thenet and Pr. Vincent Lagente.  
My thesis committee: Dr. Muriel Mercier-Bonin and Dr. Céline Cougoule.  
My lab team has helped and taught me: Corinne Rolland, Anissa Edir, Céline Deraison, 
Chrystelle Bonnart, Mireille Sebbag, Anne Françoise Tilkin, Muriel Quaranta, Claire 
Racaud-Sultan, Aude Rubio, Audrey Ferrand, Emmanuel Mas, Catherine Blanpied, Teresa 
Perez, Ana Carolina Florence, Cléo Désormeaux, Christel Devaud, Alexandre Denadai 
Souza, Dimitri Hamel, David Sagnat, Laura Guiraud, Claire Rolland, Morgane Sébert, 
Raphaël Durant, Eric Phonesouk, Julien Pujo and Carla Cirillo.  
The administrative and technical service: Eric Martínez, Christelle Margarita, Laurence 
Doumenc, Danièle Gasparotto and Caroline Merlo. 
Special mention goes to: Morgane Sébert, for all the adventures we have lived and your help 
during these years. Céline Meyer, for your nice sense of humour, positivism and soirées. Ugo 
Sardo and Dimitri Hamel, for your great company while drinking vin blanc moelleux. Julien Pujo, 
for your positivism and cell-sitting my beloved cells. Claire Rolland, for your help and support. 
Raphael Durant, Erick Phonesouk, for your useful and funny French classes. Muriel Quaranta, 
for your useful help in the lab. Lina Perdomo, Jan Bolting and Henri Becanne to make Toulouse 
a better place. Lidia Yshii, Audrey Belot, Sokchea Khou, Alix Vignolle, Cléo Désormeaux, 
Alison Henderson, Anna Currubí, Guillem Lambies, Mari Cabaleiro, Elena Morandi and 
Clàudia Canadell. 
I am also hugely appreciative of the 10th Summer School of Medicine (SSM10) committee 
organiser. SSM10  gave me the priceless opportunity to meet people from all around the world, 
has taught me everything about drug development and has given me the chance to get to know 
Brazil and its fascinating culture. Also my sincere thanks to FAPESP (Fundação de Amparo à 
Pesquisa do Estado de São Paulo) for sponsoring my trip to Brazil. Special thanks goes to two 
special girls I met at the congress. Susana Medina and Thamiris Gomez. Your friendship, your 
kindness, your valuable advice and your Portuguese classes made SSM10 an amazing and 
treasured experience. I am also extremely grateful to Milena Da Rosa Mota to have walked me 
through São Paulo and taught me about Brazil. 
There are three girls I met in Paris who had supported me ever since, and I will never forget. 
Despite the distance and sometimes the time difference, we always find moments to keep this 
friendship tight and remember the great time we spent together and how much we wish we were 
back in Paris. Thank you Nicole del Castillo for always finding time to call me. Our nostalgic 
skypes make me feel like we are still chit-chatting in the kitchen of the foyer, without internet. I 
am looking forward to seeing you in LA, to visiting your hometown and the paradisiac California 
beaches. Thanks to you too, Victoria Dietrich. Paris was just the first city that linked us. I am so 
glad we could meet many times and visit so many cities.  Which one is next? Special thank goes to 
Acknowledgment 
 
6 | 
 
 
Anna Karagezian. Paris was just a tasting adventure to get ready for Toulouse. You have given 
me moral support, kindness and friendship ever since. You have comforted me during the hardest 
moments. I cannot imagine la ville rose without you. Thank you for your trust in making me the 
witness at your wedding.  
També agraïr tot el suport rebut per la Núria Ros i la Clàudia Romero. Gràcies per a les vostres 
càlides abraçades, per els bons retrobaments a Barcelona i per a totes les llargues tardes de 
confesions i preocupacions, drama i emocions. Gràcies per la dosi de felicitat que vau donar-me 
pujant a Toulouse i passant un cap de setmana inoblidable. Gràcies per tot el vostre optimisme i 
suport mural, per a la vostre amistat i per ser al meu costat aquests últims anys. 
A special person I have admired ever since I met her is Carla Cirillo. Your Mediterranean warm 
heartedness, your straightforward personality and your generosity have made Toulouse a better 
place. You are a true friend ever since we began to share this experience. During the most difficult 
times you have given me the most important moral support and encouraged me to never give up. 
You have been a source of positive energy and motivation. Although Saturno does not always help, 
never back off from your goals. You are an amazing person and an excellent scientist. I feel very 
lucky to have got to know you well. Take care of Ciro, it is such a nice fish. 
Gràcies a la meva família per tot el suport rebut tots aquests anys. Als meus germans el Roger i 
l'Oriol, als nebodets nouvingut l'Artur i l'Emma i a la meva cunyada la Isabel. Roger, mercès per 
pujar i fer-me companyia pels meus aniversaris. Tot i que el pròxim cop no crec que hi hagi gofres 
per esmorzar, espero que em vinguis a veure allà on sigui.  
I gràcies infinites a vosaltres, Papes. Perquè si estic escrivint aquests agraïments és gràcies a 
vosaltres. Per haver confiat en mi, per entendre les meves necessites i per haver-me donat totes les 
oportunitat que podíeu. Tot i que no és fàcil no tenir-vos físicament a prop, saber que creieu en mi 
m'ajuda a continuar endavant i no rendir-me. Gràcies per ser al meu costat i per tenir cura de la 
Cendra. Aquesta tesi va dedicada a vosaltres. 
 
 
 
 
 
 
 
 
 
 
  
7 | 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Everything is toxic, it all depends on the dose” 
 
 
  
Summary 
8 | 
 
 
  
Summary 
9 | 
 
The involvement of the three main Inflammatory Bowel Disease 
pathways and the secretion of trypsin proteolytic activity on intestinal 
epithelial cells 
 
Acronyms and abbreviations ......................................................................................................... 12 
Summary figures ................................................................................................................................ 15 
INTRODUCTION .................................................................................................................................. 17 
Chapter 1. Biology of the intestine ................................................................................. 18 
1. General overview of the gastrointestinal tract  ................................................. 19 
2. Biology of the intestine ............................................................................................... 19 
2.1 Histology of the intestine  .................................................................................................. 19 
2.2 Cellular organization of the intestine ........................................................................... 20 
2.3 The five different cell types .............................................................................................. 22 
A) Enterocytes and colonocytes ............................................................................. 22 
B) Goblet cells  ............................................................................................................... 22 
C) Paneth cells ............................................................................................................... 22 
D) Enteroendocrine cells ........................................................................................... 23 
E) Other minor cells  .......................................................................................... 23 
 
Chapter 2. Central role of the colonic barrier ............................................................ 24 
1. The main role of intestinal mucosa ......................................................................... 25 
2. Physical barrier  ............................................................................................................. 26 
2.1 The junctions of the epithelial barrier ...................................................................... 26 
A)  Tight Junctions  ....................................................................................................... 26 
i) Occludin............................................................................................................. 27 
ii) Claudins ............................................................................................................. 27 
iii) Tricellulin ......................................................................................................... 28 
iv) Junctional adhesion molecules  ............................................................... 28 
B) Adherens junctions  ............................................................................................... 28 
C) Desmosomes ............................................................................................................. 29 
2.2 Mucus layer of the intestine ........................................................................................... 29 
3. Bio-chemical barrier ..................................................................................................... 31 
3.1 Antimicrobial peptides  ...................................................................................................... 31 
3.2 Immunity of the colonic mucosa..................................................................................... 33 
A) Toll-like receptors .................................................................................................. 34 
B) NOD-like receptors ................................................................................................ 34 
C) Inflammasome ......................................................................................................... 35 
D) Gut-associated lymphoid tissue ........................................................................ 35 
 
Chapter 3. Inflammatory Bowel disease ...................................................................... 36 
1. General introduction ................................................................................................... 37 
2. Crohn’s disease .............................................................................................................. 37 
3. Ulcerative colitis ........................................................................................................... 38 
4. Epidemiology .................................................................................................................. 39 
Summary 
10 | 
 
4.1 Incidence and prevalence  .................................................................................................. 39 
4.2 Age and gender disparity .................................................................................................... 40 
4.3 Geographical distribution ................................................................................................... 40 
5. Etiology ............................................................................................................................. 41 
5.1 Genetic susceptibility ........................................................................................................ 41 
5.2 Environmental risk factors ............................................................................................. 42 
A) Smoking ......................................................................................................................... 42 
B) Diet................................................................................................................................... 43 
C) Medication .................................................................................................................... 43 
D) The hygienic hypothesis ......................................................................................... 44 
E) Lifestyle: Stress and exercise ................................................................................ 44 
F) Appendectomy ............................................................................................................ 44 
6. Therapies  ........................................................................................................................ 45 
6.1 Pharmaceutical treatment ................................................................................................... 45 
A) Anti-inflammatory drugs ........................................................................................ 45 
B) Immunosupressives ................................................................................................. 45 
C) Antibiotics and probiotics ...................................................................................... 45 
D) Biological agents ........................................................................................................ 46 
6.2 Surgery ......................................................................................................................................... 46 
6.3 Faecal Microbiota transplantation .................................................................................... 46 
 
Chapter 4. Pathogenesis of Inflammatory Bowel Disease ............................................ 47 
1. Defective physical and biochemical mucosa barrier ....................................... 48 
1. 1 Impaired Epithelial Junctions ............................................................................................ 49 
1.2 Defective mucus layer ............................................................................................................ 49 
1.3 Defective antimicrobial factors .......................................................................................... 50 
2. Immunology factors ..................................................................................................... 52 
3. The role of microbiota  ............................................................................................... 53 
3.1 Commensal microbiota .......................................................................................................... 53 
3.2 Microbiota in IBD ..................................................................................................................... 55 
4. Genetic polymorphism involve in IBD pathophysiology ................................ 55 
4.1 NOD2 ........................................................................................................................................... 56 
A) NOD2 mechanism of action ................................................................................... 56 
B) NOD2 in CD ................................................................................................................... 57 
4.2 Autophagy ................................................................................................................................. 57 
A) Basal autophagy ......................................................................................................... 57 
B) Autophagy Risk Variants in IBD .......................................................................... 58 
C) NOD2 and the link with autophagy .................................................................... 59 
4.3 Endoplasmic reticulum Stress  ......................................................................................... 59 
A) Endoplasmic reticulum stress and cellular homeostasis .......................... 59 
B) Endoplasmic Reticulum Stress in IBD ............................................................... 61 
 
Chapter 5. Proteases in the gut and IBD  ..................................................................... 64 
1. Proteases in the gut ...................................................................................................... 65 
2. Proteases and their inhibitors  ................................................................................ 66 
2.1 Matrix Metalloproteinases .................................................................................................... 66 
Summary 
11 | 
 
2.2 Serine proteases  ....................................................................................................................... 66 
2.3 Cysteine proteases .................................................................................................................... 68 
3. Mechanism of action of proteases........................................................................... 68 
4. Inflammatory Bowel Disease meet proteases .................................................... 70 
4.1 Epithelial metalloproteases and their inhibitors in IBD ........................................ 71 
4.2 Epithelial serine proteases and their inhibitors in IBD .......................................... 71 
4.3 Epithelial cysteine proteases ............................................................................................ 72 
5. Protease-based treatments to target IBD  ........................................................... 74 
Chapter 6. Our intestinal in vitro models  .......................................................................... 75 
1. Epithelial cell model ...................................................................................................... 76 
2. Caco-2 cells model .......................................................................................................... 76 
3. HT29-mtx cell model ..................................................................................................... 77 
AIMS AND HYPOTESIS ...................................................................................................................... 79 
RESULTS ................................................................................................................................................ 82 
1. Project 1. The relationship between activation of NOD2 and trypsin-like proteolytic 
activity secretion in intestinal epithelial cells. ....................................................................... 83 
2. Project 2. Autophagy signaling pathway and the release of trypsin-like proteases in 
intestinal epithelial cells. ................................................................................................................. 85 
3. Project 3. Endoplasmic reticulum stress boosts trypsin activity and release by enterocytes 
and alters barrier function ............................................................................................................. 91 
a. Paper publication  ................................................................................................. 93 
b. Extra caco-2 results  .......................................................................................... 132 
c. HT29mtx results  ................................................................................................ 137 
GENERAL DISCUSSION AND CONCLUSIONS ............................................................................ 139 
ANNEXES ............................................................................................................................................. 151 
BIBLIOGRAPHY ................................................................................................................................ 181 
 
Acronyms and abbreviations 
12 | 
 
Acronym and abbreviations 
 
5-ASA 5-aminosalicylic acid  
6-MP 6-mercaptopurine  
Agr2 Anterior Gradient 2  
AIEC Adherent-invasive Escherichia coli  
AJs Adherent junctions  
AMPs Antimicrobial peptides  
APC Antigen-presenting cell  
APs Activating peptides  
APEH Acylaminoacyl-peptidase 
ASUC Acute severe ulcerative colitis  
ATF6 Activating transcription factor 6 
ATG16L1 Autophagy-related 16-like 1 
ATGs Autophagy genes  
AZ Azathioprine 
BiP Binding immunoglobulin protein 
BIR Baculovirus inhibitor repeat  
Caco-2 Cancer coli-2 
CARD Caspase recruitment domain  
CBC Complete blood count  
CD Crohn’s disease  
CDI Clostridium difficile infection 
CFU Colony-forming units  
CHOP CCAAT/enhancer-binding protein homologous protein 
CMA Caperone-mediated autophagy  
CSs Corticosterois  
CYLD Cylindromatosis/turban tumor syndrome gene CYLD 
DAG Diacylglycerol  
DAP D-glutamyl-mesodiaminopimelic acid  
DC Dendritic cells 
DED Death effector domain 
DSS Dextran sodium sulphate 
DAG1 Dystroglycan 
EBSS Earle's Balanced Salt Solution 
ECM Extracellular matrix  
eIF2a Eukaryotic translation initiation factor 2 
EPIC Investigation into Cancer and Nutrition  
EPS Extracellular polymeric substances 
ER Endoplasmic reticulum 
ERAD ER-associated degradation  
ERK Extracellular signal-regulated kinases 
ER-Stress Endoplasmic reticulum stress  
FMT Fecal microbiota transplants 
Acronyms and abbreviations 
13 | 
 
GADD34 Damage-inducible protein 34 
GALT Gut-associated lymphoid tissue  
GI Gastrointestinal tract  
GPCRs G-protein-coupled receptors  
GPI Glycophosphatidylinositol  
GRP78 Glucose-regulated protein 78 
GWASs Genome-wide association studies 
IBD Inflammatory Bowel Disease  
IBS Irritable bowel syndrome 
IECs Intestinal epithelial cells  
IFN-γ Interferon gamma 
IFX Infliximabor 
Ig Immunoglobulins  
IP3 Inositol 1,4,5-triphosphate 
IRE-1α /-β Inositol-requiring enzyme-1α - /β  
IRGM  Immunity-related GTPase family M 
Iκκ IκB kinase  
JAM Junctional adhesion molecules 
JNK C-Jun amino-terminal kinases 
LC3 Protein 1 light chain 3  
LDH Lactat deshidrogenasa 
LP Lamina propria 
LRR Leucine-rich repeats 
MAMPs Microbial associated molecular patterns 
MAPK Mitogen-activated protein kinases  
MCP1 Monocyte chemoattractant protein 1 
MDP Muramyl dipeptide  
MLC Myosin II light chain  
MLCK Myosin light chain kinase  
MMPs Matrix metalloproteases  
MST1 Macrophage-stimulating protein 
NE Neutrophil elastase  
NF-κB  Nuclear factor kappa-B  
NOD NOD-like receptors 
NOD1 Nucleotide-binding oligomerization domain  1  
NOD2 Nucleotide-binding oligomerization domain  2 
NS Nutrient Starvation 
NSAID Nonsteroidal anti-inflammatory drugs  
PAMPS Pathogen associated molecular patterns  
PARs Protease-activated receptors  
PBMC Peripheral blood mononuclear cell  
PERK Protein kinase-like ER kinase  
PGN Bacterial peptidoglycan 
PKC Protein kinase C  
PPs Peyer’s patches  
Acronyms and abbreviations 
14 | 
 
PRR Pattern recognition receptors  
PYD Pyrin domain  
RLMβ Resistin-like molecule-β  
RLRs RIG-I-like receptors  
ROS Reactive oxygen species  
S1P Site-1-protease  
SBTI Soybean trypsin inhibitor  
SCFA Short chain fatty acids  
sIgA Secretory IgA  
SLPI Secretory leukocyte protease inhibitor  
SPINK1 Human pancreatic secretory trypsin inhibitor 
sPLA2 Phospholipase A2  
TAMPs Marvel protein family  
TEER Transepithelial electrical resistance  
TFF3 Trefoil-factor 3   
TIMPs Tissue inhibitors of metalloproteinases  
TIR Cytoplasmic Toll-IL-1 receptor 
TJs Tight Junctions  
TLRs Toll-like receptors  
TNF-α Necrosis factor alpha  
UC Ulcerative colitis  
UPR Unfolded protein response  
USP4 Ubiquitin-specific peptidase 4 
XBP1s X-box binding protein 1 splice  
ZO Zonula occludens  
 
 
Summary of tables and figures 
15 | 
 
Summary of tables and figures 
 
INTRODUCTION 
Figure 1. Lower gastrointestinal anatomy 
Figure 2. Illustration of the four layers of the digestive tract wall 
Figure 3. Organization of the small intestine and the colon 
Figure 4. Illustration of the epithelial cells that represent the intestine 
 Figure 5. Intestinal epithelial barrier 
Figure 6. Intracellular adherent complexes 
Figure 7. Tight Junction complex 
Figure 8. Structural model of Adherens Junctions 
Figure 9. Desmosome scaffold complex 
Figure 10. Schematic model of the mucus organization in the small intestine and colon 
Figure 11. Biological function of antimicrobial peptides 
Figure 12. Immunity receptors on IECs 
Figure 13. The worldwide prevalence of IBD in 2015 
Figure 14. Structure of the defence lines of the intestinal barrier 
Figure 15. Normal gut vs IBD gut 
Figure 16. Composition of intestinal microbiota 
Figure 17. NOD2 protein 
Figure 18. Autophagy mechanism 
Figure 19. The three major sensors of UPR 
Figure 20. Apoptosis signaling under ER stress 
Figure 21. Protease wheel 
Figure 22. Different mechanism to activate PARs 
Figure 23. Scheme of the mechanism of action of proteases in the GI 
Figure 24. Illustration of TEER measurement 
Figure 25. Differentiation of Caco-2 cells on a filter support 
Figure 26. Transwell sytem used during our experiments 
 
Table 1. Human intestinal AMPs 
Table 2. Vienna and Montreal classification  
Table 3. Montreal classification of extent of Ulcerative Colitis 
Summary of tables and figures 
16 | 
 
Table 4. Montreal classification of severity of Ulcerative Colitis  
Table 5. AMP involved in IBD 
Table 6. Proteases involved in IBD 
 
RESULTS 
Figure 1. Trypsin like activity quantification after MDP stimulation 
Figure 2. Trypsin-like activity after autophagy induction 
Figure 3. mRNA levels of TJ under ER-stress 
Figure 4. Cysteine-like activity 
Figure 5. LDH cytotoxic activity 
Figure 6. Autophagy induction modulates intestinal barrier alteration 
Figure 7. mRNA expression of other serine proteases or inhibitors 
Figure 8. The impact of PAR1 antagonist on intestinal barrier homeostasis 
Figure 9. PAR1 antagonist decrease CXCL8 release 
Figure 10. PAR2 cleavage 
Figure 11. The impact of MLCK on permeability 
Figure 12. mRNA relative expression of the three trypsinogen genes 
Figure 13. ER-stress alters intestinal homeostasis 
Figure 14. Up-regulation of PAR2 and -4 in HT29-mtx cells treated with ER-stress inducer 
 
Table1. Sequence of primers 
 
DISCUSSION 
Figure 15.  The three main IBD pathways and trypsin activity 
Figure 16. The impact of ER-stress on intestinal biology 
Figure 17. Impact of proteases on intestinal biology 
Figure 18. Impact of ER-stress on trypsin activity secretion 
 
Introduction 
 
17 | 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 1. Biology of the intestine 
Chapter 2. Central role of the colonic barrier 
Chapter 3. Inflammatory Bowel Disease 
Chapter 4. Pathogenesis of Inflammatory Bowel Disease 
Chapter 5. Proteases in the gut and IBD 
Chapter 6. Intestinal in vitro models 
 
 
Introduction 
Content at a Glance 
Chapter 1. Biology of the intestine 
 
18 | 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
General overview of the GI tract 
Biology of the intestine 
Histology of the intestine 
Cellular organization of the intestine 
The five cellular cell types 
 
 
Biology of the intestine 
Chapter 1 
Content at a Glance 
Introduction 
 
19 | 
 
1. General overview of the gastrointestinal tract  
The gastrointestinal tract (GI) is an essential tube which progresses through the middle of the 
body, from the mouth until the anus, including the following segments: mouth, oesophagus, 
stomach, small and large intestine and anus (Figure 1). The main function of the digestive tract is 
to digest and absorb nutrients and water from the ingested food as energy source for the body 
(Sherwood 2010).  
The part from the small intestine to the anus is considered as the lower part of the gastrointestinal 
tract. The small intestine, also called small bowel, starts right after the stomach and is divided in 
three part including the duodenum, the jejunum and the ileum. The large bowel is subdivided 
into the colon, the cecum, the appendix and the rectum and is the most distal segment of the GI 
tract. With about 1.5 m of length and with a diameter of 6-7.5 cm the principal role of the large 
bowel is to absorb water and minerals and to store the waste remains as feces.  
The cecum is considered as the first part of the large bowel. The ileum, last division of the small 
intestine, empties into the cecum acting as a junction between small and large intestine. At the 
bottom of the cecum, the appendix, a finger like projection, is part of the immune tissue of the 
gut, carrying lymphocytes. The colon (Figure 1) is divided in four parts – ascending colon, 
transverse colon, descending colon and the sigmoid colon – then straightens out to form the 
rectum (Kiela and Ghishan 2016). The colon absorbs water and mineral from food residues, the 
remains are eliminated as feces.  
 
Figure 1. Lower gastrointestinal anatomy. The lower part of the gastrointestinal tract comprises 
the jejunum and ileum of the small intestine and the large intestine that includes the colon, the 
appendix, the rectum and the anus. Extracted from National Cancer Institute website 
(http://www.cancer.gov). 
 
 
2. Biology of the intestine 
 Histology of the intestine 
Although small differences are found between the small and large intestine, both share a common 
structure. In cross-sections, the intestine wall has four layer of specific tissues including the 
innermost mucosa, the submucosa, the muscularis externa layer and the outermost serosa.  
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Mucous membrane is the innermost layer of the mucosa, adjacent to the epithelial layer and has 
a protective role. Below, the mucosa middle layer is termed lamina propria (LP). It is made up of 
a thin layer of loose connective tissue which includes a complex network of blood vessels, 
lymphatics, immune cells, and other components, providing the epithelium physical support and 
nutrition. It also includes the gut-associated lymphoid tissue (GALT) responsible to protect from 
luminal microbe invasion. The underlying tissue, muscularis mucosa is a thin band of smooth 
muscles that separates the mucosa from the submucosa.  
Beneath the mucosa, the submucosa provides the digestive tract with flexibility and elasticity. It 
is a thick layer of irregular connective tissue that contains blood, lymphatic vessels and nerves, 
such as the submucosal plexus, that extends into the mucosa and muscularis externa providing 
nutrients supplies.  
Adjacent to the submucosa the muscularis externa is composed of smooth muscle. It is divided 
in two layers – inner circular layer and an outer longitudinal layer –these layers organize gut 
movement or peristalsis. Between the two layers is housed a neuronal network, including the 
myenteric plexus. 
The outermost connective tissue covering the intestinal wall is the serosa. It consists of a thin 
layer of connective tissue and a thin layer of cells that secrete serous fluids that avoid organ 
friction (Howell and Wells 2011). 
 
 
 
 
 
 
 
 
 
 
Figure 2. Illustration of the four layers of the digestive tract wall. The innermost mucosa, the 
submucosa, the muscularis externa layer and the outermost serosa. adapted from (Sherwood 
2010) 
 
 Cellular organization of the intestine 
The complex morphology of the gut is organized in two parts including the crypt and the villus 
(Figure 3). The crypt of Lieberkuhn is a tight invaginated space that comprises the stem cell 
compartment, a population of proliferating epithelial cells responsible of the self-renewal of the 
epithelium. Gut stem cells proliferate, migrate and differentiate along the intestinal crypt and 
undergo apoptosis every 3-7 days to renew the highly dynamic tissue, essential to maintain 
epithelial homeostasis (Clevers 2013; Dehmer et al. 2011).  
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The villi are finger-like projections of the intestinal wall, of approximately 0.5 -1.6 mm in length, 
that greatly expand gut absorptive surface area. The presence of microvilli within the villi 
enhances even more the absorptive surface. The villus is irrigated with capillaries and lymph 
vessels to mediate the transport of absorbed nutrients into the body (Figure 3) (In et al. 2016; 
Barker 2013). An important feature that differs from the small to the large intestine is the 
presence of villi. The small bowel exhibits a huge villi surface to fulfil its absorptive role. On the 
contrary, the lack of villi on the colon is associated with dry out of fecal bolus. 
 
Figure 3. Organization of the small intestine and the colon. Illustration of the colon (left) and 
small intestine (right). The villi are covered with mature cells, including absorptive enterocytes 
or colonocytes, together with mucus-secreting goblet cells. Those cells are renewed every 5 days 
and are shed into the lumen to become part of the excreted residues. The crypts are covered with 
more immature epithelial cells, including progenitors and stem cells and also secretory cells such 
as Paneth cells. Adapted from (Medema and Vermeulen 2011) 
 
The inner surface of the intestine is composed by a single-cell columnar layer of highly polarized 
intestinal epithelial cells (IECs). The villi are coated with five differentiated intestinal cell types 
classified in two groups – absorptive and secretory- depending on their functions. In the small 
intestine the most common cell type is enterocytes, considered as the absorptive lineage and the 
three remaining cell types are secretory cells including -Paneth cells, goblet cells and 
enteroendocrine cells (Figure 3 and 4). Three other minority of cell types belong to the intestine 
monolayer including M cells, cup cells and tuft cells (Figure 3  and 4) (Coskun 2014; Maloy and 
Powrie 2011). The lack of Paneth cells, and the presence of colonocytes, as colonic absorptive 
cells instead of enterocytes, constitute the two main differences between small and large intestine 
(Noah, Donahue, and Shroyer 2011). 
 
Paneth cells 
Stem cells 
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 The five different cell types 
A) Enterocytes and colonocytes 
Enterocytes and colonocytes, represent 80% of both small and large intestine. Their main function 
is to select and absorb nutrients apically and export them basally. The apical cell surface is 
composed by a microvillus brush border and a thick layer of glycocalyx, a glycoprotein gel-
forming layer composed of several carbohydrates as a backbone molecule and mucins(Noah, 
Donahue, and Shroyer 2011). Glycocalix is a meshwork of approximately 0.5 µm that projects from 
the apical cell surface of enterocytes overlaying the intestinal surface, providing extra absorption 
and including crucial enzymes needed for the final step of digestion(Maury et al. 1995). Besides, 
enterocytes and colonocytes are also capable of producing mucins and antimicrobial peptides 
(Pelaseyed et al. 2014; Bahar and Ren 2013). Antimicrobial peptide content is described in 
chapter 2 section 3.1. Mucus layer content is described in chapter 2 section 2.2. 
 
B) Goblet cells  
The most abundant secretory lineage, goblet cell, is responsible of producing a wide variety of 
mucins forming a tightly attached mucus layer in the intestine. The mucus layer is the first line 
of defence against physical and chemical damage generating a physical barrier between luminal 
bacteria and the epithelial cells. The presence of mucous-producing cells is richer in the colon than 
in the small intestine, increasing the proportion from the duodenum (4%) to the descending colon 
(16%) providing extra-lubrication to the stool passage towards the colon (Barker 2013). The 
distal colon is protected by two different mucus-layers, including an inner dense layer and an 
outer loose layer, while small intestine is covered by a single mucus-layer. The inner layer, 
impermeable to bacteria, is 50-500 m thick and it is basically made up of the gel-forming MUC2 
mucin skeleton (Noah, Donahue, and Shroyer 2011; van der Flier and Clevers 2009; Malin E V 
Johansson et al. 2011). Mucus layer content is described in chapter 2 section 2.2.  
 
C) Paneth cells 
Paneth cells, located at the basis of the crypts of the small intestine, are secreting cell types 
specialized in producing an array of antimicrobials into the mucus layer, besides crypt 
development. The biological function of antimicrobial peptides (AMPs) is to target 
microorganisms of the lumen, both resident microbiota and harmful pathogens. Paneth cells, 
found in the crypt of the small bowel, are characteristic for their extensive endoplasmic reticulum 
and Golgi due to their intense secretory activity and they contribute to the stem cell niche (Buckley 
and Turner 2017; Bevins and Salzman 2011). The presence of Paneth cells’ granuls, including 
AMP, intestinal trefoil-factor -described in chapter 2 section 1.2- and growth factors, are crucial 
for crypt formation in the small gut in (Porter et al. 2002). Paneth cells are absent in the colon. 
AMPs are described in chapter 2 section 3.1. 
 
D) Enteroendocrine cells 
Enteroendocrine cells are a minority proportion of the overall epithelial cell population – 1% 
approximately- randomly located along the intestinal wall. Although at least 15 subtypes of 
enteroendocrine cells have been described, they all share the same morphology. Apically, they 
possess microvilli extended to the luminal content, and their cytoplasm is characterized by the 
presence of secretary vesicles. Those cells sense ingested food of the luminal surface and respond 
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by diffusing hormone peptides, apically or basally, that activate nerve fibres and/or travel through 
the bloodstream. Moreover, the secretion of peptide hormones is pivotal for the physiological and 
homeostatic function of the gut (Cummings and Overduin 2007; Gunawardene, Corfe, and Staton 
2011). 
 
E) Other minor cells  
There are three additional minor cell types present in the intestine including microfold (M) cells, 
cup cells and tuft cells. M cells specifically located into the follicle-associated epithelium (FAE) 
of both isolated lymphoid follicle or Peyer patches, two major component of the GALT, driving the 
foreigner material by transepithelial transport from the lumen to the lymphoid tissue within the 
mucosa. They interact with immune cells of Peyer’s patches controlling the immune response and 
tolerance (Kucharzik et al. 2000). Known as brush cells, Tuft cells cover a small fraction -0.4% - of 
the intestinal surface. These cells, present in the airways and the digestive system, have a unique 
morphology and distinctive features typical of chemosensory cell type involved in the defence 
towards parasites (Gerbe, Legraverend, and Jay 2012). Finally cup cells, restricted to the ileum, 
represent up to 6% of total epithelial cells, and likewise M cells, they express vimentin (Fujimura 
and Iida 2001).  
 
 
Figure 4. Illustration of the epithelial cells that are present in the intestine.  
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1. The main role of intestinal mucosa 
The gastrointestinal mucosa has two critical functions: act as a physical barrier and as a 
selective filter between the inner and the outer environment. 
The human gut mucosa is exposed to a wide diversity of resident microbes and harmful antigens. 
Therefore, to handle a peaceful coexistence between the healthy intestine and their commensal 
bacteria and to avoid the passage of foreign antigens into the inner body, the host is equipped with 
a wide variety of mechanisms. Besides, mucosa epithelium act as a selective filter allowing the 
translocation of essentials nutrients, ions and water from the lumen into the body. To keep a 
flawless intestinal homeostasis, the integrity of all protective mechanisms of the mucosal 
barrier, including physical and biochemical defences, need to be harmonized. First, a well-
integrated epithelia monolayer is essential to avoid the leakage of the intestine. Epithelial 
integrity is regulated by a set of adhesive complex of proteins including Tight Junctions (TJ), 
Desmosomes and adherens junctions (AJs) (Figure 5). The adhesion complexes give integrity 
and selective permeability to the gut monolayer (Snoeck, Goddeeris, & Cox, 2005). Second, a 
physical thick layer of mucus covers most of the epithelia of the intestinal tract, especially the 
colon. It is composed of mucins secreted by goblet cells, providing the first contact to harmful 
antigens, toxins and other materials in the intestinal lumen. Chemical defences, such as 
antimictobial peptides (AMPs), produced by enterocytes, Paneth cells  and goblet cells confer 
additional protection (Halpern MD, 2015). Lastly, specific immune mechanisms of surveillance 
present in IECs and other immune cells carry innate microbial receptors that controls and 
monitor the luminal bacteria. In order to recognize microbial pathogens, IECs among other cells, 
carry the pattern recognition receptors (PRR), essential to initiate the innate immune signal 
that drives the necessary response to kill harmful microbes (Wlodarska, Kostic, & Xavier, 2015). 
Toll-like receptors (TLRs) and nucleotide-binding oligomerization domains are the two major 
forms of PRR known.   
 
 
Figure 5. Intestinal epithelial barrier. A single layer of epithelial mucus separates the intestinal 
lumen from the submucosa. Epithelial barrier integrity prevents bacterial translocation by 
secreting a broad spectrum of antimicrobial factors and a thick mucus layer that cover all 
intestinal surface. In addition intercellular interactions are essential for cell sealing. Adapted with 
permission from (Halpern MD, 2015). 
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2. Physical barrier 
 The junctions of the epithelial barrier  
In order to fulfill the intestinal barrier challenge, IECs are held together by three intracellular 
adhesion complexes, Tight Junctions (TJ), Desmosomes and adherens junctions (AJs) (Figure 
6). These cell-cell interconnections, likely formed between two different cell types, are crucial for 
the paracellular transport and barrier integrity providing mechanical properties to the barrier 
function (Antoni, Nuding, Wehkamp, & Stange, 2014). An important feature of the intestinal 
epithelium is the high polarization of the IECs. Due to the asymmetric organization of specific 
protein along the cell, such as TJs, AJs or ion distribution, the composition between the apical and 
the basolateral pole differs (Cereijido, Contreras, Shoshani, Flores-Benitez, & Larre, 2008). IECs 
polarization contributes to intestinal functions like absorption and secretion. Increased intestinal 
permeability is associated to several GI disease such as inflammatory bowel disease (IBD), 
mentioned in chapter 4 (Zeissig et al., 2007).  
 
 
 
 
 
 
 
 
 
Figure 6. Intercellular adherent complexes. IECs are held together by a set of adhesive complex 
of proteins - Tight Junctions (TJ), Desmosomes and adherens junctions (AJs). Adapted from 
(Henderson, Van Limbergen, Schwarze, & Wilson, 2011).  
 
A) Tight Junctions  
The TJ network is the apical-most junctional complex that delimits the border between apical and 
basolateral domain. They are composed by four different families of transmembrane proteins 
including occludin, claudin, tricellulin and junctional adhesion molecules (JAM) (Figure 7). 
Occludin, claudin, tricellulin are structures proteins with two extracellular loops and two 
cytoplasmic domains. The intracellular tail of TJs connects with cytosolic scaffold proteins, such 
as the zonula occludens (ZO) proteins family, which consecutively binds to the actin 
cytoskeleton. In order to sustain the contractile tension caused by the TJs, the cytoskeleton, is 
closely interconnected to a peri-junctional ring of myosin II light chain (MLC). The 
phosphorylation of MLC via myosin light chain kinase (MLCK) induces contraction of the actin-
myosin cytoskeleton leading to a TJs opening and leakage across intestinal epithelium (Feighery 
et al., 2008; Turner et al., 1997).  Disruption of TJs integrity leads to a decrease of transepithelial 
electrical resistance (TEER)-mentioned in chapter 6 section 1-, a manner to measure 
paracellular flux.  
Tight 
Junctions 
Adherens 
Junctions 
Desmosome
s 
Chapter 2. Central role of the colonic barrier 
 
27 | 
 
i) Occludin 
Occludin was the first transmembrane components of TJ to be discovered, in 1993. Occludin is 
mainly expressed in epithelia and endothelial cells, but its functions are not fully delineated. In 
vivo and in vitro data have shown that Occludin plays a role in the regulation of the paracellular 
permeability by maintaining the integrity of TJs network (Al-Sadi et al., 2011). Occludin is an 
integral membrane protein made up by four domains-two extracellular loops, two cytoplasmic 
domains, a long carboxyl region and a short N-terminus region. Regulation and localization of 
Occludin is arranged by phosphorylation on multiples residues sites- tyrosine, serine and 
threonine. Kinases, such as protein kinase C (PKC) and phosphates, regulate occludin 
phosphorylation and its localization to TJs. Highly phosphorylated occludin is selectively localized 
at TJs regions. However, depending on the phosphorylated residues such as Tyrosine 
phosphorylation, it triggers dissociation of the occludin-ZO1 complex. On the contrary, non-
phosphorylated molecules are mainly located at the basolateral membrane (Dörfel & Huber, 2012; 
Gonzalezmariscal, 2003). 
Cytosolic C-terminus domain anchors to several TJ scaffold proteins, such as PDZ-domain 
containing ZO proteins, which, in turn, link to the actin-cytoskeleton (Figure 7). Intracellular 
scaffold proteins are localized at the cytoplasmic surfaces of junctional structures to establish 
specialization and localization of the junctions. Thus cytoplasmic platforms such as PDZ-domain-
containing zona occludens proteins (ZO-1, ZO-2 and ZO-3) constitute a bridge between 
transmembrane proteins and the actin-cytoskeleton to mediate intracellular and extracellular 
signals (Figure 7). Some TJs can also interact with non-PDZ domains such as cingulin, which 
connects the junctional membrane protein to ZO-1 (Groschwitz & Hogan, 2009; Lee, 2015; Umeda 
et al., 2004). 
 
 
Figure 7. Tight Junction complex. The TJs are the most apical junctional complexes which create 
a selective permeability between adjacent IECs. It is made up by a branch network of sealing 
strands including, occludin, claudins, tricellulin and JAMs. Extracted from (Lee, 2015). 
 
ii) Claudins 
Like Occludin, the transmembrane protein Claudins also form the core of the TJs and control for 
ion selectivity and permeability. To date, 24 Claudins have been identified and their functions 
differ depending on their tissue-specific expression. Like Occludin, some Claudins are regulated 
and localized to TJs via phosphorylation. The two extracellular loops, hemophilic and/or 
heterophilic, interconnect with neighbouring cells, establishing a selective permeability and ion 
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channel-forming. The cytosolic C-terminus tail anchors Claudins to the actin-cytoskeleton via 
scaffold proteins including ZO-1, ZO-2 and ZO-3 (Itoh et al., 1999). Some of the pores forming 
claudins reduce intestinal permeability whereas others alter paracellular selection. Claudins-1, -
5 and -7, fulfill the formation of the barrier function decreasing permeability (Günzel, 2017). On 
the other hand, claudin-2,  -15 and -16 possess the “leaking” phenotype, increasing transepithelial 
resistance (TEER)(Furuse, Furuse, Sasaki, & Tsukita, 2001; Overgaard, Daugherty, Mitchell, & 
Koval, 2011).  
 
iii) Tricellulin 
Located in the tricellulin TJ, the newest discovered TJs tetraspanin protein, tricellulin (marvelD2) 
and marvelD3, together with marvelD1 (occludin) are members of the TJ-associated Marvel 
protein family (TAMPs). These three proteins share a conserved MARVEL (MAL and related 
proteins for vesicle trafficking and membrane link) domain that contributes to epithelial function 
and TJs regulation (Oda, Otani, Ikenouchi, & Furuse, 2014; Riazuddin et al., 2006). 
 
iv) Junctional adhesion molecules  
Junctional adhesion molecules (JAM) is the last component of the TJs complex. The JAM family 
including mostly A and B subtypes belongs to the immunoglobulin superfamily which comprises 
two IgG-like fold extracellular domains and one cytoplasmic tails. Two homophilic and 
heterophilic extracellular domains, from two different JAM, are required to stabilize cell-cell 
junctions to regulate the cellular function and paracellular permeability. Besides homeostatic 
functions, JAMs are required for cell migration and proliferation (Nava et al., 2011). Intracellular 
C-terminus domain interacts with the scaffolding and cytoplasmic proteins , such as ZO-1, which 
in turn, links to the actin cytoskeleton (Campbell, Maiers, & DeMali, 2017; Monteiro et al., 2013). 
 
B) Adherens junctions 
Underneath the tight junction, adherens junction, also termed zonula adherens, form the major 
lateral cell-cell adhesion belt connecting transmembrane proteins, intracellular adaptor proteins 
and actin filaments. The AJs consist in two adhesive proteins units; the most commune AJs 
structure is formed by cadherin-catenin (Figure 8). 
 
 
Figure 8. Structural model of Adherens Junctions. The most studied AJ complex is the cadherin-
catenin network. The main function is to maintain the physical cohesion between IECs.  Extracted 
from (Perry, Lins, Lobie, & Mitchell, 2010). 
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Classical epithelial (E)-cadherins anchor to the catenin complex – α-, β-, and p120 catenin. 
Through the armadillo repeats, the N-terminus domain of p120 catenin and β-catenin (also 
termed plakoglobin) binds directly to the intracellular domain of E-cadherins. β-catenin C-
terminus domain, in turn, binds to α-catenin which links to the cytoskeleton. α -catenin has the 
ability to bridge the filaments of actin with E-cadherin (Figure 8). The extracellular domain of E-
cadherins interacts with neighbouring cells that mediates cell-cell adhesion (Groschwitz & Hogan, 
2009; Niessen, 2007). Together, these AJs complexes provide a strong mechanical connection 
required to maintain the integrity of the epithelial barrier (Niessen, 2007).  
 
C) Desmosomes 
The intracellular junction desmosomes are essential for mediating strong cell-cell cohesion and 
for maintaining a mechanical seal between cells. Thus, they are abundant in the epidermis and 
myocardium tissues due to their exposure to repetitive mechanical forces. Placed in the basal side 
of IECs, desmosomes are intracellular junctions with an extracellular tail that anchors to 
neighbouring desmosomes, and a cytoplasmic domain that anchors to cytoskeleton-associated 
proteins. Altogether, the desmosome complex forms a network that provides mechanical strength 
to the intestine named scaffold complex, and it consists  in three units: two intracellular 
components and one cell to cell (Figure 9)(Hatzfeld, Keil, & Magin, 2017). Intracellularly, actin 
bind to the desmosomal adhesion molecules by the linkage of intermediate filaments (keratins). 
Thus, intermediate protein linkage is mediated by desmoplakin (linker 1) and the armadillo 
proteins plakoglobin and plakophilin (linker 2). To sum up, intermediate filaments bind to linker 
1. Linker 1, in turn, binds to the linker 2 that binds to the desmosomal cadherins complex, 
conforming integrity and plasticity to the epithelium (Garrod and Chidgey 2007). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Desmosome scaffold complex. Desmosomes are crucial for strong cell-cell adhesion, 
and their failure can provoke disease. They are also involved in fundamental processes like cell 
proliferation, differentiation and migration. Extracted from (Garrod & Chidgey, 2008) 
 
 Mucus layer of the intestine  
The mucus layer covers the whole epithelium of the GI tract keeping harmful antigens away from 
the epithelial monolayer. The small intestine presents a single and discontinuous mucus layer 
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whereas the large bowel consists in double and well defined mucus layer. Due to the high number 
of bacteria living in symbiosis in the colon, the mucus layer is essential to avoid the contacts of 
pathogens with the intestinal mucosa (Figure 10). Moreover, the lubrication ability of the mucus 
is crucial to improve intestinal transit (In et al., 2016). 
 
 
Figure 10. Schematic model of the mucus organization in the small intestine and colon. Two 
layers of adherent mucus are present in the large bowel. Goblet cell-derived mucin are mostly 
present in the colon. Adapted from (M. E. V. Johansson, Larsson, & Hansson, 2011) 
 
Mucins, the main protein of the mucus, are stored and secreted, by goblet cells – described at 
chapter 1 section 2.B –. Mucins are subdivided in two groups: the secreted mucins and the 
transmembrane mucins. The secreted mucin (MUC2, MUC5 and MUC6) form long polymers and 
are tissue-specifically expressed. On the other hand, transmembrane mucins (MUC1, MUC3, 
MUC4, MUC12, MUC13, MUC16, and MUC17) are adherent to the apical cell surface of IECs (Malin 
E V Johansson, Sjövall, & Hansson, 2013). These cell-membrane-associated mucins belong to the 
inner mucus layer of the distal colon and form an important element of the glycocalyx –mentioned 
in chapter 1 section 2.B - and epithelium protection (Malin E V Johansson et al., 2011; Thornton, 
2004).  
Mucin proteins are translocated into the endoplasmic reticulum (ER) where they are folded and 
form disulfide-bonded dimers. Thereafter, mucins PTS domains (tandem repeats) rich in proline 
(P), threonine (T), and serine (S) become densely O-glycosylated in the Golgi apparatus. This 
highly glycosylated mucin domains have a high capacity to bind water that contributes to the gel-
forming properties of the mucus (Ijssennagger, van der Meer, & van Mil, 2016). 
The mucus layer of the distal colon consists in two different mucus coats including an inner layer 
firmly adherent to the epithelium and an outer loose mucus layer (Figure 10) (Atuma, Strugala, 
Allen, & Holm, 2001; M. E. V. Johansson et al., 2011; Malin E V Johansson et al., 2011). The inner 
firm mucus layer, free of bacteria is transformed into another mucus layer expended in volume. 
The loose outer mucus layer is in contact with bacteria and can be degraded by their enzymes. 
Bacteria strains can bind to the outer mucus thanks to the abundant glycans present in MUC2 
mucin. The major component and the skeleton of the mucus layer is the gel-forming mucin MUC2 
(Thornton, 2004). 
Other important peptide produced by goblet cells that regulates the physical barrier and stabilizes 
mucin polymers are trefoil-factor 3 (TFF3) and Resistin-like molecule-β (RLMβ)(table 1) 
(Peterson & Artis, 2014). RELMβ belongs to the resistin-like molecules including four members: 
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RELM-α, -β, -γ and resistin. Unlike the other proteins of the family, RELMβ is tightly produced by 
goblet cells and secreted apically into the lumen content. Although its function is not fully defined, 
RELMβ is induced upon bacterial colonization and promotes MUC2 secretion and inflammation 
control by the stimulation of Th2 cytokines. Within the inflammatory area, RELMβ regulates 
macrophages and T cells resident in the gut (Artis et al., 2004; McVay et al., 2006). On the other 
hand, TFF3, also named intestinal trefoil factor, is predominantly expressed by goblet cell-derived 
peptide in the small intestine and colon, and it is abundantly secreted into the lumen surface. 
TFF3, belongs to the trefoil peptide family which includes the gastric peptides pS2 (also named 
TFF1) and spasmolytic polypeptide (also called TFF2), all of them are involved in gastrointestinal 
epithelial restitution (Sands & Podolsky, 1996). TFF3,  is involved not just in the structural 
integrity of the mucus but also provides epithelial healing, IECs migration and turnover as well 
as resistance to apoptosis (Taupin, Kinoshita, & Podolsky, 2000). 
Within the mucus layer, the apical IECs surface is covered with secretory IgA (sIgA). They serve 
as a first line of defence and display antibacterial properties protecting the gut mucosa from 
enteric toxins and harmful microorganisms. SIgA is capable of controlling the inflammation and 
regulating immune response to commensal microbiota, pathogens and antigens by a system 
known as immune exclusion (Mantis, Rol, & Corthésy, 2011). SIgA blocks the access of the 
bacteria to epithelial receptors, retaining the pathogen within the mucus and facilitating its 
expulsion by peristaltic movements of the intestine (a J. Macpherson et al. 2008). They shape the 
intestinal microflora by re-transporting antigens across the mucosa barrier to dendritic cells, 
subsets in GALT, which promotes pro-inflammatory signals associated with uptake of pathogens.  
 
 
 
3. Bio-chemical barrier 
3.1 Antimicrobial peptides 
Antimicrobial peptides (AMPs) belong to the innate immune defence and play a homeostatic key 
role maintaining the composition of the commensal flora and intestinal homeostasis. AMPs are 
found in the most exposed areas of the body to microbes, such as skin, eyes, oral mucosa, lung or 
intestinal mucosa. AMPs are produced by Paneth cells, goblet cells and enterocytes. This defence 
peptides possess a wide-spectrum of antibacterial properties towards pathogens and 
microbiota, both Gram-positive and Gram-negative (Dupont et al., 2015). Besides killing bacteria, 
some AMPs possess non-antimicrobial functions such as immune modulator. These peptides 
reinforce the total immune response by a range of mechanisms: as a chemoattractant to recruit 
immune cells, pro-inflammatory cytokines or as a Toll-Like Receptor ligand –mentioned in 
chapter 2. section 3.2 A- (Islam et al., 2001).  
AMPs are usually cationic, not longer than 50 amino acids, and positively charged to prevent the 
diffusion of the peptide into the lumen. These features are ideal to trap the peptide into the mucus 
layer and to target the negatively charged bacteria surface (Hancock & Diamond, 2000; Zasloff, 
2002). Depending on the peptide, the bactericidal mechanism of action differs. The peptide kill 
bacteria by (a) disruption of membrane integrity, (b) inhibiting DNA or RNA synthesis or (c) 
targeting specific intracellular molecules (Figure 11) (Bahar & Ren, 2013).  
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ANTIMICROBIAL PEPTIDES 
 
 
Figure 11. Biological function of antimicrobial peptides. AMPs act not just as a bacteria killer 
but also modulate host immune response. Bactericidal AMPs bind to the bacterial membrane by 
electrostatic interaction and kill them by disrupting their membrane or by inhibiting crucial 
intracellular functions. Immunoregulatory AMPs recruit or activate immunocytes by 
chemoattraction or by acting as a TLR ligand that leads to the activation of pro-inflammatory 
downstream signaling pathways. Adapted from (Zhang & Gallo, 2016). 
 
Defensins and cathelicidins are the two major mammalian antimicrobial peptides.  
Defensins are cationic peptides with three intramolecular disulphide bonds. To date, three 
subclasses of defensins have been described (α, β and θ) (table 2). Although the α-, and β-defensins 
have been identified in humans (O’Neil et al. 1999), θ-defensinse has been characterized from 
primates’ leukocytes (M E Selsted, 2004). Six human α-defensins have been characterized. Up to 
4 different α-defensins are expressed by neutrophil, known as a human neutrophil peptide-1 
(HNP1, HNP2, HNP3 and HNP4). Human defensine-5 and -6 (HD-5, HD-6) are tissue-specific only 
expressed by Paneth cells in the small intestine. Compared to α-defensins, four different β-
defensins have been identified (hBD1-4) in human. In mice, it has been described 6 different α-
defensins, named cryptdins (crypt defensins) and up to 45 different β-defensins gens (Michael 
E Selsted & Ouellette, 2005).  They are quite abundant within the GI tract, especially in the colon, 
mainly expressed by epithelial cells. While hBD1 is constitutively expressed along the small and 
large colon, hBD2, -3, and -4 are induced by pro-inflammatory or pathogen stimuli, through PPR-
activated signals – mentioned in chapter 2 section 3.2 A- which, in turn, activate transcription 
factor nuclear factor kappa-B (NF-κB) (O’Neil et al., 1999).   
Secreted at the surface of the colonic crypts, like defensins, cathelicidins are another dominant 
class of AMPs. Although about 30 subfamilies of cathelicidin have been identified in mammalian, 
only LL-37/hCAP18 and CRAMP have been found in human and mice, respectively (Dürr, 
Sudheendra, & Ramamoorthy, 2006). These peptides carry a large spectrum of bactericidal 
activity against Gram-negative and -positive bacteria. Stored in neutrophils, macrophages and 
epithelial cells as secretory granules, cathelicidins are released upon leukocyte activation 
(Kościuczuk et al., 2012; Zanetti, 2005). 
Paneth cells are the main source of AMPs in the small intestine, and beside α-defensins, they secret 
phospholipase A2 (sPLA2), RegIII, and lysozyme C. AMPs are regulated and stored as inactive 
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peptides in secretory granules. Triggered by bacteria among other stimulus, the granules are 
release on the lumen and are cleaved by trypsin or matrix metalloproteinase to generate the 
peptide mature form (Tollin et al., 2003; Wang, 2014). 
 
Human intestinal AMPs 
Class  Antimicrobial Cellular type Expression 
α-Defensins NHP-1, -2 and -3 Neutrophils/Bone 
marrow 
Constitutively express 
HD5 and HD6 Paneth cells Constitutively express 
β-Defensins hBD1 Enterocytes Constitutively express. 
hBD2, hBD3 hBD4 Enterocytes Induction during 
inflammation 
Cathelicidins LL-37 IECs/inflammatory 
cells 
Induction during 
inflammation 
Other AMPs RegIII Paneth 
cells/enterocytes 
Induction during 
inflammation 
sPLA2 Paneth cells Constitutively express 
Increased under 
inflammation 
CCL20 Paneth cells Induction during 
inflammation 
Lysozyme C Paneth cells Constitutively express. 
Increased under 
inflammation 
BPI IECs Induction during 
inflammation 
RELMβ H.s. Goblet cells Induction during 
inflammation 
   
Table 1. Human intestinal AMPs. Adapted from (Muniz, Knosp, & Yeretssian, 2012) 
 
AMPs constitute a shield towards commensal microbiota. Dysregulation of peptide production 
changes the composition of commensal microbiota and disrupts intestinal homeostasis. Failure of 
AMPs expression and secretion is associated with human disease such as obesity or Irritable 
Bowel Syndrome (Zhang & Gallo, 2016).  
 
3.2 Immunity of the colonic mucosa 
In order to protect the GI tract from viruses, bacteria, fungi, or parasites, the intestinal mucosa 
needs to recognize and respond to foreign organism and harmful substances. To identify and 
protect the GI tract from those, the intestinal mucosa is equipped with several weapons. IECs 
express various recognition molecules such as the pattern recognition receptor (PRR). These 
receptors recognized a broad spectrum of bacteria or microorganism structures, known as a 
pathogen/microbial associated molecular patterns (PAMPs or MAMPs). PRRs are mostly 
constitutively expressed in innate immune cells including dendritic cells (DC), macrophages, 
neutrophils and also in IECs. However, these receptors can also be induced by harmful stimuli. To 
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date, PPRs are classified in four subclasses including Toll-like receptors (TLRs), RIG-I-like 
receptors (RLRs), NOD-like receptors (NLRs) and DNA receptors (cytosolic sensors for 
DNA)(Loo & Gale, 2011). TLRs and NLRs are the two major classes.  
 
A) Toll-like receptors 
TLRs are the most studied PRRs and are the first sensors of pathogens. They are type 1 
transmembrane protein including an extracellular domain leucine-rich repeats (LRRs) that 
mediates the PAMPs/MAMPs recognitions and a cytoplasmic domain Toll-IL-1 receptor (TIR) 
that activates downstream signaling.  
TLRs are classified in 10 family members in human and 13 receptors in mouse (TLR-1-10) and 
each one detects different PAMPs from pathogens (Kawai & Akira, 2011). The type of cell and 
location of the receptor is critical to its function. Intracellular TLR-7, -8 and -9 are expressed in 
the endosome to detect nucleic acids from infiltrated bacteria or virus (Figure 12). On the other 
hand, TLRs 1, -2, -4, -5, -6 and -10 are expressed at the cell surface and recognize a broad number 
of cell surface ligands from pathogens (Fukata, Vamadevan, & Abreu, 2009). With the exception of 
TFR3, upon specific stimulation, TLRs, recruit MyD88 (myeloid differentiation primary-response 
protein 88), which triggers the signalling pathways of NF-κB or mitogen-activated protein kinases 
(MAPK), leading to the expression of inflammatory cytokines (Abreu, 2010; Akira & Takeda, 
2004).  
 
Figure 12. Immunity receptors on IECs. TLRs located on the plasma membrane are sensors 
either by PAMPs or DAMPs. Nevertheless, intracellular receptors including TLR3, -7 and -9 
recognize invading viruses or bacteria. The difference between the two NODs is the double amino-
terminal CARD present in NOD2. Adapted from (Strober, Murray, Kitani, & Watanabe, 2006) 
 
B) NOD-like receptors 
NLR recognize a wide range of pathogen ligands within the cytoplasm of the cells. NLRs consist in 
three domains: the LRRs domains recognizes microbial products, a central nucleotide-binding 
effector domain termed NACHT (or termed NBD) and a N-terminal region that consists of death 
effector domain (DED) pyrin domain (PYD), caspase recruitment domain (CARD), or 
baculovirus inhibitor repeat (BIR) domain region for downstream signalling (Proell, Riedl, Fritz, 
Rojas, & Schwarzenbacher, 2008). NLRs protein family consist in 22 members, classified 
depending on the N-terminal domain (DED, PYD, CARD or BIR). The first NLRs described to 
monitor the cytosol were NOD1 (Nucleotide-binding oligomerization domain 1) and NOD2 
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(Nucleotide-binding oligomerization domain 2) (Figure 12). NOD1 and NOD2, encoded by the 
gene CARD4 and CARD15 respectively, are intracellular pattern-recognition molecules involved in 
the recognition of the core structures of bacterial peptidoglycan (PGN). NOD1 is trigged by d-
glutamyl-meso-diaminopimelic acid (DAP), found in a Gram-negative and some Gram-positive 
bacteria, while NOD2 recognizes the muramyl dipeptide (MDP), widely expressed among both 
Gram-negative and -positive bacteria (Yoon, 2012). NOD1 and NOD2 share the common regions 
NACHT and LRR, in contrast, NOD1 N–terminal effector consist in a single CARD domain whereas 
NOD2 incorporate two (Figure 12). 
Upon stimulation of specific bacteria motifs, NATCH domain oligomerizes leading to the 
interaction of CARD-CARD-containing kinase RIPK2, which in turn, initiates the recruitment of 
intramolecular adaptors. Once this recruitment is accomplished, downstream signalling by 
nucleus translocation of the cytosolic NF-κB takes place. In addition, stimulation of NOD1 and 
NOD2 can lead to the activation of MAPKs such as p38, extracellular signal-regulated kinases 
(ERK) and c-Jun amino-terminal kinases (JNK) (Kelsall, 2005; Kobayashi et al., 2002). Both 
signaling pathways lead to the translation of genes involved in inflammation.  
 
C) Inflammasome 
Inflammasome is a multi-protein complex located in the cytoplasm composed by NLR family 
members or absent in melanoma 2-like receptor (AIM2)(Med, 2016). When they sense PAMPs 
or DAMPs stimulus, NLR or AIM2 oligomerize triggering downstream signalling cascade including 
the proteolytic cleavage of pro-IL1 family cytokine to its mature form leading to cell death (Kumar, 
Kawai, & Akira, 2011; Med, 2016). 
 
D) GALT, gut-associated lymphoid tissue 
GALT consists of isolated lymphoid follicles present in all segments of the small and large 
intestine, or regrouping to form Peyer’s patches (PPs) along the small intestine. PPs are 
considered as the immune sensors of the gut since they are able to discriminate between harmful 
antigens and commensal bacteria. GALT hold specialized cells termed M (microfold), which are 
able to transport luminal antigens and pathogens towards the underneath immune cells. Immune 
cells regulate the immune response with either tolerance or inflammation response (Jung, Hugot, 
& Barreau, 2010).  
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1. General Introduction 
Inflammatory Bowel Diseases (IBD) are chronic idiopathic inflammation of the gut. The most 
common forms included Crohn’s disease (CD) and ulcerative colitis (UC). UC pathogenesis is 
characterized by a superficial contiguous inflammation of the mucosa and sub-mucosa surface 
extending proximally from the rectum, but always confined to the colon. Unlike UC, CD is typically 
defined by a transmural inflammation that might affect any part of the GI tract from mouth to 
anus, although often the inflammation is located in the terminal ileum and the colon (Van 
Assche et al., 2010).  
IBD are complex diseases involving environment and genetic factors. It is believed to occur in 
genetically predisposed individuals whom immune response to intestinal microbes is abnormal 
after being exposed to specific environmental factors (Siegel et al., 2016). More than 163 loci are 
known to confer susceptibility to IBD. Nevertheless, genetic mutations are not enough to explain 
the increased IBD prevalence in developed countries, evidencing that environmental factors play 
also a crucial role in IBD pathophysiology (Abraham & Cho, 2009; Lees, Barrett, Parkes, & Satsangi, 
2011).  
The incidence rates of UC and CD differ geographically. The highest incidences of IBD have been 
reported in Westernized countries including North America, northern Europe and Australia. IBD 
have emerged in previously low-incidence nations, such as in the Eastern Europe and Asia, a rise 
of incidence has also been observed in the pasts years (Jacques Cosnes, Gowerrousseau, Seksik, & 
Cortot, 2011). This incidence increase may be linked to rapid socio-economic changes 
transforming the societies. Some examples are the changes from agricultural to manufacturing 
industry, the urban lifestyle, the diet or the increased pollution (Molodecky et al., 2012). 
 
 
 Crohn’s Disease 
CD is a heterogeneous, relapsing inflammation condition present throughout the entire GI tract, 
from the mouth to the anus. The most common locations affected are the colon and the terminal 
ileum. From the oral to mid-ileum, the affected portions are less than 5% of cases (Article, 2004; 
Laube et al., 2017). It is a heterogeneous disease comprising different and complex phenotypes 
depending on the age of onset, the location of the inflammation and the symptoms of the disease. 
The diagnosis is based on a combination of clinical medical history, medical examinations, 
symptoms, serologic tests, endoscopy and histopathology exams (van Hogezand, Witte, 
Veenendaal, Wagtmans, & Lamers, 2001). Quantification of Fecal markers such as calprotectin 
and lactoferrin are used to determine intestinal inflammation. Because these markers are also 
increased in UC, they are not used to diagnose the disease, but to monitor the severity of IBD and 
predict the relapses in patients (Sipponen et al., 2008). Clinical features of CD are persistent 
diarrhoea, abdominal pain, fever, occasional bleeding, weight loss and fatigue (Chang, Chang, 
Chang, & Chang, 2017). Complication for the disease course includes colonic ulcerations, known 
as fistulas and increased risk for colon cancer.  
Patients with CD are classified according to the Montreal classification considering the age of 
onset, disease location and behaviour (table 2)(Satsangi, Silverberg, Vermeire, & Colombel, 2006). 
CD is featured by a discontinuous and transmural inflammation, most commonly involving the 
ileocecal area. Anatomical criteria of severity are characterized as deep ulcerations damaging the 
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muscle layer, or mucosal detachments with also ulcerations limited to submucosa but prolonged 
to more than one third of a colonic segment (Van Assche et al., 2010). 
 
 
 
 
 Ulcerative colitis 
UC affects the rectum and a variable extent of the colon involving most of the times only the 
innermost mucosa. It manifests as continuous portions of inflammation and ulceration and is 
characterized by atypically relapsing and remitting course (Dignass et al., 2012). The UC 
inflammation is defined to the mucosal surface, although in severe course of the disease, it may 
penetrate. It exists different varieties of UC depending on the inflammation location. Disease 
placed only at the most distal part of the colon and rectum is referred as ulcerative proctitis; 
inflammation from the descending colon is termed limited or distal colonic left-sided; and disease 
comprising the entire colon is named pancolitis (Koutroubakis, 2010; Whitlow, 2004) .  
Mild symptoms of UC include a progressive loosening of the stools, chronic abdominal pain and 
bloody diarrhoea. UC patients experience a gradual onset of symptoms from mild to severe. 
Approximately 20% of patients develop at least one severe acute exacerbation, sometimes 
requiring hospitalization. Severe symptoms comprises, loss of appetite that results in weight loss 
and lack of nutrients, mucus and blood in the stools, fever and anaemia (Edwards & Truelove, 
1963; Head, Jurenka, & Ascp, 2003).  
To diagnose UC and exclude other similar diseases such as CD, a patient history is required. Other 
tests required early in the diagnostic include a complete blood count (CBC) and a fecal occult 
blood, both use to check intestinal blood loss and anaemia. Colonoscopy or sigmoidoscopy are 
other techniques used to confirm the disease (Dignass et al., 2012). Patients with Acute and 
severe ulcerative colitis (ASUC) are diagnosed with bloody stool frequency ≥6 per day, together 
with any sign of systemic toxicity like tachycardia >90 bpm, temperature >37.8 °C, 
haemoglobin<105 g/l or an erythrocyte sedimentation rate >30 mm/hm. These patients with 
severe colitis are often hospitalized (Hindryckx, Jairath, & D’Haens, 2016).  
Montreal classification incorporates an assessment of disease extent and severity. Montreal 
criteria of disease extent of UC define colitis macroscopic disease as proctitis, left-sided and 
pancolitis (table 3). Montreal classification of severity is characterized as remission. Mild, 
moderate and severe (table 4). ASUC classification is defined by the Truelove and Witts criteria 
(Satsangi et al., 2006; Spekhorst et al., 2014).  
 
Vienna and Montreal classification for Crohn’s disease 
To solve out the issue of sub-classification of CD by phenotype, the investigators have 
proposed a disease classification and established a unified clinical, serological and molecular 
classification of IBD. In 1998, the World Congress of Gastroenterology (WCB), hold in Vienna, 
claffified CD regarding the age of onset, the disease location and the behaviour of the disease 
(table 1). In 2005, WCG took place in Montreal, where Vienna classification was slightly 
modified. Montreal revision has not changed the three predominant parameters, but have 
made some modifications in each of these categories (table 2) (Satsangi et al., 2006). 
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Table 2. Vienna and Montreal classification  
 
 
Table 3. Montreal classification of extent of UC 
 
 
Table 4. Montreal classification of severity of UC  
 
 
 
 Epidemiology 
4.1 Incidence and prevalence  
In the latest 19th century, Wilks and Moxon reported, for the first time, the term of UC. Historically, 
in early 20th century Dr. Burrill Crohn, Dr. Leon Ginzburg and Dr. Gordon Oppenheimer published 
a research article identifying the two different IBD subtypes: CD and UC (Arora & Malik, 2016; 
Crohn, Burril. Ginzburg, 1932). Since the middle of the 20th century, IBD rates appeared as a 
growing problem in the western world and at the turn of the 21st century, prevalence of UC or CD 
in industrialized countries is up to 0.5% of the total population and the incidence range is from 
10 to 30 per 100,000 (Molodecky et al., 2012).  
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The annual incidence rates of CD in developed countries are estimated to be: 20.2 per 100,000 
person-years in North America, 12.7 per 100,000 person-years in Europe and 29.3 per 100,000 
person-years in Australia. In contrast, developing countries like Asia has a low incidence rate of 
0.54 per 100,000 person-years (Molodecky et al., 2012; Ng, Tang, et al., 2013; Wilson et al., 2010). 
In addition, annual incidence rates of UC are: from 7.6 to 19.5 per 100,000 person-years in 
North America, from 1.7 to 13.6 per 100,000 person-years in Europe and from 0.3 to 5.8 per 
100,000 person-years in Asia (Burisch, 2014). Whereas in the past, UC had higher prevalence than 
CD, in the past few decades CD incidence has raised. Prevalence of UC in North America is 170–
250 per 100,000 person- years and 43–294 per 100,000 person- years in Europe. For CD the 
prevalence in North America are 25–300 per 100,000 person- years (Bernstein et al., 2006; 
Pinchbeck, Kirdeikis, & Thomson, 1988).  
 
4.2 Age and gender disparity 
Despite the fact IBD can occur at all ages, the onset peak of age is generally between 20-30 for CD 
and 30-40 for UC. Some studies have reported a second peak of CD occurrence between 60-70 
years of age (A. N. Ananthakrishnan, 2015; Burish & Munkholm, 2015). Whilst 7-20% of IBD 
patients are children, 60-85% are adults, the majority of them being under 40 years of age.  
IBD affects with similar proportions males and females. Nevertheless, there is a modest 
preponderance of CD in females, whereas UC is predominant in males (Russel & Stockbrügger, 
1996). On the contrary, in the paediatric population, the distribution of the gender tendency is 
reversed having more males with CD than females (Auvin et al., 2005).  
 
4.3 Geographical distribution 
IBD has been characterized as a disease of industrialized nations of the Western world. During 
the 19th century, countries with higher socioeconomic status experienced a fast shift in 
agriculture, manufacturing, transportation, diet, urbanization and an increased exposure to 
hygiene (Gearry, 2016; Kaplan, 2015). These changes lead to chronic immune-mediates diseases, 
like IBD, to appear. Some studies suggest that IBD is not driven by ethnicity, but rather by the 
surroundings that fosters us.  
IBD occurs in individuals of any ethnic groups, such as African-American, Asia-American or 
Hispanics whose families have lived in industrialized countries for several generations. Recent 
studies show that in Asian countries (Japan or Korea), the incidence of IBD is still low, but 
increasing (Kaplan, 2015; Karlinger, Györke, Makö, Mester, & Tarján, 2000). To highlight this 
point, the UC incidence in Hong Kong in 1970 was 0.1 per 100,000 and CD was hardly recognized. 
Incidence rate: Incidence is a measure of probability of occurrence of new cases of a disease 
in a population within a specific period of time. Incidence is calculated as: number of new cases 
of a disease in a specified period of time divided by the size of the population initially disease 
free. 
Prevalence rate: Prevalence rate measure how commonly a disease or specific condition 
occurs in a population at a particular point in time (years). The prevalence is calculated by 
dividing the number of cases with the disease or condition at a given time point by the total 
number of individuals examined.  
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In 2000 the incidence of UC was reported from 1.6 to 2.1 per 100,000, and CD caught up almost 
1.3 per 100,000 (Zheng et al. 2005; Tan and Goh 2005; Chow et al. 2009). Other new industrialized 
nations, like Brazil, India, and Turkey, are experiencing similar patterns of increased incidences 
of UC and CD (Figure 13). This data attributes to a shared environmental factor of origins, together 
with an improved health care infrastructure to diagnose the disease. 
 
 
Figure 13. The worldwide prevalence of IBD in 2015. Extracted from (Kaplan, 2015) 
 
 
 Etiology 
5.1 Genetic susceptibility 
Both distinguished forms of IBD occur in a genetically susceptible individual. High-throughput 
genotyping strategies, including the meta-analysis of the genome-wide association studies 
(GWASs), have greatly advanced our understanding and highlight the importance of genetic risk 
factors in IBD. GWASs have reported 163 genetic risk loci that contribute to the susceptibility of 
UC or CD (Jostins et al., 2012). Moreover, these studies have also demonstrated a substantial 
overlap between CD and UC in genetic susceptibility (Budarf, Labbé, David, & Rioux, 2009; 
Zhernakova et al., 2009). Of these 163 loci, 110 conferred risk to both forms of IBD, whereas 23 
loci were unique to UC and 30 loci were unique to CD (McGovern D, Kugathasan S, Cho JH). 
 
New genetic findings from recent GWASs, have identified a variety of pathways implicated in the 
pathogenesis of IBD, suggesting a diversity of risk-conferring loci. Most of these genes are 
essential for the maintenance of the intestinal homeostasis including barrier integrity, 
epithelial restitution, innate and adaptive immune regulation, microbial regulation, reactive 
oxygen species (ROS), autophagy, endoplasmic reticulum stress (ER-stress) and metabolic 
pathways crucial for cellular homeostasis (Kohr, Gardet, & Xavier, 2011; Sturm & Dignass, 2008). 
In 2001, nucleotide-binding oligomerization domain containing 2 (NOD2) was the first 
susceptibility gene identified for CD associated risk variants. Autophagy-related genes, IRGM 
and ATG16L1, are genetic variants that confer increased risk to develop CD, highlighting the 
importance of autophagy and phagocytosis in immune responses in CD pathogenesis. Another 
pathway that has recently emerged in the pathophysiology of IBD is the unfolded protein response 
(UPR), induced by ER-stress. ER-stress has been genetically linked with both subtypes of IBD 
through the candidate gene X-box binding protein 1 splice (XBP1s) (Fritz, Niederreiter, Adolph, 
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Blumberg, & Kaser, 2011). IBD loci genes associated to dys-regulated immune response to 
microbes and impairing the regulation of the inflammation are interleukin-23 pathway (IL-23), 
IL-10, STAT and JAK2, involved in both, CD and UC, pathogenesis (Budarf et al., 2009). These loci 
mutations affect a wide range of biological pathways including autophagy genes, leading to an 
aberrant elimination of bacteria, and essential pathways genes associated with cellular 
homeostasis and the regulation of immune system.  
 
 
 
IBD has been reported to be a polygenic disorder and population-based studies demonstrated 
to be familial in 5–10% of cases and sporadic in the remainder (Halme et al., 2006). The 
concordance rate in monozygotic twins is higher in CD (30-40%) than in UC (10-15%), suggesting 
that non-genetic components, such as the relevant environmental exposure, may play a pivotal 
role in the expression of UC rather than CD (Spehlmann et al., 2008). Furthermore, IBD-disease-
associated polymorphisms do not explain the shift in temporal trend analyses of incidence over 
the past generations(Kaplan, 2015; Kohr et al., 2011). Population-based studies illustrate that IBD 
susceptibility genes between the Western nations and newly industrialized countries differ. For 
examples, NOD2 and ATG16L polymorphisms increase the risk of developing CD in European 
progeny, whereas NOD2 variants in Asia are different than those detected in caucasian and 
ATG16L1 is not CD-associated. Thus, depending on the interaction gene-environment, individuals 
with IBD may manifest different phenotypes of UC and CD (Kaplan, 2014; Ng et al., 2012). 
 
5.2 Environmental risk factors 
Although the discovery of genetic variants associated with IBD has progressed rapidly, gene 
mutation alone is not sufficient to explain the changing epidemiology of CD and UC. Environmental 
determinants are considered to have a strong role in mediating the risk of IBD, although no single 
environmental risk has been proven to have a definite causative function (Bernstein 2012). It is 
believed that those environmental risk factors involved in the onset and/or the course of IBD have 
an influence on the gut microbiota composition and mucosal immune system including breast-
feeding, maternal birth exposure, diet, stress, smoking, antibiotics or vaccination (Danese, Sans, & 
Fiocchi, 2004; Hrnčířová, Krejsek, Šplíchal, & Hrnčíř, 2014; Sartor, 2010). 
 
A) Smoking 
Smoking has both positive and negative effects in IBD. Several studies reported that smoking 
increases the risk of developing CD and exacerbates its clinical course including early surgery and 
postoperative recurrence. On the other hand, smoking cessation improves prognosis of CD. In 
 
Genome-wide association study (GWAS) 
GWAS is a method that identifies genes involved in human disease. This technique search the 
genome-wide set for small variations, termed single nucleotide polymorphisms or SNPs, that 
typically occurs more frequently in people with a certain disease than in people without the 
disease. At the same time, this study can scan hundred and thousands of SNPs and researchers 
can highlight genes that may contribute to an individual’s risk of developing a particular 
disease. 
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contrast, smoking has a protective effect on UC (J Cosnes, Beaugerie, Carbonnel, & Gendre, 2001; 
Danese et al., 2004). Over the past decades, Western countries have dropped the prevalence of 
smoking, for examples in 1980, 40% of the adult population were smokers in UK, whereas in 2013 
the number was down to 13%. On the contrary, newly industrialized countries are experimenting 
a rise on the prevalence of smoking, although the incidence of CD is still low (Giovino et al., 2012). 
Thus, environmental components of IBD influence population differently depending on the world 
region. A recent experimental study suggested that 64 polymorphism variants associated with 
developing IBD were altered by tobacco smoking (Yadav et al., 2017).  
 
B) Diet 
Given the location of high incidence of IBD, a strong relationship between dietary components and 
the disease pathophysiology has been considered. The rising rates of IBD in USA and Europe 
coincided with the expansion of fast food chains, manufactured food and increased used of 
aluminium foils and antibiotics (Ng, Bernstein, et al., 2013). A French study reported variation in 
the incidence of CD between the north and south of France, due to difference in dietary 
components exposure. Dietary patterns in southern regions consist of a high intake of fruits and 
vegetables, fish, olive oil and wine with a low intake of high-fat animals, alcohol and potatoes. On 
the contrary, the north of France consumes a “western diet” distinguished by high intake of eggs, 
potatoes, butter, added-fats and beer (Perrin et al., 2005). Several studies from Europe classify 
increased sugar intake as the most consistent dietary factor linked to IBD. A Dutch study ranges 
chocolate and sugary drinks as a likely risk factor for IBD with animal proteins in the third 
position (Jantchou, Morois, Clavel-Chapelon, Boutron-Ruault, & Carbonnel, 2010; Russel et al., 
1998; Sakamoto et al., 1995). The Investigation into Cancer and Nutrition (EPIC) study associated 
a high intake of linoleic acids (n-6 polyunsaturated fatty acid) with an increased risk to develop 
UC (Tjonneland et al., 2009). A Japanese study associates the elevated intake of animal protein 
and dietary fat, specially n-6 fatty acids with less n-3 fatty acid, with the contribution to the 
development of CD (Shoda, Matsueda, Yamato, & Umeda, 1996). 
 
C) Medications 
Several medications including oral contraceptives, nonsteroidal anti-inflammatory drugs 
(NSAIDs), antibiotics and postmenopausal hormone therapy have been associated with increased 
risk of IBD (Ashwin N. Ananthakrishnan et al., 2012; Cornish et al., 2008). Antibiotics are known 
to alter the gut bacterial composition that contributes to abnormal gut immune response and 
dysbiosis. The use of antibiotic during the first year of life, known to acquire the commensal 
microbiota in the new-born, is associated with an elevated risk of developing allergic disease in 
the future (Farooqi & Hopkin, 1998). Previous studies have analysed the relationship between 
newly diagnosed IBD patients and antibiotic exposure. CD has been associated with antibiotic 
exposure in both adult and paediatric patients with IBD (Hildebrand, Malmborg, Askling, Ekbom, 
& Montgomery, 2008; Shaw, Blanchard, & Bernstein, 2011). 
The regular use of NSAIDs, excluding aspirin, seems to be associated with increased incidence of 
CD and UC (Ashwin N. Ananthakrishnan et al., 2012). A British meta-analysis has associated the 
use of oral contraceptives agents with risk of CD (Cornish et al., 2008). 
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D) The hygiene hypothesis 
The “hygiene hypothesis”, proposed for the first time by Strachan et al.(Strachan, 1989), 
postulates that due to the industrialization and urbanization of society, children are less exposed 
to microbes triggering an abnormal host immune response, and leading to autoimmune disease 
and infections. This “hygiene hypothesis” argues that infections in early childhood protect from 
developing allergic diseases. Children from westernized countries are protected from lethal 
infections in early childhood, which in contrast are common in developing countries. This low 
exposure to severe infection increases the risk of developing allergic diseases (Wills-Karp, 
Santeliz, and Karp 2001). In a case-control study, Gent et al. have found that CD was more frequent 
in individuals who had hot-water taps and isolate bathrooms (Gent et al., 1994). Another study 
from Spain has shown that living in urban areas, high socioeconomic status and high educational 
levels were risk factors for CD and UC. On the other hand, childhood gastroenteritis and 
respiratory infections were protective factors (López-Serrano et al., 2010). The new biodiversity 
hypothesis suggests that decreased contact of people with natural habitats and biodiversity might 
adversely affect the gut microbiota and its immunomodulatory capacity. This declining 
biodiversity may contribute to increase the prevalence of allergies and chronic inflammatory 
disease in urban areas (Hanski et al., 2012).  
 
E) Lifestyle: Stress and exercise 
External factors such as psychological stress can trigger gut inflammation through several 
mechanisms including the autonomic nervous system and the hypothalamus–pituitary– adrenal 
axis. Both mechanisms lead to the production of pro-inflammatory cytokines, activation of 
lymphocytes and alteration of gut commensal bacteria and intestinal permeability (Bonaz & 
Bernstein, 2013). Observational studies have shown a relationship between major life stressors, 
depression and anxiety with an increased risk of developing IBD. Relapse, surgery, reduced 
sensitivity to immunosuppressive therapies and hospitalization are factors associated to patients 
with established IBD and depression or anxiety (Ashwin N Ananthakrishnan et al., 2013; Bonaz & 
Bernstein, 2013). A German study associates sedentary occupations such as office work, 
administration and mechanics, with increased risk for developing IBD, whereas manual labour 
(such as construction, cleaning and maintenance) were linked with a low risk of IBD (Sonnenberg, 
1990). Supporting this data, other cohort studies have shown that physical activity is associated 
with a 44% reduction in risk of CD but no of UC.  
 
F) Appendectomy 
Similar to smoking, appendectomy, a surgical operation to remove the appendix, has divergent 
effects on CD and UC. A case-control study from Sweden reported that patients, younger than 20 
years old, who underwent appendectomy, had a lower risk of developing UC. Besides, the same 
cohort found a long-term elevated risk of CD up to 20 years after the surgery (Kaplan et al., 2008). 
It is important to highlight that patients who had appendectomy for inflammation and not for non-
specific abdominal pain were reported. Studies from Europe and Asia have reported that the 
appendectomy has a protective effect for the development of UC (Andersson, Olaison, Tysk, & 
Ekbom, 2001). French and Australian studies investigated that UC patients who had their 
appendix removed before diagnosis were more unlikely to require immunosuppressive therapy 
(Radford-Smith et al., 2002) or colectomy (Jacques Cosnes et al., 2002). In an experimental mouse 
model, appendectomy for appendicitis improved colitis state, although increased the risk of 
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colorectal neoplasia when appendicitis was not present (Harnoy et al., 2016). However, the 
association between CD and appendectomy is ambiguous. Several studies have reported an 
increased risk factor for CD patients who had undergone appendix removal (Andersson, Olaison, 
Tysk, & Ekbom, 2003; Frisch et al., 2001) although other studies have shown a protective effect or 
no connection (Reif et al., 2001; Russel et al., 1997). In summary, this apparent contradiction 
might be explained by the divergent biological mechanism involved in CD and UC.  
 
 
 Therapies 
Ideally, therapy should be a rapid outcome and have low rate of side effects. The main goals of 
drug treatment in IBD is to induce maintenance of remission, to achieve mucosal healing, to 
avoid surgical intervention and to decrease the likelihood of colon cancer as a main 
consequence of chronic inflammation (Iacucci, De Silva, & Ghosh, 2010). The treatment of IBD 
includes medical treatment and/or surgical intervention in those patients who do not respond 
to conservative measures. The primarily therapeutic goal includes normalization of physiological 
functions and restoring nutritional deficits (water, nutrition and mineral homeostasis), 
improvement of the quality of life and psychosocial support and protection against aggressive 
disease. The secondarily therapeutic goal includes stable remission, better prognosis and lower 
risk of relapse and decrease risk of colon carcinoma (Triantafillidis, Merikas, & Georgopoulos, 
2011). As mentioned above, IBD is the result of several combined effects and therefore, each 
patients displays different clinical picture and different responses to therapy (Schirbel & Fiocchi, 
2010). 
 
6.1 Pharmaceutical treatment 
Conventional treatments include five major categories including anti-inflammatory drugs, 
immunosuppressive molecules, antibiotics and probiotics and biologic agents.  
 
A) Anti-inflammatory drugs 
Mesalazine or 5-aminosalicylic acid (5-ASA) is considered as a pleiotropic drug since it acts at 
several steps of the pathological process of IBD. It is used for the treatment of mild to moderate 
severity of active UC and for maintaining remission. (Baumgart, Vierziger, Sturm, Wiedenmann, & 
Dignass, 2005). Corticosterois (CSs) suppress inflammation at the very early onset inhibiting 
vascular permeability, vasodilatation and neutrophil infiltration (Ito, Chung, & Adcock, 2006). CSc 
are an effective treatment to induce remission in active CD and UC patients.  
 
B) Immunosuppressives 
Immunosuppressives reduce the activation of the immune system by inhibiting proliferation and 
efficacy of lymphocytes. Immunosuppressant drugs include: Azathioprine and 6-mercaptopurine, 
Methotrexate, Tacrolimus, Cyclosporin and Infliximab (Triantafillidis et al., 2011).  
 
C) Antibiotics and probiotics 
The terminal ileum and the large bowel are the most frequently affected areas in IBD, representing 
the sites with higher concentration of bacteria. As mentioned above, enteric flora is altered in both 
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types of IBD (Matsuoka & Kanai, 2015) and therefore the use of antibiotics or probiotics may 
benefit patients with IBD. Antibiotics are frequently more used in CD than in UC. Several experts 
have shown that the use of antibiotic as a first-line therapy or in combination with 
immunosuppressive drugs may be the ideal strategy to treat patients with CD (Greenberg, 2004; 
Nitzan, Elias, Peretz, & Saliba, 2016).  
Probiotics are defined as live non-pathogenic microorganisms which, when administrated to 
animal or human, improve the microbial balance in the GI tract. They include Saccharomyces 
boulardii yeast or lactic acid bacteria, like Lactobacillus and Bifidobacterium spp (Federico et al., 
2009; Pothoulakis, 2009). 
 
D) Biological agents 
TNF-α blockade is a powerful strategy used in both CD and UC. Several anti-TNF-α monoclonal 
antibodies are available in the United States, including infliximab, adalimumab, and 
certolizumabpegol. Only the first two are licensed for use in Europe (Triantafillidis et al., 2011). 
Clinicians recommend anti-TNF-α therapy in patients with moderate to severe CD not responding 
to conservative treatment and in patients with severe UC refractory to other medical therapies. 
TNF-α blocking therapy has improved long-term outcomes like symptom management, 
endoscopic recurrence and mucosal healing and is being recommended for use in the earlier 
course of the disease.  
 
6.2 Surgery 
Anti-TNF-α biologics have revolutionized IBD treatment either as monotherapy or together with 
immune-modulators. This pharmacological treatment is sufficient to induce remission in patients 
with moderate-to-severe CD and UC. Despite these new advances, surgery is still necessary in 30-
40% of CD patients and 20-30% of UC patients at some point during the course of the disease 
(Bouguen & Peyrin-Biroulet, 2011; Hancock & Mortensen, 2008). Surgery for severe CD is not 
curative and patients undergo through resection when conservative treatment are unable to 
achieve symptomatic control. Unlike CD, surgery in patients with UC is curative and necessary 
when failure of medical management occurs, severe bleeding and toxic megacolon or perforation.  
 
6.3 Fecal microbiota transplantation  
Fecal microbiota transplants (FMT), also termed as a stool transplant, is a therapy to reestablish 
a normal gut microbiota composition by introducing fecal bacteria from a healthy individual into 
a diseased patient. The reconstruction of balanced microbiota through FMT has been highlighted 
as a potential therapeutic strategy for IBD. A meta-analysis from Kassam et al., that used FMT 
treatment, showed 90% of clinical resolution in patients with recurrent Clostridium difficile 
infection (CDI) (Kassam, Lee, Yuan, & Hunt, 2013). Another randomized study, conducted by et 
van Nood al. compared FMT with antibiotics in CDI patients. Cure was achieved in 91% of FMT 
group, whereas only 31% was observed in the antibiotic group (van Nood et al., 2013) . The use 
of FMT to restore a sustained balance in altered microbiota has proven to be successful in treating 
recurrent CD. Currently, several phase I trials of FMT for IBD patients are ongoing, expecting to 
achieve remission and a final treatment for UC and CD (Matsuoka & Kanai, 2015). 
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The GI tract is a complex interface that provides physical barrier against luminal environment 
meanwhile it enables the absorption of dietary nutrients and the exclusion of harmful compounds 
from the intestinal lumen. The ability to control the passage of molecules throughout the mucosa 
is defined as the intestinal barrier function (IBF). The first line of defence is the lumen itself 
where bacteria and antigens are degraded by digestive secretions from the stomach, pancreas and 
liver (Figure 14). Still within the lumen, commensal bacteria also contribute to the defence by 
producing antimicrobial substances and by competing for nutrients (Gerova, 2016). In the 
intestine, like in many other surfaces, microorganisms are organized as biofilms. Luminal 
microorganisms are essential to the modulation of the immune host response and their 
organization in biofilms seems to be important in such effect (Macfarlane, Bahrami, & Macfarlane, 
2011). The second line of defence is the mucus layer, rich in secreted IgA and AMP, thereby 
preventing the access of bacteria to the epithelium (Figure 14). The third barrier is composed by 
the well-sealed monolayer of IECs that avoids toxic molecules and enteric pathogens from 
entering thought the gut tissue. Finally, the ultimate barrier is the mucosal immune system.  
 
 
Figure 14. Structure of the defence lines of the intestinal barrier. (1) The first line of defence 
is the lumen (2) the second is the layer of mucus. (3) Third, the IECs monolayer and the last one 
(4) the gut immune system. Adapted from (Gerova, 2016). 
 
The passage of components from the lumen through the epithelium is achieved by two distinct 
mechanisms: paracellular and transcellular permeability. Paracellular passage is controlled by 
the set of tight junctions and adherens junctions sealing the intestinal monolayer (apical passage 
of water and small molecules). Large particles such as antigens and microbes use the transcellular 
route to cross the epithelium through  enterocytes, dendritic and M cells (Garrett, Gordon, & 
Glimcher, 2010; Salim & Söderholm, 2011).  
Many human diseases including inflammation, metabolic alteration, infection and, neurologic 
dysfunctions are linked to a deficiency of the IBF. Some of them, as IBD, exhibit alterations on the 
four IBF’s defense line.  
 
1. Defective physical and biochemical mucosa  
Dysfunctional gut barrier is a feature of intestinal inflammation. IBD are characterized by an 
exaggerated immune host response towards commensal microbiota which triggers an 
1 
2 
3 
4 
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uncontrolled chronic intestinal inflammation. The interactions within the intestinal barrier are 
altered in IBD context, causing increased intestinal permeability and exposure of luminal 
content to the immune cells underneath the lamina propria (McGuckin, Eri, Simms, Florin, & 
Radford-Smith, 2009). Recent genetic studies have demonstrated the relevance of innate 
intestinal response in IBD aetiology (Coskun, 2014). Defective bacterial and toxic molecules 
clearance, apical sealing complexes, and innate barrier have been involved in the pathogenesis of 
IBD (Salim & Söderholm, 2011) 
 
1.1 Impaired Epithelial Junctions 
It has been demonstrated that patients with both forms of IBD display increased intestinal 
paracellular permeability which breaks down the physical intestinal barrier and its functions 
(Michielan & D’Incà, 2015). Several clinical studies reported abnormal distribution and 
expression of TJs (Lee, 2015; Salim & Söderholm, 2011). A clinical study has shown that patients 
with CD and UC have a disrupted intestinal barrier function with reduced epithelial resistance 
(TEER). Occludin, Claudin-5 and -8 were downregulated and re-localized off the tight junction 
complex, whereas Claudin-2 was strongly upregulated (Zeissig et al., 2007). Another study 
showed the loss of epithelial JAM-A expression in patients with IBD, concluding that JAM-A is 
essential for the maintenance of mucosal integrity and permeability (Vetrano et al., 2008). 
Another study documented that MLCK expression and its enzymatic activity, MLC 
phosphorylation, are enhanced in IBD with a correlation between increased activity and disease 
activity. Thus, active IBD patients have a cytoskeletal dysregulation (Blair, Kane, Clayburgh, & 
Turner, 2006).   
Inflammatory cytokines including TNF-α and IFN-ɣ, which are elevated in the intestine of IBD, are 
able to modulate the transcription of TJs proteins. Moreover, TNF-α induces apoptosis of 
enterocytes interfering then with the distribution of TJs that seal the gaps left (Schmitz et al., 1999; 
Suenaert et al., 2002). IFN-ɣ or TNF-α might alter paracellular permeability by promoting MLCK 
and therefore increasing myosin light chain phosphorylation. Inhibition of MLCK reverses 
increased permeability, indicating an association between inflammatory cytokines and MLCK 
activation (Zolotarevsky et al., 2002). Neutralization of TNF-α resulted in a marked suppression 
of gut inflammation and reduced apoptosis of epithelial cells (Marini et al., 2003). 
 
1.2 Defective mucus layer 
As mentioned above, goblet cells are specialized in the secretion of mucus in the intestine. 
Reduced number of goblet cells is a pathological feature of UC rather than CD (Figure 15) (Pullan 
et al., 1994). Despite, most of the hypothesis concerning UC pathophysiology focus on the 
abnormal immunological response, several papers have investigated the importance of the 
defective inner mucus layer present in active UC (Johansson, Sjövall, & Hansson, 2013). The 
thickness of the mucus layers is reduced in patients with UC with increased bacteria adherence in 
the lining intestinal epithelia and infiltrated bacteria and leukocytes within the mucus of UC 
biopsies (Swidsinski et al., 2007). Some studies have observed that the lack of MUC2 in mice 
induces a severe colitis and even cause cancer by altering intestinal crypt morphology and cell 
maturation and migration (Van der Sluis et al., 2006; Velcich et al., 2002). A study from Chad K. 
Heazlewood et al. reported that mice with Muc2 mutation present altered Muc2 biosynthesis, 
decreased stored mucin in goblet cells, increased barrier permeability and enhanced pro-
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inflammatory cytokines including IL-1β, TNF-α and IFN-γ in the distal colon. Accumulation of 
aberrant muc2 biosynthesis triggers ER-stress and UPR in goblet cells. Despite this, 
inflammation, apoptosis and wound repair are observed in both inflamed and non-inflamed 
colonic tissues of MC2-deficient mice (Heazlewood et al., 2008). Together, these findings highlight 
aberrant mucus layer as the main issue in patients with UC rather than hyperactive immune 
system.  
 
 
Figure 15. Normal gut vs IBD gut. Healthy gut (left) and impaired mucosal barrier in patients 
with IBD (right). Intestinal mucosa of IBD is characterized by metaplasic Paneth cells, decreased 
number of goblet cells, impaired seal between IEC, and deregulation of AMP, decreased mucus 
layer and therefore, pathogens invasion and chronic inflammation. Adapted from (Michielan & 
D’Incà, 2015). 
 
1.3 Defective antimicrobial peptides 
A particular feature of the pathophysiology of CD is the reduced expression of α-defensins and 
dysregulated expression of β-defensins (Gersemann, Wehkamp, & Stange, 2012). It has been 
reported that patients with IBD have metaplastic Paneth cells, normally restricted to the small 
bowel, re-localized in the colonic mucosa with altered function. Thus, secretion of α-defensins 
along the colon is found in patients with CD (Cunliffe et al., 2001; Müller, Autenrieth, & Peschel, 
2005). In healthy individuals, Paneth cells produce large amounts of HD5 and HD6 (α-defensins) 
to protect the mucosal epithelium against harmful pathogens. Some research groups have 
demonstrated that the production of α-defensins in ileal CD is deficient, although it is still 
controversial whereas the number of Paneth cells is affected (Elphick, Liddell, & Mahida, 2008; 
Simms et al., 2008). Deficient α-defensins results in an aberrant antimicrobial shield reducing 
its antibacterial killing capacities and, therefore, being more susceptible to inflammation (table 
5)(L.Zhang, R.Gallo. 2016).  
Unlike the reduction of α-defensins in patients with CD, β-defensins HBD1–3, secreted by goblet 
cells in the colon, are found increased in patients with both forms of IBD. Although goblet cells are 
specialized in the secretion of mucus in the intestine and Paneth cells are the main producers of 
AMP, goblet cells can also produce antimicrobial factors (Antoni, Nuding, Wehkamp, & Stange, 
2014).  
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Mucosal HBD1, normally constitutively expressed, is notably reduced in colonic biopsies of CD 
and UC patients (Jan Wehkamp et al., 2003). On the other hand, HBD2 and HBD3 are largely 
increased, especially in inflamed colonic mucosa of patients with UC (table 6) (Jan Wehkamp et 
al., 2002, 2003). RELMβ is strongly expressed in the lumen of the ileum mice treated with Dextran 
sodium sulphate (DSS). Although the molecule does not alter mucosal barrier function its gene 
deletion reduces the severity of colitis in mice model (McVay et al., 2006). REGIII is also found 
overexpressed in colitis model initiated by DSS (Ogawa et al., 2003). REG family is found increased 
in gastric and colorectal cancers (Zheng et al., 2011). 
The AMP cathelicidins (hCAP18/LL-37) are found significantly increased in both inflamed and 
non-inflamed colonic tissue of UC patients but not CD (Schauber et al., 2006) whereas serine 
proteases inhibitors including Elafin and secretory leukocyte protease inhibitor (SLPI), which 
also act as AMPs, are enhanced strongly only in inflamed colon of UC (Schmid et al., 2007). 
TFF3, secreted together with MUC2 by goblet cells, is involved in the viscosity of the mucus. 
Increased presence of TFF3 in the mucus leads to enhanced viscosity of the mucus, suggesting an 
association of TFF3-mucin to regulate the mucus gel (Kanai, Mullen, & Podolsky, 1998). Although 
TFF3-lacking mice do not develop spontaneous colitis, they demonstrated an increased 
susceptibility to DSS-induced colitis. These findings suggest that mucus quality is important to 
protect against colitis (Mashimo, Wu, Podolsky, & Fishman, 1996; McGuckin et al., 2009).  
 
 
 
Taking all this into account, IBD patients exhibit a depressed intestinal barrier associating a 
disruption of the IEC barrier integrity and a continuous leakage from the lumen of the intestine to 
the inner body, which leads to a permanent inflammation of the gut. 
 
Human Antimicrobial Factors 
Antimicrobial Intestinal 
location 
Cellular location Changes in IBD 
HD5 Ileum  Paneth cells Reduced in ileal CD 
HD6 Ileum  Paneth cells Reduced in ileal CD 
hBD1 Colon  Epithelial and inflammatory cells Reduced in CD and UC 
hBD2 Colon Epithelial and inflammatory cells Increased in UC 
hBD3 Colon Epithelial and inflammatory cells Increased in UC 
RELMβ Colon Goblet cells Increased in DSS model 
REGIII  Paneth cells  Increased in DSS model 
Dextram Sodium sulphate (DSS) 
Dextram Sodium sulphate is widely use to induce colitis in moude model to mimic UC and CD 
pathophysiology. DSS is administrated in the drinking water and after 7 days the animal 
develops an acute or chronic inflammation in the intestine. Although the mechanisme of action 
of DSS is not yet clear, it seems that the detergent damafes the mucosal epithelium of the large 
intestine enhancing the intestinal permeability and allowing the dissemination of luminal 
content into the inner body (Sambasivarao, 2013).  
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Elafin Colon Epithelial and inflammatory cells Increased in inflammatory 
cells 
Decreased in epithelium 
SLP1 Colon Epithelial and inflammatory cells Increased in UC 
Cathelicidins Colon Epithelial and inflammatory cells Increased in UC 
Table 5. AMP involved in IBD. Adapted from (Gersemann et al., 2012) 
 
 
2. Immunological Factors 
Available evidences confirm that the aberrant innate and adaptive immune pathways 
contribute to the intestinal inflammation in IBD patients. The colonic epithelium lies close to a 
high density niche of diverse microbes with a continuous network of interactions. Intestinal 
immune system controls against harmful pathogens at the same time that it allows immune 
tolerance to resident commensal microbiota. Perturbation of this balance leads to intestinal 
inflammation and seems to predispose humans to develop IBD (Abraham & Medzhitov, 2014). 
Immunological studies have focused on the innate immune mucosal response including the 
epithelial barrier integrity, innate bacterial sensing, autophagy and UPR (Y. Z. Zhang & Li, 2014). 
Experimental evidences from in vitro, in vivo and human studies suggest that several pathways 
may influence with inflammatory cascades in patients with IBD. 
IBD patients exhibit a disturbed gut innate immune mechanism. The innate immune response 
is not specific to a particular pathogen and allows the host to mount a quick response to 
aggression, within minutes or hours. This type of immunity responds to recognition of microbial 
antigens mediated by TLRs and NOD-like receptors (Meeting et al., 2000). In healthy conditions, 
PRRs in colonic mucosa are low but constitutively expressed, located basolaterally, to prevent the 
interaction with luminal microbes (Yamamoto-Furusho & Podolsky, 2007). Genetic studies have 
evidenced that several innate immune genes are involved in the pathogenesis of IBD, including 
NOD2 and TLR2 and -4 (Hausmann et al., 2002; Hugot et al., 2001).  
A decade ago, Franchimont et al. reported that TLR4 Asp299Gly polymorphism was associated 
with both UC and CD (Franchimont et al., 2004). TLR4- and myD88-deficient mice had altered 
mucosal healing and disturbed barrier function after DSS administration (Rakoff-Nahoum, Hao, & 
Medzhitov, 2006), suggesting that TLR4 signalling pathway is involved in the initiation of 
intestinal inflammation. A British study shows that mRNA levels of TLR4 are higher in inflamed 
colonic mucosa than in non-inflamed controls in active disease of both IBD types (Hausmann et 
al., 2002; Levin & Shibolet, 2008). In healthy colonic epithelium TLR4 expression is found in small 
amounts on IEC, maintaining a basal state of activation. Upregulation of TLR4 and its accessory 
molecules, CD14, LBP, and MD-2, leads to increased inflammatory cytokines such as IFN-γ and 
TNF-α both known to be present in active IBD (Abreu et al., 2002; Nagai et al., 2002). 
To date, TLR2 is the only TLR able to directly modulate the complex network of epithelial TJ in 
the intestine. Several studies conducted by E. Cario et al. have shown that stimulation of TLR2 
protects TJ integrity and enhances TEER of IECs through apical redistribution of ZO-1. In TLR2-
deficient cells, inflammatory stress stimulus, induced TJ-loss and decreased integrity of the 
barrier (Ey, Eyking, Gerken, Podolsky, & Cario, 2009). In vivo studies demonstrated that TJ 
disruption together with anti-apoptosis failure was observed in TLR2- and MyD88-KO mice under 
inflammatory stress. Stimulation of TLR2 through its ligand PCSK, protects IECs barrier integrity 
Chapter 4. Pathogenesis of IBD 
 
53 | 
 
and decreases intestinal permeability, improving the clinical signs in acute DSS colonic 
inflammation in mice (E. Cario, Gerken, & Podolsky, 2007; Elke Cario, 2010).  
In contrast, other studies demonstrated that TLR-2 and/or -4 ligands are able to increase 
paracellular permeability and expression of inflammatory cytokines including TNF-alpha, IL-1β 
and IL-8, thereby leading to chronic inflammation in mice  (Hedl, Li, Cho, & Abraham, 2007). 
However, MDP (Nod2 agonist) stimulation reduced TLRs agonist effects, inducing intestinal 
permeability normalization, reduced cytokines expression and weakening of colonic 
inflammation. Nod2 mutation or deletion prevented the protective effect of MDP. This protective 
effect was described to be achieved by blocking the nuclear translocation of NF-κB  induced by 
TLRs pathways (Barreau et al., 2010; T Watanabe, Kitani, Murray, & Strober, 2004). 
 
 
3. The role of microbiota  
3.1 Commensal microbiota 
Microorganisms inhabit in our skins, noses, mouths, gastrointestinal tracts and genital tracts and 
build a magnificent symbiotic ecosystem within our body. In humans, over 1012 colony-forming 
units (CFU) of commensal microorganism populate our GI tract.  The three domain of life including 
Arche, Bacteria and Eukarya and viruses are present within the GI microbiota (Donaldson, Lee, & 
Mazmanian, 2015). About 1-2 Kg of microbes constitutes the most complex ecosystem in our body. 
This microbiota not only helps nutrient and drug metabolism but also plays a pivotal role in 
preventing pathogenic colonization and intestinal homeostasis (Rajilić-Stojanović, 2013).   
Among the four predominant bacteria phyla, Firmicutes, Bacteroides, Proteobacteria and 
Actinobacteria present in the healthy human large intestine, the Gram-positive Firmicutes and 
Gram-negative Bacteroidetes are the most abundant (Maria Gloria Dominguez-Bello, Blaser, Ley, 
& Knight, 2011). The interplay between gut commensal flora, IECs and innate and adaptive 
immune cells play a crucial role in maintaining the homeostasis of the intestine preventing 
inflammation or immune-mediated disease (Maynard, Elson, Hatton, & Weaver, 2012). 
Along the GI tract, the diversity in number and phyla of microbes is due to the acidic pH coming 
from the gastric, the bile acid and the level of oxygen (O’Hara & Shanahan, 2006). Stomach and 
small intestine possess an acid habitat along with high levels of oxygen and a wide range of 
antimicrobial factors that roughly shape the composition of the microflora. Moreover, the 
bacteria in the small intestine get washed down very quickly, in contrast with the colon, where 
transit is slower and bacteria can adhere to the mucus. Therefore, the gut flora in the small gut is 
lower than in the colon and it is composed by facultative anaerobes bacteria that tolerates the 
acidity in addition of the ability to compete with other bacteria (Figure 16) (Donaldson et al., 
2015). The microbial microbiota is shaped differently every day depending on the diet, occasional 
infections, or the uptake of drugs such as antibiotics (Tremaroli & Bäckhed, 2012).  
The neonate gut is sterile and the colonization begins right after birth, influenced by the manner 
of delivery, diet and hygiene (Grölund, Lehtonen, Eerola, & Kero, 1999). C-section or natural birth 
influence the microbiota’s development, which might contribute to modifications on the normal 
gut physiology. Intestinal bacteria are essential to establish a mutualistic relationship within the 
gut and influence the energy balance of the body, drug metabolism, selection of pathogenic strains 
and maturation of the immune system (M. G. Dominguez-Bello et al., 2010). Beneficial 
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microbiota plays a crucial role on the development and function of a tolerant immune system and 
avoids overgrowth of opportunistic pathogens. Commensal microbiota has the potential role to 
induce pro- and anti-inflammatory responses shaping the composition of the bacterial 
communities and modulating the proper function of the immune system. One of the other ways 
the gut immune system uses to verify the overgrowth of pathogenic population is by producing 
immunoglobulins (Ig) such as IgA. Some bacteria, especially Gram-negative, activate resident DC 
which, in turn, activate plasma cells to secrete IgA in the intestinal mucosa (He et al., 2007). The 
gut immunomodulation is then perfectly orchestrated with both the innate and adaptive immune 
system. The immunomodulatory components that participate in the intestinal protection are; the 
GALT, regulatory and effector T cells, secretory plasma cells IgA and macrophages and dendritic 
cells residents in the lamina propria.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Composition of the intestinal microbiota. The environment becomes gradually 
anaerobic along the intestine and up to 99% of the flora in the colon is anaerobic. Extracted from 
(Donaldson et al., 2015). 
 
The intestinal microbiota is involved in many important functions in the GI tract. The normal 
commensal flora produces essential nutrients for the host. For example, bacteria are involved in 
numerous metabolic activities, such as fermentation of carbohydrates, use of nitrogenous 
substance and biotransformation of bile acid and other steroids, which provide an important 
energy source for the host (Bäckhed et al., 2012; Macfarlane, Macfarlane, & Durand, 2003; Rajilić-
Stojanović, 2013). Short chain fatty acids (SCFA), such as butyrate or acetate, are the result of 
intestinal fermentation, which are absorbed by the enterocyte and used as energy. Moreover, as 
mentioned above, bacteria synthesize essential vitamins such as vitamin K and B, which cannot 
be produced by the host. The intestinal microflora is also involved in lipid and protein 
metabolisms. Recent studies have also shown the ability of intestinal flora to metabolize 
xenobiotics and drugs (Clayton, Baker, Lindon, Everett, & Nicholson, 2009).  
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3.2 Microbiota in IBD 
Dysbiosis is defined by an abnormal composition of the microbiota mainly described to be related 
to an abnormal ratio between beneficial and harmful bacteria. Dysbiosis breaks down the host-
bacteria mutualism and is likely one of the defining issues in the development of IBD (Hold et al., 
2014). Recent metagenomics studies suggest that not only the quantity of microbiota is reduced 
but also the quality of microbial composition is modified, with a reduction of Firmicutes and 
Bacteroidetes (Comito & Romano, 2012; Scaldaferri & Fiocchi, 2007). Among the phylum 
Firmicutes, the reduced presence of the Fecalibacterium prausnitzii species has been well 
reported in patients with CD in contrast to healthy controls. This bacteria might be essential to 
maintain colonic homeostasis since its reduction decreases the protection of the gut mucosa 
(Sokol et al., 2009).   
Bacteria that belongs to Proteobacteria are known to be the most pathogenic phylum in humans. 
They are found increased in patients with IBD. This interesting shift might be a key factor involved 
in the pathophysiology of the disease, suggesting that Proteobacteria play a harmful role in the 
initiation and/or the maintaining states of chronic inflammation in IBD patients (Mukhopadhya, 
Hansen, El-Omar, & Hold, 2012). It is well documented that patients with IBD have increased 
levels of Escherichia coli, especially the pathogenic variant Adherent/Invasive E. coli (AIEC) 
attached at the surface of the ileal epithelium (Darfeuille-Michaud et al., 2004). In addition, 
quantities of the molecular enterotoxin B. fragilis expressed by Bacteroides fragilis has been 
found altered in patients with active IBD (Prindiville et al., 2000). There is also an alteration of 
microbiota composition between inflamed areas and non-inflamed mucosa associated with a 
deficit in function and production of AMP such as defensins (Matricon, Barnich, & Ardid, 2010). 
The disturbance of commensal microbiota in the pathophysiology of IBD also affects the 
production of bacteria metabolites. CD and UC patients display a decreased production of SCFA, 
which is mainly produced in the lumen of the colon. Besides being a major source of energy for 
IECs, SCFA are known to exert anti-inflammatory effects (Thibault et al., 2010). 
Biofilms are composed by a group of microorganism, attached to a surface, embedded together 
with an extracellular matrix named extracellular polymeric substances (EPS). Biofilms are largely 
found in the lower GI tact, playing an important role digesting substances (Macfarlane et al., 2011). 
Biofilms are formatted by to phases: the adhesion phase, where bacteria adhere to a substrate 
surface, and the maturation phase where bacteria proliferate and differentiate. Depending on 
the genetics of each microorganism specie, the biofilms display the ability to disseminate or 
increase biofilm formation. Moreover some biofilms-derived form might get resistant to 
environmental stress such as antibiotic treatment, leading to chronic infections (Srivastava, 
Gupta, Kumar, & Kumar, 2017). Parket et al. shown in 2003 the thigh relationship between 
pathogenic biofilm formation and inflammatory disease such as IBD (Parsek & Singh, 2003). Some 
studies focus on bactericidal and antibiofilm therapies to treat IBD.  
 
 
4. Genetic polymorphism involved in IBD pathophysiology 
As mentioned in chapter 3 section 5.A, genetic predisposition and environment factors are the two 
main imputs favouring the development of IBD. Studies of the genetic loci implicated in IBD 
reported that different pathways, essential for the maintenance of intestinal homeostasis, are 
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disrupted. This section focuses on the three main pathways involved in IBD including NOD2, 
autophagy and ER-stress (Liu & Stappenbeck, 2016).  
 
4.1 NOD2 
A) NOD2 mechanism of action 
In healthy conditions, NOD2, encoded by the CARD15 gene, recognizes muramyl dipeptide 
(MDP)-mentioned in chapter 2 section 3.2 B-, a fragment of peptidoglycan (PGN) found in the 
cell walls of both Gram-positive and negative bacteria. Upon ligand sensing, NOD2 undergoes auto 
or hetero-oligomerization with Nod1 and/ or other Nod2 receptors, which, in turn, activate the 
downstream adaptor molecule RIP2 (also termed RICK). This NOD2-RIP2 interaction seems to be 
essential for the induction of cytokines, since mice carrying RICK mutation do not respond to MDP 
stimulation (Henckaerts & Vermeire, 2007; Park et al., 2007). Activation of RIP2 recruits and 
activates TAK1complex (TAK1-TAB2-TAB3), which leads to activation of IκB kinase (Iκκ) 
complex. Iκκ phosphorylates and degrades NF-κB inhibitor (IκBa) which activates NF-κB 
(Philpott, Sorbara, Robertson, Croitoru, & Girardin, 2014). On the other hand, NOD2 activates also 
MAPK signalling pathway thought the regulation of ERK1, ERK2, JNK and p38 (W Strober & 
Watanabe, 2011). Both signalling pathways NF-κB and MAPK trigger pro-inflammatory 
signaling cascade including the expression of TNF-α, IL-6, IL-8 and some defensins (Fritz et al., 
2005; Rubino, Selvanantham, Girardin, & Philpott, 2012). 
PGN is also recognized by TLR-2, and like NOD2, TLR2 activation results in NF-κB activation and 
therefore induction of pro-inflammatory cytokines (Borm, van Bodegraven, Mulder, Kraal, & 
Bouma, 2008). Because TLR2 and NOD2 are activated by PGN targeting NF-ΚB, both signalling 
pathways might coordinate pathogen responses. Watanabe. et al have shown that in 
physiological conditions, NOD2 inhibits TLR-2-driven activation of NF-κB, to control colonic 
inflammation induced by commensal microbiota (NOD2 is a negative regulator of Toll-like 
receptor 2–mediated T helper type 1 response). Cells depleted in TLR2 do not respond to PGN 
stimulation leading to a failure of PGN-induced cytokine production. Macrophages lacking NOD2 
stimulated with PGN produced more IL-12 than NOD2-sufficient macrophages. To evidence a 
possible cross-regulation between TLR2 and NOD2, APC cells with and without NOD2 were co-
stimulated with PGN and MDP. NOD2-sufficent cells reduced the production of IL-12, meaning 
that NOD2 might regulate negatively PGN-induction(Tomohiro Watanabe, Kitani, Murray, & 
Strober, 2004). Although it has not been corroborated yet, speculation is that in the absence of 
NOD2, PGN induces the activation of NF-κB producing large amounts of pro-inflammatory 
cytokines. In contrast, MDP downregulates PGN-mediated signaling through TLR2, regulating 
inflammation against microbiota (Warren Strober, Murray, Kitani, & Watanabe, 2006).   
Besides the regulatory role of NF-κB induction, NOD2 is able to act as a bacterial killer, it induces 
cytokines and stimulates and maturates antigen-presenting cells (APC), thereby regulating the 
adaptive immune response (Philpott & Viala, 2004). 
 
B) NOD2 in CD 
In genome-wide-associated studies from the Human Genome Project, three NOD2 
polymorphisms Arg702Trp, Gly908Arg, and Leu1007fsinsC, were found associated to a genetic 
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risk factor for CD. These three mutations are located in the LRR domain affecting the recognition 
and the fixation of MDP (Figure 17) (Hugot et al., 2001; Ogura et al., 2001).  
 
 
 
Figure 17. NOD2 protein. Within LRR region, triangles indicate an amino acid change due to a CD 
associated polymorphism. Adapted from (Philpott et al., 2014). 
 
CD is a consequence of an excessive response to commensal organisms leading to mucosal 
immune system reactivity and increasing Th1-cell mediated inflammation. Although the 
mechanism by which NOD2 mutation influences the development of CD is poorly understood, CD-
associated NOD2 polymorphisms lead to a loss of function of MDP-downstream pathways, 
promoting gut inflammation and compromising the ability to control gut microflora 
(Chamaillard et al., 2003; Mondot et al., 2012).  
Two different hypotheses have been suggested to explain the possible association of NOD2 with 
CD susceptibility. The first model is that in the absence of functional NOD2 protein, TLR2 and/or 
TLR4 are not negatively regulated and this leads to an excessive NF-κB response and production 
of inflammatory cytokines by innate and adaptive immune cells , which in turn, drives gut 
inflammation (Becker et al., 2003; Macpherson & Harris, 2004). Besides, IECs NOD2 
polymorphisms have been associated with a reduced capacity to produce AMPs, altering this line 
of host defence. Moreover, CD patients displayed a reduction of α-defensin-5 and -6 in the ileal 
mucosa, especially in those patients with NOD2 polymorphisms (J Wehkamp et al., 2004). It has 
been shown that Paneth cells deficient for NOD2 have a decreased mRNA expression of α-
defensin. Moreover both WT and NOD2-/- mice challenged with L. monocytogenes are susceptible 
to liver infection, although knock-in NOD2 mice exhibit severe bacterial infection (Kobayashi et 
al., 2005b). Nonetheless, these data are contradicted by some other research articles showing that 
deficient α-defensin production is not associated with NOD2. For instance, J. Robertson et al. 
demonstrated that NOD-2-deficient mice did not exhibit any modification in bacterial 
communities or the expression of immune signs(Robertson et al., 2013). However, another study 
contradicted the previous one and showed that Nod2-mutated mice, mimicking CD mutation in 
NOD2, present a gain-of-function that leads to increased IL-1β (Maeda et al., 2005). However 
these results cannot be reproduced neither in human studies using macrophages or peripheral 
blood mononuclear cell (PBMC) , nor in animal studies (Inohara et al., 2003; J. Li et al., 2004).  
 
4.2 Autophagy 
A) Basal autophagy 
Autophagy is a self-degradative process important for cell survival and that regulates the source 
of energy at critical moments in response to nutrient starvation. It also plays a role in removing 
misfolded proteins, clearing damaged organelles, it breaks down intracellular pathogens and 
processes them for APC (Glick, Barth, & Macleod, 2010). A basal level of autophagy is needed for 
the cells to adapt to their environment, and to exert surveillance in order to maintain tissue 
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homeostasis (Mizushima, Levine, Cuervo, & Klionsky, 2008). Autophagy is a crucial feature in the 
maintenance of gut homeostasis. The intestine is continually challenged by physical and chemical 
stressors. While maintaining an accurate balance between host tolerance and microbial loads, 
autophagy induced by internal and external inputs, provides control and adaptation to cells under 
cellular stress. Autophagy can be divided in three different types, all of them leading to 
intracellular proteolytic degradation: macro-autophagy, micro-autophagy and chaperone-
mediated autophagy 
Macroautophagy refers to non-selective intracellular degradation and it consists in four different 
steps including: initiation, nucleation, elongation and fusion. A double membrane-bound vesicle 
engulfs random cargo followed by elongation and maturation of the vesicle into autophagosome. 
Orchestrated by several number of autophagy genes (ATGs), autophagosome merges with the 
lysosome driving the cargo to degradation (Figure 18) (Glick et al., 2010). The autophagy gene 
ATG16L1 (autophagy-related 16-like 1) plays a crucial role in the stabilization of the 
autophagosome. Together with ATG12-ATG, the complex associates with the outer member of the 
autophagosome generating from associated protein 1 light chain 3 (LC3)-I to LC3-II and thereby 
supporting the elongation and maturation of autophagosome (Figure 18) (Fujita et al., 2008; 
Mizushima et al., 2001).  
Unlike regular autophagy, micro-autophagy is a non-selective lysosomal degradation by which 
cytosolic cargo is taken up straight by the lysosome via invagination of its own membrane (W. W. 
Li, Li, & Bao, 2012). In chaperone-mediated autophagy (CMA), substrate proteins are carefully 
translocated into the lysosomal lumen through a translocation complex of chaperones located in 
the lysosomal membrane. CMA involves a selective timed degradation of specific proteins with a 
regulatory cell function (Cuervo & Wong, 2014). 
 
Figure 18.  Autophagy mechanism. Autophagy is a multi-step process which includes initiation, 
formation of autophagosomes, a double membrane-bound vesicle that engulfs and delivers 
cytoplasmic material to lysosomes, for digestion, maturation, and degradation.  Adapted from 
(Tomoya Iida, Kei Onodera, 2000) 
 
B) Autophagy Variants as risks factor for IBD 
Genome-wide association studies have identified variants in autophagy genes ATG16L1 and 
IRGM (immunity-related GTPase family M) as genetic risk factors for CD, involving autophagy 
pathway in the course of the disease (Lassen et al., 2014; Parkes et al., 2007).  
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GWA approaches have identified a threonine-to-alanine substitution (T300A) in the autophagy 
gene ATG16L1associated with increased risk of developing CD but not UC. To date, 58.1% of CD 
patients carry this variant, particularly patients with ileal CD (Wellcome trust consortium Case, 
and Consortium 2007; Prescott et al. 2007). CD patients, homozygous for ATG16L1/Ala300 
variant, present “loss-of-function” autophagy due to the impairment of autophagosome 
formation which, in turn, displays an altered capacity to handle and clear cytoplasmic content 
such as bacteria (Muzes, Tulassay, & Sipos, 2013). Human epithelial cells coding ATG16L1 variant 
show aberrant engulfment and degradation of internalized Salmonella within the autophagosome 
(Kuballa, Huett, Rioux, Daly, & Xavier, 2008). Another study shows that ATG16L1 mutant intestinal 
cells exhibit a deficiency for pathogenic adherent-invasive Escherichia coli (AIEC) clearance. This 
pathogen colonizes ileal lesions of CD patients, compared to control cells which are able to control 
the replication of the pathogenic bacteria (Bedran-Russo, Karol, Pashley, & Viana, 2013). 
Moreover, hypomorphic mice ATG16L1/T300A risk allele (ATG16L1HM mice), Paneth cells 
exhibited abnormalities in their granules of secretion containing AMPs. Its aberrant phenotype 
includes, fewer and disorganized granules with a disrupted granule exocytosis, decreased 
number of lysozyme and increased transcription of inflammatory mediators (Cadwell et al., 
2008). The same study reports that patients with CD homozygotes for the ATG16L1 risk variant 
display similar impaired structure in Paneth cells than those observed in ATG16L1KO mice. Also, 
impaired autophagy is associated with nucleation and elongation of autophagosome in goblet 
cells, driving a deficiency in mucus secretion (Patel et al., 2013). IRGM is the second autophagy-
related gene identified in a genome-wide association study associated with CD. A single nucleotide 
polymorphism exhibits a decreased expression of IRGM and decreased capacity of autophagy to 
clear up intracellular bacteria (Mccarroll et al., 2009). Brest et al. have demonstrated that mutated 
IRGM alters autophagy efficiency compromising the intracellular control of bacteria invasion, 
leading to infection in CD patients (Brest et al., 2011).   
 
C) NOD2 and the link with autophagy 
NOD2 has also been described to play a pivotal role in the induction of autophagy to eliminate 
intracellular pathogens (xenophagy). NOD2 is known to interact with ATG16L1, a molecular key 
within the autophagy network (T Watanabe et al., 2004). Previous studies showed that NOD2 
recruits ATG16L1 and co-localize at the plasma membrane to facilitate the initiation of the 
autophagosome (Balzola, Bernstein, Ho, & Lees, 2010). However, cells with NOD2 mutation failed 
to recruit ATGL16, impairing the autophagosome formation (Balzola et al., 2010). Thus, 
malfunction of NOD2 impacts not only the killing and handling of pathogenic microbes but also its 
presentation by the major histocompatibility complex class II (MHC-II) to induce immune 
response (Cooney et al., 2010; Hold et al., 2014).  
 
4.3 Endoplasmic reticulum Stress  
A) Endoplasmic reticulum stress and cellular homeostasis 
The ER is an essential subcellular organelle responsible for the synthesis and maturation of 
proteins that traffic through the secretory pathway. It confers an optimal environment to 
assemble and maturate proteins. The “milieu” of the ER contains molecular chaperones and 
folding factors essential for the quality control of the folding protein (Hetz, Martinon, Rodriguez, 
& Glimcher, 2011). Within ER, take place the co-translational and post-translational 
modifications of proteins including formation of disulfide bonds, signal-peptide cleavage, N-
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linked glycosylation and glycophosphatidylinositol (GPI)-anchor (Ellgaard & Helenius, 2003). 
Failure of protein folding is detected before it reaches the final folded state and is degraded 
through the ER-associated degradation (ERAD) pathway.  
Aggregation of unfolded or misfolded proteins due to changes in the environment such as 
modification of Ca2+ levels, oxidation-reduction conditions, or inflammation leads to a dysfunction 
within ER, termed then ER stress (Wang & Kaufman, 2014). ER-stress triggers UPR in order to 
adapt cells to harmful environment and to solve ER disturbances (A. Kaser & Blumberg, 2010). In 
order to bring back the folding capacity of the ER, UPR signaling pathway decreases the folding 
demand by downregulating the transcription of gene set and increasing its abilities to clear the 
misfolded proteins via ERAD. UPR also upregulates the transcription of genes involved in quality 
and control of folding proteins. The three main sensors of UPR are ER transmembrane proteins 
including inositol-requiring enzyme-1α and β (IRE1α and β), protein kinase-like ER kinase 
(PERK), and activating transcription factor 6 (ATF6) (Figure 19)(Schröder & Kaufman, 2005; 
Walter & Ron, 2012). If those mechanisms fail in adapting the cell to new conditions and 
recovering ER homeostasis, the cell undergo cell death by apoptosis. 
In homeostatic conditions, ER chaperone binding immunoglobulin protein (BiP), also named 
glucose-regulated protein 78 (GRP78), maintain UPR sensors inactive by interacting with their 
luminal domain (Figure 19). Aggregation of unfolded or misfolded proteins disassociates BiP from 
the luminal domains of the ER-stress sensors, thereby initiating UPR downstream signalling 
pathway (Cao, 2015).  
 
 IRE1 
IRE1 (type I transmembrane kinase) displays two isoforms, IRE1α expressed ubiquitously and 
IREβ mainly expressed by the epithelial cells of the gut and respiratory tract (Figure 19). Once BiP 
is unbound from the N-terminal domain of IRE1, the protein dimerizes and auto-phosphorylates 
in order to become active. Activated IRE1splices 26-base intron from XBP1 mRNA (Yoshida et al., 
2003). This new spliced form, XBP1s, is a unique transcription factor that regulates genes 
responsible for ERAD and a number of subsets of ER chaperones (A. Kaser, Lee, Franke, & 
Glickman, 2008; Mimura et al., 2016).  
 
 PERK 
Similar to IRE1, PERK (type I transmembrane kinase) undergoes auto-phosphorylation and 
oligomerization upon ER-stress. Activated PERK suppresses global protein translation by 
phosphorylating the α-subunit of eukaryotic translation initiation factor 2 (eIF2a) (Figure 19). 
Besides reduced mRNA translation, PERK activation selectively translates a subset of mRNA such 
as the transcription factor ATF4, which regulates the gene expression involved in antioxidant 
response, amino acid biosynthesis and cell survival promotion (Harding et al., 2000; Wang & 
Kaufman, 2014). ATF4 also induces the transcription of CCAAT/enhancer-binding protein 
homologous protein (CHOP), which is required for ER stress-mediated apoptosis and the 
transcription of DNA damage-inducible protein 34 (GADD34), to arrest cell growth (Cao, 2015). 
Prolonged ER-stress, due to misfolded proteins or oxidative stress or altered Ca2+ homeostasis, 
drives the cell to apoptosis through upregulation of CHOP and therefore activation of caspase-8 
signaling cascade (Min Lu, David A. Lawrence, Scot Marsters, Diego Acosta-Alvear, Philipp 
Kimmig, Aaron S. Mendez, Adrienne W. Paton, James C. Paton, 2014).  
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 ATF6 
Upon aggregation of misfolded proteins, ATF6 (type II transmembrane protein) dissociates from 
BiP and traffics to the Golgi apparatus, where it is processed in its luminal domain by site-1-
protease (S1P) and in its transmembrane region by S2P (Figure 19). Cleaved ATF6 regulates the 
transcription of UPR-targeted genes including, ER chaperone genes, components of ERAD, and it 
promotes protein folding, maturation and secretion as well as the expression of XBP1 (Yamamoto 
et al., 2007; Yoshida, Matsui, Yamamoto, Okada, & Mori, 2001). ATF6 is a crucial transcriptional 
regulator of the mammalian UPR and its absence might result in cell death due prolonged ER 
stress.  
In addition to regulating UPR target genes, IRE1, PERK and ATF6 target the apoptotic downstream 
signaling pathway NF-κB and JNK. Activation of NF-κB under stress conditions drives the cell to 
modulate apoptotic pathways. In response to ER stress, IRE1α binds to the Iκκ complex which 
in turn, activates NF-κB (Figure 20)(Hu, Han, Couvillon, Kaufman, & Exton, 2006). 
 
B) Endoplasmic Reticulum Stress in intestinal inflammation and IBD 
Recently, IBD genetic studies have identified susceptible risk alleles, such as XBP1 and ARG2 
(Anterior Gradient 2), both involved in ER-stress and UPR signalling cascade, associated with the 
pathogenesis of IBD. Previous studies showed that genetic deletion of components involved in 
UPR are linked with spontaneous intestinal inflammation and/or enhanced sensitivity to DSS to 
induce colitis (a Kaser and Blumberg 2009) 
Animal studies reported that induction of ER-stress in mice with IECs-specific deletion of XBP1 
exhibit an spontaneous development of intestinal inflammation carrying the hallmarks of 
human IBD including loss of Paneth cells, mononuclear and polymorphonuclear cells infiltration 
and severe ulcerations in the small bowel (A. Kaser et al., 2008). IECs of the small intestine of 
Xbp1KO mice present an increased GRP78, leading to enhanced apoptosis, a reduced number 
of Paneth cells and the absence of its secretory granules, together with decreased release of 
AMPs. Thus, dys-regulation of ER-stress contributes to spontaneous inflammation in the small 
intestine, and compromises host defence against enteropathogens (Hosomi, Kaser, & Blumberg, 
2015). Similar to mice-deficient for Nod2 or ATG16L1 which are associated with handling and 
cleaning pathogens defects, hypomorphic XBP1 mice also show a defective intracellular bacteria 
sensing. Aberrant XBP1 provokes an accumulation of unfolded and misfolded proteins, not letting 
important proteins such as AMPs translate and secret correctly. This means that ER-stress 
pathway is important for the AMPs activity in the epithelium to control bacterial invasion 
(Cadwell et al., 2008; Kobayashi et al., 2005a). Paneth cell–specific deletion for Xbp1 promotes 
also spontaneous ileal inflammation, as observed in IEC Xbp1-deficient mice (Adolph et al., 2013).  
XBP1-mediated signalling is the most conserved branch of UPR, which prevents constitutive ER-
stress and plays a key role in inflammatory and immune processes (Bettigole & Glimcher, 2015; 
Kaufman & Cao, 2010). However, mechanisms by which XBP1-defiency leads to intestinal 
inflammation are not well defined yet. Basal levels of ER-stress are always present in the intestine, 
but when cells are not able to properly manage the stress, the intestine undergoes through 
spontaneous inflammation and epithelial cells are more sensitive to environmental factors 
triggering gut inflammation. Mice with Xbp1-deficiency promote massive activation of IRE1 in 
ileal mucosa, leading to the activation of JNK and NF-κB pathways, which, in turn, increase the 
production of inflammatory mediators in the gut such as TNF-α, IL-1 and monocyte 
chemoattractant protein 1 (MCP1) (Mahdi, Rizvi, & Parveen, 2016). Previous studies have 
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demonstrated that colonic epithelial cells from patients with UC have a dys-regulated activation 
of eIF2a leading to changes in protein translation, including anti-oxidative enzymes, junctional 
proteinsa nd secretory pathways, and altered colonic mucosa barrier function (Tréton et al., 
2011). Ravindran et al have demonstrated PERK protein upregulation in inflamed colonic tissue 
of UC and CD patients, compared to healthy controls (Ravindran et al., 2016). 
Another study showed that IRE1β-/- mice exhibited increased ER stress and early exacerbated 
inflammation upon DSS colitis (Bertolotti, 2001). In 2013, Tsuru et al. reported that IRE1β is 
involved in the translation and secretion of mucin. IRE1 β-deletion mice accumulates aberrant 
MUC2 in the lumen of ER of goblet cells increasing the ER stress signal such as ER distention and 
increased XBP1 mRNA splicing form. These results suggest that IRE1β promotes the folding and 
secretion of mucins in Goblet cells (Tsuru, 2013). The development of spontaneous colitis and 
rectal bleeding is observed in IRE1α-deficient mice along with diminished number of goblet cells 
and damaged intestinal barrier function. ER-stress signals showed downregulation of Xbp1s 
mRNA and upregulation of CHOP (H.-S. Zhang et al., 2015).  
Another study observed that CHOP exacerbates the development of colitis by contributing to 
apoptosis of colonocytes. CHOP-deficient mice show an improvement upon colitis and a decreased 
number of apoptotic cells compared to wild-type mice. In conclusion this study reported that 
down-regulation of CHOP might contribute to ameliorate colitis (Namba et al., 2009).  
Anterior Gradient 2 (Agr2) is a protein disulfide isomerase that plays an important role 
regulating intestinal homeostasis. Agr2-/- mice display abnormal location of Paneth cells into the 
villi of the ileum impairing the secretion of its proteins. These mice also have a decreased number 
of goblet cells, Mucin2 expression and a constitutive induction of ER stress in intestinal mucosa. 
These results suggest a correlation between Agr2 in intestinal homeostasis, ER stress and the 
etiology of IBD (Zhao et al., 2010) 
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Figure 19. The three major sensors of UPR. Three families of signal transducer, ATF6, IRE1 and 
PERK, sense the accumulation of misfolded proteins in the lumen of ER, and transfer the signal to 
the nucleus to regulate the transcription of UPR target genes. The transcriptional response 
increases the capacity of protein folding at the same time that downregulate the translation of 
proteins and increases degradation through ERAD. Extracted from (Kadowaki & Nishitoh, 2013) 
 
 
 
 
Figure 20. Apoptosis signalling under ER stress. Extended ER-stress or dysfunction of the UPR, 
induced apoptosis signalling through IRE1 and PERK pathways. Active PERK increases levels of 
CHOP which, in turn, activates the transcription of GADD34. GADD34 dephosphorylates eIF2a, 
increasing protein load into the ER. On the other hand, activated IRE1 promotes activation of NF-
κB, JNK and p38, involved in apoptotic-induced response. Adapted from (Kadowaki & Nishitoh, 
2013). 
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1. Proteases in the gut  
Proteases, also known as proteinases and peptidases, are degradative enzymes for protein 
catabolism that hydrolyse a peptide bond to generate amino acids (López-Otín and Bond 2008). 
Proteases play a crucial role in controlling various biological processes, both intra- and 
extracellularly. They regulate and generate new bioactive molecules, modulate protein-protein 
interaction and process crucial cellular information. Thus, in the gut, proteases influence stem cell 
mobilization, blood coagulation, inflammation, autophagy, apoptosis and other multiple vital 
cellular functions (Antalis et al. 2007).  
Proteases consist of 2% of the mammalian genome and they can be distributed in five groups 
depending on the mechanism of hydrolytic cleavage: serine-, metallo-, cysteine-, aspartate- and 
threonine proteases. Serine, Metallo and Cysteine proteases are the most important proteases 
regulating biological functions (Figure 21).   
 
 
 
 
Figure 21. Protease wheel. Scheme of the phylogenetic tree of human and mouse proteases. 
Proteases are classified in five catalytic classes and 63 different families. Metalloproteases are the 
biggest class of enzymes in both organisms. Adapted from (Puente et al. 2003) 
 
The proteolytic activity needs to be tightly regulated since exaggerated proteolysis might lead to 
tissue damage. As it will be discussed further, dysregulation in protease balance has been 
reported in gastrointestinal diseases such as IBD or Irritable bowel syndrome (IBS) (Nathalie 
Vergnolle 2016). The proteolytic activity is regulated by various mechanisms in order to keep 
the ideal balance. First, proteases are synthesized as inactive zymogene that becomes activated 
through proteolytic cleavage by upstream protease, pH shift or dimerization. Another manner to 
regulate its activity is by natural endogenous inhibitors (Van Spaendonk et al. 2017; Edgington-
Mitchell 2016). The protease inhibitors present in the GI tract come from either circulation 
(distant production from other digestive organs such as liver), or locally produced by IECs or 
infiltrated inflammatory cells (Nathalie Vergnolle and Chignard 2006).  
The GI tract is the organ containing the highest amount of proteases, both endogenous and 
exogenous. The microbial community, including bacteria yeast and helminths, are also an 
important source of proteases (Carroll and Maharshak 2013). Besides complex cellular signalling 
pathways, proteases in the gut are critical for digestion and maintenance of protein homeostasis 
(Edgington-Mitchell 2016). IECs themselves express a wide spectrum of proteases crucial for the 
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regulation of their environment, such as matrix metalloproteases that help in the turnover of the 
extracellular matrix (ECM) (Naito and Yoshikawa 2005). Proteases influence the regulation of 
intestinal permeability, either by targeting directly the tight junction proteins that seals the 
IEC monolayer or indirectly through the activation of protease-activated receptors (PARs) - 
Described in chapter 5 section 3- (Nathalie Vergnolle and Chignard 2006).  
 
 
2. Proteases and their inhibitors  
2.1 Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a group of zinc- dependent endopeptidases known to 
degrade and remodel components of the ECM. They are secreted as inactive zymogens by 
different cell types including mesenchymal cells, T cells, polymorphonuclear leukocytes, 
keratinocytes, tumor cells and enterocytes (Pender and MacDonald 2004). Depending on their 
substrate specificities, MMPs are subdivided in six groups: Collagenases, gelatinases, 
stromelysins, matrilysins, membrane-types MMPs and non-classified MMPs.  
Besides ECM turn over, MMPs are involved in other tissue maintenance functions such as wound 
healing and regulation of a broad range of molecules such as chemokines, cytokines, growth 
factors, cytoskeleton and junctional proteins (Rodríguez, Morrison, and Overall 2010). 
Dysregulation of MMP activity leads to the development of several pathologies including chronic 
inflammatory diseases  as IBD and cancer (Louis et al. 2000). 
Endogenous inhibitors of MMPs, known as tissue inhibitors of metalloproteinases (TIMPs) are 
classified in four groups: TIMP-1-4 (Brew and Nagase 2011). Dys-function or altered expression 
of TIMPs is associated with inflammation and tissue damage. TIMPs are tissue-specific, 
constitutively or inductively expressed and their transcription depends on some cytokines and 
growth factors (Murphy 2011) . 
 
2.2 Serine proteases  
Serine proteases are enzymes that hydrolyze peptide bonds in proteins, in which serine serves as 
the nucleophilic amino acid at the active site. Serine proteases are the most abundant group of 
proteases including over 26,000 serine peptidases classified into 13 clans and 40 families. Serine 
proteases are widely distributed in nature and present in the three domains of life (archaea, 
bacteria, and eukaryote) and even in viral genomes (Page and Di Cera 2008). Widespread 
throughout the human body, serine protease are usually endopeptidases which hydrolyse the 
peptide bond in the middle of a polypeptide chain. However, exopeptidases, that cleave only 
terminal amino acid residue, have been also found involved in the digestion. They act at a neutral 
pH and are involved in many diverse biological processes such as digestion, blood coagulation, 
apoptosis and fight infections (Cera 2009). The mechanism of action of serine proteases is 
described to attack the carbonyl moiety of the substrate peptide bond to form an acyl-enzyme 
intermediate.  
Mammalian serine proteases comprise plasminogen activators, chymotrypsin, trypsin and 
proteolytic enzymes produced by polymorphonuclear cells, such as cathepsin G and neutrophil 
elastase. Bacteria from commensal microbiota are also an important source of proteases present 
in the GI tract. 
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As mentioned above, a broad spectrum of proteases inhibitors is crucial to regulate the 
enzymatic activity. It exists two families of endogenous serine proteases inhibitors, Serpins and 
Chelonianins. Both inhibitors bind to the target protease disrupting its active site in an 
irreversible manner. Serpins are the largest and most widely distributed superfamily of protease 
inhibitors (Law et al. 2006). They circulate throughout the GI tract regulating serine proteases 
including trypsin, chymase, tryptase, elastases, and cathepsin G (Nathalie Vergnolle 2016). 
Another family of extracellular serine protease inhibitor, chelonianin, includes secretory 
leukocyte proteinase inhibitor (SLPI) and elafin (Zani et al. 2009). Chelonianin family inhibits 
the proteolytic activity of neutrophil serine proteases (NSPs) such as elastase, proteinase 3, and 
cathepsin G.  
 
 Trypsin-like serine protease 
Trypsin-like belong to the group of serine endopeptidase, produced and secreted as inactive 
zymogen precursors for the most part in the pancreas. The inactive zymogen (or trypsinogen) 
becomes active by enterokinase cleavage in the duodenum, where they act as major digestive 
enzymes (Rinderknecht 1986). Besides digestive properties, active trypsin forms are involved in 
proteolytic cascade by activating other proteases. Trypsinogens cleaves a peptide bond on the 
carboxyl- terminal side of arginine or lysine residues except when these residues are directly 
associated with a proline residue (Siepen et al. 2007).  
Human pancreatic juice produces three different isoforms of trypsinogen: Trypsinogen-1 
(cationic), trypsinogen-2 (anionic) and trypsinogen-3 or mesotrypsin. They are expressed not 
only in the pancreas, but also in other tissues, such as in various epithelial cells tissues, human 
brain and tumors (Koshikawa et al. 1997). Trypsinogens are encoded by the PRSS (protease 
serine) gene: PRSS1 (trypsinogen-1), PRSS2 (trypsinogen-2), found at proximal loci on 
chromosome 7q35, and PRSS3 (trypsinogen-3 or mesotrypsin), located on chromosome 9q13 
(Itkonen 2010; Chen and Ferec 2000). While cationic and anionic trypsins share 96% of homology, 
trypsin-3 shares 87.8% and 88.7% identity with trypsin-1 and trypsin-2 respectively. Trypsin-1 
and trypsin-2 are the most abundant isoforms secreted by the pancreas, accounting for 13% and 
6% of pancreatic juice respectively. Both enzymes are responsible for protein degradation 
associated with physiological digestion and are inhibited by serpins.  
On the other hand, human trypsin-3, the latest trypsinogen to be discovered,  is found in a lower 
proportion secreted by pancreas and it is known to be resistant to inhibition by proteases 
inhibitors (Rinderknecht, Renner, and Carmack 1979). No endogenous inhibitor of trypsin-3 
has been identified so far. Hence, trypsin-3 possesses the catalytic ability to cleave the reactive 
sites of canonical trypsin inhibitors including soybean trypsin inhibitor (SBTI) or human 
pancreatic secretory trypsin inhibitor (SPINK1) (Sahin-Tóth 2005; Gangaraju Vamsi K. Lin 
HaifanRichárd Szmola, Zoltán Kukor 2009). Besides trypsin-3, exist at least two other 
differentially-spliced forms of PRSS3, trypsinogen-4 and -5, encoded by alternative promotors 
and expressed differently depending on the tissues. Trypsinogen-4 is highly expressed in human 
brain and at lower levels in other tissues and tumors. Trypsinogen-5 expression is localized 
specially in the brain, gut, uterus and keratinocytes (Rowen et al. 2005; Salameh and Radisky 
2013).  
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Recently, it has been discovered the implication of trypsin-3, produced by epithelial cells, in some 
disease such as IBS (Kerckhoffs et al. 2008; Rolland-Fourcade et al. 2017) . This section will be 
mentioned below.  
 
2.3 Cysteine proteases 
Most of the cysteine proteases are found intracellularly. Besides their fundamental functions of 
catabolism and protein processing, cysteine proteases mediate other signalling pathways 
involved in programmed cell death and inflammation. Cysteine group comprises caspases, 
autophagins, calpains and deubiquitinases intracellularly and cathepsins B, K and L extracellularly 
(Nathalie Vergnolle 2016). Caspases are a well-known family of cysteine proteases that play a 
role in cell death. Caspase 8 is involved in apoptosis and inflammation, both activating NFKB 
signalling pathway leading to pro-apoptotic gene transcription (Man, Kanneganti, and Jude 2016). 
It has been reported that increased cysteine proteases affect the intestinal mucosa integrity 
targeting inflammation and cell death signalling pathways (Ruemmele, Seidman, and Lentze 
2002). Cathepsins play an important role in degrading intracellular proteins, and maintaining the 
intestinal epithelium turnover and homeostasis(Tamhane et al. 2016). Altered activity of caspases 
or cathepsins is associated with IBD(Menzel et al. 2006).  
To avoid unwanted protein degradation, like other proteases, cysteine proteases are synthesized 
as inactive precursors. The zymogen form blocks the active site containing the cysteine to 
substrate entry. Cysteine protease zymogen becomes active by the help of accessory molecules 
and by trans-activation from other enzymes or by auto-activation under the influence of acidic pH 
(Verma, Dixit, and Pandey 2016). 
 
 
3. Mechanism of action of proteases. 
Protease-activated receptors (PARs), are seven-transmembrane domain receptors, and 
constitute a family of four G-protein-coupled receptors (GPCRs) with a unique mechanism of 
activation by proteolysis. To date, four different PARs have been discovered: PAR1, -2 , -3 and -4 
(Soh et al. 2010). PARs are widely expressed in human tissues, predominantly in vascular, immune 
cells, IECs, and nervous systems. Proteases signal to a multiple variety of cells to regulate a set of 
crucial biological processes, involved in physiology regulation and diseases (Figure 22) (N 
Vergnolle et al. 2001; Hyun et al. 2008). These receptors are activated by serine-, cysteine-
proteases and MMPs (Nathalie Vergnolle 2008).  
Activation of PARs is an irreversible proteolytic cleavage. After proteolytic activation, the 
receptor cannot be reactivated and undergoes through endocytosis via a clathrin-mediated 
process, where most of them are ultimately degraded into lysosomes (Hoxie et al. 1993). 
Proteases bind to and cleave at a specific site of the extracellular N-terminal domain of PARs to 
unmask a new N-terminus tethered ligand. The newly generated N-terminal domain binds to the 
second extracellular loop and triggers intracellular signalling (Figure 22) (Amadesi and Bunnett 
2004). The tethered ligand sequence is different for each PARs. Synthetic peptides, also termed 
activating peptides (APs), mimic the tethered ligand of each different PARs and are capable of 
activating the receptor even without proteolytic cleavage. However, the analogues of the PAR3 
tethered ligand has not been identified yet (N Vergnolle 2000). In addition to activating PARs by 
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generating the new tethered ligand, proteolytic cleavage can also silence their activation by a 
process called “disarming”. Proteolysis cleaves the amino acid downstream from the PAR 
tethered ligand sequence, therefore the receptor is prevented from inducing a signal (Figure 22 
C) (Elste and Petersen 2010; Nathalie Vergnolle and Chignard 2006).  
GPCRs, including PARs, consists of an α-subunit (Gα) linked with αGβγ dimer that binds directly 
with the intracellular tail of the receptor. PARs signal transduction pathway activates multiple 
signalling pathways which regulate many biological functions. PAR-initiated signalling activates 
phospholipase C, which produce diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) 
which mobilize Ca2+ from the endoplasmic reticulum to the cytosol. Besides, PAR downstream 
effectors include activation of MAPK and NF-κB pathway. These pathways are linked with cellular 
proliferation and the activation of pro-inflammatory mediator genes, respectively (Adams et al. 
2011; Ossovskaya 2004). 
 
 
Figure 22.  Different mechanism to activate PARs. (A) Proteolytic cleavage. (B) Receptor 
activation by binding the synthetic peptide on the second extracellular loop without proteolytic 
cleavage. (C) Proteolytic disarming. Adapted from (Ramachandran et al. 2012). 
 
In the gut, PARs are ubiquitously expressed, including intestinal epithelial cells, neurons, 
inflammatory cells, etc. These receptors are present in both sides of the polarized IECs, apically 
and basolaterally, suggesting that luminal, circulating and secreted proteases can activate them 
(Nathalie Vergnolle 2008). Given that GI tract is a rich source of proteases, particularly produced 
during disease, PARs might play a crucial role regulating multiple processes. Proteases coming 
from coagulation cascade, inflammatory cells, microbiota and intestinal epithelial cells are able to 
cleave and trigger PAR signalling to maintain the gut homeostasis, ion exchange, motility, 
permeability, inflammation, visceral hypersensitivity and healing mechanisms (Figure 22) 
(Amadesi and Bunnett 2004; Nathalie Vergnolle 2016; N. Vergnolle 2005).  
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4. Inflammatory Bowel Diseases meet proteases 
Proteases involved in disease possess multiples mechanism of action to participate in the 
pathogenesis course (Figure 23). Proteolytic cleavage increases the bioactivity of pro-
inflammatory mediators such as CXCL8 (also termed IL-8) and CXCL5, cleaved by proteinase-3 
and cathepsin G, respectively. Proteases also contribute in the activation of programmed cell 
death such as caspases and autophagins (Chin et al. 2003) and also through the initial activation 
of PARs. Some proteases from probiotic bacteria are capable of digesting the glycan composition 
of the mucus, thereby modifying mucus structure (Subramani et al. 2010). Finally, proteolytic 
activity also cleaves Igs present at the intestinal mucus surface, thereby altering the composition 
and function of intestinal immune response (Brezski et al. 2009).  
 
 
Figure 23. Scheme of the mechanism of action of proteases in the GI. Extracted from (Nathalie 
Vergnolle 2016). 
 
Excessive concentrations of proteolytic activity have been found in the stools of patients with 
UC and CD, as well as supernatants of biopsies from these patients (Cenac et al. 2007; Carroll and 
Maharshak 2013). Several studies have reported the important role of proteases in maintaining 
chronic gut inflammation. During inflammation, secretion and activity of proteases are increased, 
mostly produced by infiltrated and resident cells including intestinal epithelial cells, smooth 
muscle, lamina propria and leukocytes (Nathalie Vergnolle and Chignard 2006; Nathalie Vergnolle 
2008). In addition, increased fecal proteases might result from both commensal and pathogenic 
gut bacteria, which can secrete serine, cysteine and MMPs (G. T. Macfarlane et al. 1988; Steck et 
al. 2013). To date, genetic studies have found 75 genes coding for proteases and 7 genes coding 
for protease inhibitors involved in CD pathology and 14 proteases and 4 protease inhibitors genes 
identified in UC patients. The most relevant proteases genes found in IBD include 
cylindromatosis/turban tumor syndrome gene (CYLD), acylaminoacyl-peptidase (APEH), 
dystroglycan (DAG1), macrophage-stimulating protein (MST1) and ubiquitin-specific peptidase 4 
(USP4) (Cleynen et al. 2011).  
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4.1 Epithelial MMPs and their inhibitors in IBD 
Beside their role in ECM turnover, MMPs exert their proteolytic action on a wide range of 
molecules, including cytokines, growth factors, surface receptors, cytoskeleton proteins and 
junctional proteins, leading to their regulation (Rodríguez, Morrison, and Overall 2010). UC 
patients display an excessive production of MMP-7 related to severe inflammation levels (table 7) 
(Rodríguez, Morrison, and Overall 2010; Matsuno et al. 2003). IBD patients also have increased 
levels of MMP-9, which in healthy mucosa is usually undetectable. Deficient-MMP-9 mice exhibit 
resistance to experimental gut inflammation (Castaneda et al. 2005). In addition, a disruption of 
the balance between MMPs and TIMPs (MMPs inhibitors) is linked with inflammation and tissue 
damage (Mäkitalo et al. 2010). Intestinal mucosa protein extracts from IBD patients exhibit 
increased expression of MMP-1, -2, -3, -12,-13 and -14 compared to healthy gut. TIMP-1, a MMPs 
endogenous tissue inhibitors, was increased in UC biopsies, whereas TIMP-2 mRNA expression 
remains unaltered (von Lampe 2000; Mäkitalo et al. 2010).  
 
4.2 Epithelial serine proteases and their inhibitors in IBD  
Matriptase-1, membrane-type serine protease-1, is an integral transmembrane trypsin-like 
protease widely expressed in the epithelial cells covering the colon and the GI tract (Bugge, List, 
and Szabo 2007). Previous studies reported that matriptase-1 is essential in the formation and 
integrity of intestinal barrier. In Caco-2 experiments, the loss of matriptase-1 leads to leakage of 
intestinal barrier along with increased TEER and over-expression of claudin-2 (Buzza et al. 2010). 
Likewise, in vivo model have shown that Matriptase-hypomorphic mice develop severe colitis to 
DSS. Moreover, matriptase-1 expression in colonic epithelium of CD and UC patients is 
downregulated (Netzel-Arnett et al. 2012). 
Most of the studies that have investigated proteases levels in IBD patients did not take into 
consideration the proteolytic activity but only their mRNA levels or protein expression. This is a 
limitation of the models because to identify the function of proteases it is essential to investigate 
the whole net activity of proteases and their inhibitors (Nathalie Vergnolle 2016). Only few 
studies have analysed the proteolytic activity in IBD. Colonic tissue from UC and CD patients 
display increased levels of active trypsin, chymotrypsin, and elastase (Cenac et al. 2007; 
Kjeldsen et al. 1998; Bustos et al. 1998).  
Jean-Paul Motta et al. have demonstrated that inflamed and non-inflamed colonic mucosa of CD 
and UC patients have upregulated elastolytic activity. By in situ zymography the origin of 
proteolytic activity is detected in intestinal epithelial cells (J. P. Motta et al. 2012). mRNA levels 
of Elafin, an elastase inhibitor, and Secretory leukocyte protease inhibitor (SLPI) are increased in 
UC colonic biopsies but not in CD (Lawrance, Fiocchi, and Chakravarti 2001; Flach et al. 2006), 
while the study of Motta et al. reported a decreased expression of mRNA Elafin in intestinal 
epithelial cells of both UC and CD patients, using an in situ hybridization technique (Motta et al. 
2012). In IBD mouse model, the intestinal expression of elafin displayed a strong anti-
inflammatory effect against inflammatory parameters (J. Motta et al. 2011; Schmid et al. 2007).  
Moreover, Neutrophil elastase (NE), proteinase3 and cathepsin G, a chymotrypsin subfamily, 
are increased in IBD. These proteases are secreted along with other pro-inflammatory molecules 
due to inflammatory stimuli (Table 6)(Pham 2006). NE induces inflammation upregulating CXCL8 
via TLR-4 downstream signalling pathway, (Devaney et al. 2003). Cathepsin G, present during 
inflammation within the submucosa, is able to activate PAR4, although such signalling in the gut 
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and its potential pathophysiological consequences have never been studied. UC patients display 
increased colonic levels of cathepsin G and PAR4, both are related to increase paracellular 
permeability (Dabek et al. 2009). 
Tryptase and chymase are released by mast cells, which constitute another source of proteases 
contributing to IBD pathogenesis (Groschwitz et al. 2009; Raithel et al. 2001). Kallikreins and 
Granzymes are also upregulated in IBD (Moreau et al. 2005). Granzymes promote cell death by 
activating several apoptosis mediators such as caspase-3, -8 and IBD (Table 7).  PAR1-
signalling is also involved in epithelial barrier dysfunction. In vivo and in vitro experiments have 
shown that PAR1 agonist such as thrombin, increases paracellular permeability through the 
induction of apoptosis and ZO-1 disruption (Chin et al. 2003; Trapani and Smyth 2002; N. 
Vergnolle 2005).  
Most of the proteases cleaving and activating PARs belong to the serine clan of proteases. Serine 
proteases activate PARs through paracrine and endocrine signalling, and participate to vital or 
pathologic processes such as IBD, IBS or colorectal cancer (Rothmeier and Ruf 2012; Darmoul, 
Gratio, Devaud, Peiretti, et al. 2004; Nathalie Vergnolle 2016). Activation of PARs present in 
epithelial cells leads to changes in paracellular permeability. Cenac et al. (Cenac et al. 2002; 
Darmoul, Gratio, Devaud, and Laburthe 2004) have shown that in mouse model, PAR2 activation 
by trypsin, tryptase and chymase, all from serine proteases family, promotes an increase in colonic 
permeability displaying inflammation and disruption on the intestinal barrier integrity. These 
results have been supported by other studies which have shown an alteration on the intestinal 
barrier function and increased permeability using PAR2 agonists (Coelho et al. 2002; Darmoul, 
Gratio, Devaud, and Laburthe 2004). Investigation into the mechanism of action exhibited the 
involvement of calmodulin and MLCK in the PAR2-mediated modification of intestinal 
permeability. PAR2 agonist and calmodulin increase MLC phosphorylation which leads to 
epithelial cell cytoskeleton contraction and enhanced mucosal permeability. ML-7, an MLCK 
inhibitor, abolished disruption of TJ composition and function (Turner et al. 1997; Cenac et al. 
2003). Another study revealed that activation of ERK1/2 by tryptase in cultured colonocytes also 
phosphorylates MLCK, leading to epithelial cells disruption (Cenac et al. 2004).  
 
 4.3 Epithelial cysteine proteases  
Inappropriate production (up-regulation) of caspases or autophagins have been detected 
especially in UC patients, leading to activation of autophagy and apoptosis (Seidelin and Nielsen 
2006). Caspase-1 and 5 form the inflammasome complex, promoting IL1-β and IL-18 maturation, 
both pro-inflammatory cytokines involved in the pathogenesis of IBD (Siegmund 2002; Nathalie 
Vergnolle and Chignard 2006). Caspase-8 is involved in both apoptotic and inflammatory 
signalling pathway, activating respectively pro-apoptotic proteins and NF-κB (Table 7) (Man and 
Kanneganti 2016). Mice deficient in IECs for caspase - 8, a protease involved in apoptosis, necrosis 
and cell death, have shown increased cell death of epithelial cells in general and Paneth cells in 
particular, developing spontaneous inflammation in the terminal ileum and high susceptibility to 
colitis (Günther et al. 2011). Also caspase-4 and -5 have been found associated with IBD with 
increased risk of evolution towards colorectal cancer(Flood et al. 2015). Sina et al. have shown 
that cathepsin K-deficient mice treated with DSS develop severe colitis and that they improve by 
adding recombinant cathepsin K. They demonstrated that cathepsin K is highly secreted by goblet 
cells in the intestinal mucus, acting as an antimicrobial peptide shaping bacterial communities 
and anti-inflammatory properties(Sina et al. 2013). Cathepsin L has been found increased in 
colorectal adenocarcinoma accelerating cell proliferation (Tamhane et al. 2016). Another study 
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observed increased cathepsin D, B and L in intestinal macrophages from inflamed mucosa of IBD 
patients associated with tissue degradation. Inhibition of these cysteine proteases improved 
colitis (Menzel et al. 2006).  
 
Proteases involved in IBD 
  Proteases source expression in 
IBD 
S
e
ri
n
e
 p
ro
te
a
se
s 
Elastase Neutrophil/Mast cell/Monocyte/Eosino ↑ in CD/UC 
Proteinase 3 Neutrophil/Monocytes ↑ in CD/UC 
Cathepsin G Neutrophil/Monocytes ↑ in CD/UC 
NE Neutrophil ↑ in CD/UC 
Chymase Mast cell/Basophils  ↑ in CD/UC 
Tryptase Mast cell/Basophils ↑ in CD/UC 
Thrombin Hepatocyte ↑ in CD/UC 
Factor V and VIII Various (hepatocytes, placenta, leukocytes...) ↑ in UC 
Plasminogen 
activator 
Various (small intestine, colon, myocytes...)  ↓ in CD/UC 
Protein C Hepatocyte  ↓ in CD/UC 
Trypsin Various (pancreas/epithelial cells/endothelial 
cells/neuronal cells..) 
↑ in CD/UC 
Kallikreins Various (pancreas/salivary 
glands/prostate/leukocytes…) 
↑ in CD/UC 
Granzymes Leukocytes (CD8+/CD4+) ↑ in CD/UC 
M
e
ta
ll
o
p
ro
te
a
se
s 
MMP-1 Various (leukocyte/fibroblast/muscle cells/epithelial 
cells..) 
↑ in CD/UC 
MMP-2 various (muscle cells/adipocytes/lung/liver) ↑ in UC 
MMP-3 Ubiquitous (largely by smooth muscle cells) ↑ in CD/UC 
MMP-7 Pancreas/Skin/B cells/salivary gland/lung ↑ in CD 
MMP-12 Ubiquitous ↑ in CD/UC 
MMP-14 Ubiquitous (largely by myocytes) ↑ in UC 
MMP-28 Ubiquitous  (largely by lung)  = in CD/UC 
TACE/ADAM17 Ubiquitous  = in CD/UC 
C
y
st
e
in
e
 p
ro
te
a
se
s 
Caspase-1 LMPC/macrophages/epithelial cells ↑ in UC 
Caspase-3 Ubiquitous  ↓ in memory T 
cells CD 
Caspase-5 Ubiquitous ↑ in UC 
Caspase-8 Ubiquitous  ↓ in memory T 
cells CD 
Caspase-14 keratinocytes/placenta  = in UC 
Cathepsin B various (thyroid/liver/kidney/leukocytes) ↑  
Cathepsin L  Various (placenta/intestine/pancreas/macrophages) ↑  
A
sp
a
rt
a
te
  
P
ro
te
a
se
s Cathepsin D lamina propria mononuclear cells/macrophages ↑ 
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DPP4 leukocytes/smooth muscle cells/salvary gland  = or ↑  
(human/mouse) 
Aminopeptidases 
N 
Multiorgans 
kidney/prostate/intestine/liver/leukocyte/monocytes 
 = in CD/UC 
carboxypeptidase 
B2 
Hepatocyte  ↓ or ↑ 
angiotensiogen-
converting 
enzyme (ACE) 
Ubiquitous ↓ in CD/UC 
 
Table 6. Proteases involved in IBD. Origin and expression. Adapted from (Nathalie Vergnolle 
and Chignard 2006). 
 
 
5. Further treatments to target IBD 
Taken together, data reviewed in this chapter have shown the importance of proteolytic balance 
on GI diseases. In healthy conditions, the proteolytic activity is tightly regulated by proteases 
inhibitors, although this equilibrium is disrupted in organic and functional IBD pathology. A high 
number of proteases are up-regulated in IBD promoting inflammation, but others have a 
contradictory effect, decreasing some aspects of the acute inflammatory response. Thus, protease 
inhibitors have become a hot topic as possible therapeutic treatments, although characterization 
of the proteases involved in inflammation and hypersensitivity is needed. It is essential to avoid 
large spectrum of proteases inhibitors and focus on therapies targeting specific proteases. 
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1. Epithelial cell models 
As mentioned in chapter 2 section 1, intestinal epithelial monolayers consist on a physical barrier 
that allows an efficient absorption of nutrients and that secretes a wide range of biochemical 
components as AMP, mucus, cytokines or chemokines to protect the epithelium. The single cell-
layer intestinal mucosa is selectively permeable allowing bacteria metabolites, digested nutrients 
and soluble molecules (Lee 2015). Depending on the physicochemical properties of the 
compound, its size, its molecular weight and its charge distribution the mechanism of 
transepithelial transport differs. In addition, molecule interaction, mucus layer solubility and 
intestinal motility are crucial factors influencing the transport process. In vitro, intestinal motility 
is hardly reproduced especially in models of epithelial cell cultures. Therefore, study of absorption 
is a limited in in vitro models. However, in vitro culture of epithelial cells is considered a good 
model to study barrier function and transport mechanism (Verhoeckx et al. 2015; Berkes et al. 
2003).  
During the last past years the most widely used and best characterized system, which closely 
mimics the intestine conditions in vivo, has been epithelial cell lines including Caco-2 and HT29. 
While Caco-2 cultures are  a mixed cell type from human colonic carcinoma, HT29 are considered 
as mucus-secreting cells which differentiate into mature goblet cells (Lesuffleur et al. 1990).  
 
 
 
Figure 24. Illustration of TEER measurement. To the left, a monolayer of differentiated Caco-2 
cells cultured in a transwell system and an electrode placed. The short electrode tip must be touch 
the cell monolayer, while the longer tip must be in contact with the outer compartment. Adapted 
from  (Verhoeckx et al. 2015) 
 
2.  Caco-2 cells model 
Caco-2 is a heterogeneous epithelial cell line established from a human colorectal carcinoma 
developed by Jorgen Fogh at Sloan-Kettering Institute for Cancer Research (Fogh, Fogh, and Orfeo 
1977).  
Measurement of Transepithelial Electrical Resistance (TEER) 
Transepithelial electrical resistance (TEER), is a well-used value that reflects physical 
structure of epithelial monolayer and evaluates its paracellular permeability and integrity of 
TJ established between polarized cells. Thus, TEER is applied for assessing the epithelial 
barrier function (Figure 24) (Cereijido et al. 2008). 
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Although the tumor cell line was derived from a colon carcinoma, when cultured, Caco-2 
spontaneous starts to differentiate into colonocytes. Caco-2 display many characteristic of small 
bowel as they form a polarized cell layer expressing a brush border on their apical surface and 
intracellular TJ complexes. Besides, these cells express a wide number of enzymes and transporter 
proteins characteristic of enterocytes. Thus, this cell line has been used to study epithelial barrier 
function. However, a limitation is that caco-2 model is restricted to enterocytes, whereas the 
intestinal mucosa is formed by a conglomerate of absorptive cells, goblet cells, Paneth cells, 
endocrine cells and M cells among others (Hilgendorf et al. 2000; Verhoeckx et al. 2015).  
To better simulate the in vivo parameters present in the intestine, Caco-2 cells are cultured on 
permeable supports to help enterocyte differentiation after reaching the confluence state. 
Cultures of these cells on filter inserts, for 20 days, let the cell differentiate into a polarized form 
achieving a particular morphology and functionality including sucrase isomaltase, phosphatase 
alkalin enzymes or tight junction proteins (Figure 25 and 26).   
 
 
 
 
 
 
Figure 25. Differentiation of Caco-2 cells on a filter support. Cultured caco-2 cells (A) start to 
proliferate until confluence (B). Then they start to differentiate (C) until they become polarized 
with apical microvilli and enterocytes features after a 20 days of culture. Adapted from 
(Verhoeckx et al. 2015) 
 
 
Figure 26. Transwell sytem used during our experiments. From Corning vendor, 12 mm 
Transwell with 3.0 μm pore polyester membrane insert. Adapted from corning website.  
 
3. HT29-mtx cell model 
HT29 is a human colorectal adenocarcinoma cell line with mature intestinal cell features such as 
the production of mucus. The other cell variant HT29-mtx is given to HT29 cells resistant to 
methotrexate (MTX), resulting into a cell transformation mucus-secreting differentiated cells 
(Maoret et al. 1989; Lesuffleur et al. 1990)This cell line was established in 1964 by Fogh and 
Trempe from a primary tumor of a 44 years old Caucasian female. HT29-mtx are mucus-secreting 
goblet cells characterized by the production of mucus (mucins) and the formation of TJ complexes 
A B C 
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that lead to the development of confluent monolayers. In contrast with Caco-2 cells, HT29 can 
produce very high amounts of mucin. These cell types are mainly used to study food compounds 
or bacteria, which may influence mucus secreting properties in the gut. 
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Aims of the thesis and hypothesis 
 
Crohn's disease (CD) and Ulcerative colitis (UC) are chronic relapsing inflammatory bowel 
diseases (IBD) with mucosal ulcerations characterized pathologically by intestinal inflammation 
and epithelial injury. Although IBD is an idiopathic disease, over the ten past years, genetic studies 
have identified more than 170 loci of susceptibility for developing IBD. The strongest 
associations have highlighted fourth main pathways altered in IBD: bacterial sensing (NOD2 in 
CD), autophagy (ATG16L1 and IRGM in CD), Th17 Profile (IL23 receptor CD) and ER-Stress (XBP1 
UC) pathways. Environmental factors including host microbiota play also an important role in 
promoting CD and UC.  
About half of the patients with CD carry at least one polymorphism on NOD2 gene. NOD2 is a 
bacterial sensor expressed both in immune and epithelial cells, which specifically recognizes 
muramyl dipeptide (MDP), a fragment of the peptidoglycan from bacterial wall. Many studies 
have demonstrated the role of NOD2 in CD, but mechanisms by which NOD2 mutations promote 
CD are not yet understood. Many studies support the fact that a loss of function linked with NOD2 
mutations participates to the development of CD.  
Autophagy pathway is an intracellular catabolic process used to degrade and recycle cytoplasmic 
components, to maintain homeostatic cellular processes. In the context of CD, two variants genes 
of autophagy have been identified including ATG16L1 and IRGM. These polymorphisms reduce 
selective autophagy but not constitutive basal autophagy.  
Accumulation of unfolded or misfolded proteins lead to a dysfunction within Endoplasmic 
Reticulum (ER), termed ER-stress. ER-stress triggers Unfolded Protein Response (UPR) in order 
to adapt cells to harmful environment and to solve ER disturbances. CD and UC patients display 
an aberrant ER-Stress response due to a polymorphism on its downstream pathway, including 
AGR2 or XBP1. Altered ER-Stress has been found in both inflamed and non-inflamed colonic 
mucosa of IBD patients. Mice deficient for XBP1 in intestinal epithelial cells including enterocytes, 
goblet and Paneth cells develop enteritis, this epithelial deficiency is associated to a reduced 
capacity of the intestinal mucosa to control inflammation.  
The intestinal epithelium is involved in host defence by secreting antimicrobial peptides (AMPs) 
and mucus. The pathogenesis of IBD is characterized with increased intestinal permeability and 
altered expression of mucins and AMPs. A reduction of AMPs production by Paneth cells is 
described in the ileum of CD patients. An early depletion of goblet cells and the presence of 
emptied goblet cells are seen in the colon of UC patients. Recent data have described high trypsin 
proteolytic activity present in IBD tissues and stools but its origin (microbiota, immune and/or 
epithelial cells) is still debated. Recent work from the laboratory suggests that the intestinal 
epithelium is a major source of proteases and in particular trypsin activity, but the conditions 
associated with the expression and release of trypsin activity need to be better defined. Cleavage 
and activation by proteases of protease-activated receptors (PARs) has also been found 
associated with intestinal pathologies such as IBD or IBS. Trypsin proteolysis is able to cleave and 
activate PAR2 and -4, both receptors highly expressed in human intestinal mucosa. Moreover, the 
expression of PAR1, -2 and -4 is ubiquitous in the gut (epithelium, neurons, macrophages, mast 
cells, fibroblasts, infiltrated immune cells, etc) and PAR2 and -4 is up-regulated in the colonic 
mucosa of IBD patients. Inhibition of each of these receptors is a protective element against the 
development of colitis in animal models of IBD. However, little is known about the source of active 
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proteases in the gut, about their roles, and their mechanisms of action in the course of IBD, and 
which proteases could be present in the gut and be responsible for the activation of PARs.  
Although alterations of the proteolytic activity and abnormal induction of the autophagy process, 
ER stress and NOD2 pathways have been independently associated with IBD pathophysiology, no 
study has investigated the link between the trypsin proteolytic activity of intestinal mucosa and 
the three main pathways involved in IBD. 
 
The general hypothesis of this thesis is that in intestinal epithelial cells, the pathways that 
have been associated with IBD (NOD2, autophagy or ER-stress) are responsible for an 
increased secretion of proteolytic activity in general, and trypsin proteolytic activity in 
particular. Further, we hypothesized that protease activity released by activation of NOD2, 
autophagy or ER stress is responsible for epithelial dysfunctions associated with such IBD 
susceptibility pathways.  
 Our first aim was to study the three IBD-related pathways and the effect of their activation 
on the secretion of trypsin proteolytic activity by intestinal epithelial cells.  
 Our second aim was to identify the type of trypsin-like enzyme(s) enhanced in IBD 
patients and in our in vitro model of colonic epithelium.  
 Our third aim was to analyse the role of trypsin-3 in the altered caco-2 monolayer 
homeostasis induced by ER-stress.  
 As a fourth aim, we study whether a crosstalk exists between ER-stress and trypsin 
proteolytic activity.  
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Project 1. 
The relationship between activation of NOD2 and trypsin-like 
proteolytic activity secretion in intestinal epithelial cells. 
 
Introduction 
IBD is characterized by severe inflammation of the small intestine and the colon leading to 
diarrhea and abdominal pain. The two main forms of IBD are Crohn's disease (CD) and 
ulcerative colitis (UC). The NOD-like receptors NOD2, expressed in the epithelium, sense 
muramyl dipeptide (MDP) from Gram-positive and -negative bacteria. Three different 
mutations of NOD2 have been reported in ileal CD pathogenesis including Arg702Trp, 
Gly908Arg and leu1007fsinsC. In healthy conditions NOD2 tightly regulates the nuclear 
factor NF-κB ensuring ileal expression of α-defensins and secretion of chemokines and 
cytokines (Peyrin-Biroulet and Chamaillard 2007). In patients carrying NOD2 
polymorphisms, NF-κB activation is abnormal, facilitating bacteria translocation and 
triggering inflammation by TLR2 and -4 stimulation (Hedl et al. 2007). It has been observed 
that trypsin proteases are associated with UC and CD, although the source and their 
implications have to be better defined in the context of IBD.   
We hypothesized that NOD2 was able to modulate the secretion of trypsin activity by 
intestinal epithelial. Human enterocyte-like, Caco-2, and goblet cell lines HT29-mtx were 
stimulated with MDP (20µg/mL), a NOD2 inducer. 
 
Methodology  
Cell culture and reagents. Described in the paper. NOD2 was stimulated with 20µg/mL of 
MDP (sigma).  
Trypsin like activity. Described in the paper 
Statistical Analysis. Described in the paper 
 
Results 
Trypsin activity remained unchanged upon NOD2 stimulation 
2, 4 and 6 hours after MDP stimulation, trypsin-like proteolytic activity was quantified in 
the supernatant of both cell lines. As shown in the figure 1, proteolytic activity remained 
unchanged upon MDP stimulation, in both cell lines, compared to control conditions 
(vehicle).  
 
Discussion and conclusion 
One of the reasons why MDP stimulation does not modify trypsin proteolytic activity could 
be explained by the low levels of NOD2 expression in caco-2 cells. Barnich et al., reported 
the expression of NOD2 in HT29 cells although Caco-2 exhibited low level of endogenous 
NOD2 (Barnich et al. 2005). Despite, Caco-2 cell line is a model to study NOD2 response 
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Rosentiel et al. shown that although basal levels of NOD2 are low in Caco-2, stimulation of 
TNF-α/IFN-γ in caco-2 cells upregulates the expression of NOD2 (Rosenstiel et al. 2003) 
This limitation could be overcome by using transfected caco-2 cells overexpressing NOD2 
and verifying NOD2 activation through NF-κB activity. Regarding HT29 cell line, although 
they express the receptor, it seems that NOD2 does not have any impact on trypsin activity. 
Altogether, our findings suggest that no link exists between NOD2 and trypsin-like activity. 
 
Figures 
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Figure 1. Trypsin like activity quantification after MDP stimulation. A-B. Caco-2 (A) or 
HT29-mtx (B) cells monolayer where stimulated with MDP. At 2 4 and 6 hours supernatant 
was collected to measure trypsin-like activity. At least n=15 well /condition. Data expressed 
as mean±SEM were compared using one-way non-parametric anova (Bonferroni test). 
0.0
0.5
1.0
1.5
2.0
T
ry
p
s
in
 a
c
tiv
ity
 (
m
m
U
/m
L
)
2 hours 4 hours 6 hours
Results 
85 | 
 
Project 2.  
Autophagy signaling pathway and the release of trypsin-like 
proteases in intestinal epithelial cells.  
 
Introduction 
In mammalian cells autophagy was initially described as a mechanism to breakdown 
damaged macromolecules and organelles, allowing the recycling of amino acids via the 
fusion of the autophagosome with the lysosome (Christian de Duve and Wattiaux 1966; C 
De Duve 1966). Different extracellular signals trigger autophagy including cellular stress, 
amino acid deficiency, hypoxia or nutrient starvation. To date, new functions of autophagy 
have been described such as its involvement in innate and adaptive immune response.  
In the context of CD, two variants genes in autophagy have been identified, ATG16L1 and 
IRGM (Rioux et al. 2007; Salem et al. 2015). These polymorphisms reduce selective 
autophagy but not its basal levels. Patients carrying autophagy genes mutation display an 
abnormal morphology of Paneth cells with reduced size and lower number of antimicrobial 
peptides being secreted. However, a recent study has shown that pediatric CD patients 
never treated, exhibited increased autophagy in Paneth cells. It is suggested that 
disorganization of the secretion granules observed in Paneth cells of CD is due to an 
overactivation of autophagy named crynophagy (Thachil et al., gastro 2012). 
To address the question whether autophagy signaling pathway is able to modulate the 
secretion of trypsin in IBD pathophysiology, intestinal epithelial cells including Caco-2 and 
HT29-mtx, were treated with two main autophagy stressors: rapamycin and Nutrient 
starvation. Mammalian target of rapamycin signaling pathway (mTOR), is a protein kinase 
that regulates cell growth, proliferation, and survival (Ballou and Lin 2008). Rapamycin is a 
specific inhibitor of mTOR, and as such mimics cellular starvation by blocking signals 
required for cell growth and proliferation, thereby inducing autophagy. Cell responds to 
change in nutrition availability to maintain metabolism homeostasis. Nutrient starvation 
(NS) induces autophagy, providing cells with needed nutrient supplies. In cell culture 
Earle's Balanced Salt Solution (EBSS) medium is used to mimic nutrient depletion. 
 
Methodology  
Cell culture and reagents. Described in the paper. Autophagy was induced by culture 
medium Earle's Balanced Salt Solution (EBSS, sigma) or Rapamycin (0.5µM, sigma) in the 
culture medium. Cysteine proteases inhibitor E64 was used at 50µM, Sigma. 
Trypsin like activity. Described in the paper.   
Cysteine like activity. Cysteine-like activity was measured in supernatant from 6 well 
plates with the substrate Z-Phe-Arg-AMC (200µM, sigma) in Potassium phosphate buffer 
100mM (pH6), 10mM EDTA and 1mM DTT. Hydrolysis rate was measured by the 
change in fluorescence (360/460 nm excitation/emission wavelengths) every 30 seconds 
for 15 minutes at 37ºC on a microplate reader 96-well plate NOVOstar. Activity was 
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standardized to the rate generated by papain of known concentration from papaya latex 
(Sigma).   
Real-time PCR analysis. Described in the paper. Sense and antisense specific primers are 
shown in table1.  
Measures of paracellular Permeability. Described in the paper 
Measurement of cell cytotoxicity with Lactate dehydrogenase (LDH). Described in the 
paper 
Statistical Analysis. Described in the paper 
 
Table1. Sequences of oligonucleotides used for RT-qPCR experiments. PRSS1, protease 
serine 1 (cationic trypsin), PRSS2, protease serine 2 (anionic trypsin); ST14, Matriptase I; 
Elafin; ELA2a, Elastase 2A. 
Primer  Sense 5’ – 3’ Antisense  3’- 5’ 
PRSS1 CCACCCCCAATACGACAGGAAG GCGCCAGAGCTCGCAGT 
PRSS2 CCAAATACAACAGCCGG AGTCGGCACCAGAACTCAGA 
ST14 CCCAACATTGACTGCACATG TGGAGTCGTAGGAGAGGTATTC 
Elafin CGTGGTGGTGTTCCTCATC TTCAAGCAGCGGTTAGGG 
Elastase 2A ATGATAAGGACGCTGCTGCT TTAGTTATTTGCAATCACCGAATTG 
 
 
Results 
Autophagy stimulation decreased trypsin activity and mRNA relative expression of 
serine proteases in Caco-2 cell line 
Caco-2 cells monolayers were stimulated with rapamycin (0.5µM) or incubated with EBSS 
medium to induce autophagy. Results show that trypsin-like activity was decreased under 
autophagy in Caco-2 cells (Figure 2). Mucus-secreting cell line, HT29-mtx, exhibited a 
general low secretion of trypsin-like activity and its levels remained unchanged by 
autophagy induction (Figure 2).  Next, we analyzed the mRNA relative expression of a wild-
spectrum of serine proteases, including PRSS-1, PRSS-2, PRSS-3, Matriptase II and Elafin, an 
elastase inhibitor, and we observed a general downregulation of the expression of these 
proteases and of the Elafin protease inhibitor, by autophagy induction (Figure 3).  
 
Nutrient starvation induces cysteine-like proteolytic activity 
Our data showed that when autophagy is induced by nutrients starvation in both cell lines, 
a great increase of cysteine-like activity is observed (Figure 4).  
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Autophagy inducers do not induce necrosis 
To exclude the possible occurrence of cell death in our autophagy model, lactate 
dehydrogenase (LDH) cytotoxic assay was performed in Caco-2 cells (Figure 5). Our data 
demonstrate that our autophagy model, either nutrient starvation or rapamycin, does not 
induce cell death.  
 
Alteration of intestinal barrier upon Nutrient starvation 
We investigate whether autophagy induction modified intestinal barrier. Incubation of 
caco-2 cells with nutrient starvation increased paracellular permability at 6 hours (figure 
6A). This increase was inhibited when cysteine protease activity was blocked by E64 
inhibitor (Figure 6A). Moreover, mRNA expression of TFF3 was upregulated (N=7 
wells/condition. Rapamycin=2wells/condition) (Figure 6B). 
 
Discussion and conclusion  
Autophagy signaling pathway (confirmed by LC3a/b, IRGM and ATG16L1 gene expression 
(data not shown)) decreased the release of trypsin proteolytic activity by intestinal 
epithelial cells. Besides, mRNA levels of a large spectrum of serine proteases are also 
downregulated. These results clearly disproved the hypothesis originally proposed that 
autophagy could lead to an increased trypsin-like activity released by intestinal epithelial 
cells. A link between autophagy and the increased serine protease activity found in the 
stools and biopsies of IBD patients is therefore very unlikely.  
However, increased cysteine proteolytic activity was observed in NS conditions, and it was 
associated with increased permeability and TFF3 mRNA upregulation. The differences 
observed between rapamycin and NS effects might be explain by the fact that rapamycin 
induces autophagy by inhibiting mTOR, while NS senses several autophagy signaling 
pathways. Caspases belong to the cysteine protease group playing crucial roles in cell death 
and inflammation. To eliminate a possible link between the drop of trypsin activity, the 
increased cysteine activity and cell death, LDH assay was performed. The cytotoxic assay 
shown no cell death. Thus, we excluded programmed cell death in our model although 
caspases mRNA expression should be verify. Cysteine inhibitor E64 normalized paracellular 
permeability under NS condition. This results suggested that increased cysteine activity 
might be the responsible for permeability increase. Cathepsins, a cysteine protease, play an 
important role in degrading intracellular proteins, and keeping intestinal mucosa turnover 
and homeostasis (Tamhane et al. 2016). Altered activity of cathepsin D, -B and -L is 
associated with IBD (Menzel et al. 2006). Therefore, further experiments should verify the 
expression of cathepsins in NS model and to investigate their impact on intestinal biology.  
Also, NS condition upregulated TFF3 mRNA expression, a peptide involved in epithelial 
restitution and integrity of the mucus. TFF3 has been associated with cell junction 
modulation upregulating claudin-1 and decreasing claudin-2 expression (Meyer zum 
Büschenfelde, Tauber, and Huber 2006). We hypothesis that through TFF3, autophagy 
repairs epithelial damage.  
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We concluded that downregulation of proteolytic activity might be a protective mechanism 
for the cells to avoid losing essential components for the cell maintenance. On the other 
hand, NS increases cysteine activity which alters intestinal barrier. Further experiments are 
needed to verify the role of cysteine activity on intestinal barrier.   
 
 
Figures 
 
A. Caco-2        B. HT29-mtx 
 
Figure 2. Trypsin-like activity after autophagy induction. Monolayer of (A) Caco-2 or (B) 
HT29mtx were stimulated with autophagy stressors such as rapamycin or Nutrient 
starvation. Trypsin-like activity released was quantified at 2, 4 and 6 hours after induction. 
At least n=15 well /condition. Data expressed as mean±SEM were compared using one-way 
non-parametric anova (Bonferroni test). *p<0.05, **p<0.01 vs control group. 
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Figure 3. mRNA relative expression of serine proteases. Monolayers of differentiated 
Caco-2 cells were cultivated in Transwell system, and were stimulated with rapamycin or 
nutrient starvation for 6 hours. mRNA expression of PRSS-1, PRSS-2, PRSS-3, Matriptase I 
and Elafin were monitored. At least n=8 well /NS condition and n=2 well / rapamycin. Data 
expressed as mean±SEM was compared using one-way non-parametric anova (Bonferroni 
test). **p<0.01 vs control group. 
 
 
Caco-2
0
1
2
5
10
15
20
C
y
st
ei
n
e 
p
ro
te
as
e 
ac
ti
v
it
y
  (
m
m
U
/m
L
)
**
***
***
2 hours 4 hours 6 hours
 
0
2
4
6
C
y
st
ei
n
e 
p
ro
te
as
e 
ac
ti
v
it
y
  (
m
m
U
/m
L
)
***
***
***
HT29-mtx
Control
Nutrient Starvation
Rapamycin
2 hours 4 hours 6 hours
 
Figure 4. Cysteine-like activity. Monolayers of differentiated Caco-2 and HT29-mtx cells 
were stimulated with rapamycin or nutrient starvation. Cysteine activity was measured at 
2, 4 and 6 hours. At least n=10 well /condition. Data expressed as mean±SEM were 
compared using one-way non-parametric anova (Bonferroni test). **p<0.01 and ***p<0.001 
vs control group. 
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Figure 5. LDH cytotoxic activity. Monolayer of Caco-2 cells were treated with nutrient 
starvation or rapamycin. LDH activity was measured at 2, 4 and 6 hours after autophagy 
induction. At least n=5 well /condition. Data expressed as mean±SEM were compared using 
one-way non-parametric anova (Bonferroni test). 
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Figure 6. Autophagy induction modulates intestinal barrier alteration. Monolayers of 
differentiated Caco-2 cells were cultivated in Transwell system and were treated with 
nutrient starvation or rapamycin. (A) Paracellular permeability was monitored by 
measuring the apical-to-basolateral flux of dextran 4kDa–FITC after 6 hours with nutrient 
starvation with or without E64, a cysteine protease inhibitor. (B) Relative mRNA 
expressions of TFF3 after 6 hours stimulation. Data expressed as mean±SEM were 
compared using one-way non-parametric anova (Bonferroni test). **p<0.01 and ***p<0.001 
vs control group. ϕp<0.05 vs. NS group. 
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Project 3.  
Endoplasmic reticulum stress boosts trypsin activity and release 
by enterocytes and alters barrier function.  
 
 
Although IBD is an idiopathic disease, over the past ten years, genetic studies have identified 
more than 170 loci of susceptibility for the development of IBD. These genes affect in 
particular unfolded protein response (UPR)-related genes like AGR2 and X-box binding 
protein 1 (XBP1). Environmental factors and host microbiota play also an important role on 
promoting CD and UC (A. Kaser, Martínez-Naves, and Blumberg 2010).  
Accumulation of unfolded or misfolded proteins lead to a dysfunction within Endoplasmic 
Reticulum (ER), termed ER-stress. ER-stress triggers UPR which facilitates the folding, the 
exportation and the degradation of proteins through three main proteins including Inositol 
Requiring Enzyme -1 alpha and beta (IRE1αβ), pancreatic ER kinase (PERK), and activating 
transcription factor 6 (ATF6)(Cao 2015). IRE1 is the initiator protein signaling pathway of 
the UPR. During ER stress, IRE1 contributes to a non-conventional splicing of the X-box 
binding protein-1 (XBP1) mRNA, activating the transcription of the UPR genes. Recently, ER 
stress has been described to play a key role in IBD. Mice deficient for Xbp-1 in intestinal 
epithelial cells (IECs), including enterocytes, goblet and Paneth cells, develop enteritis, 
linked to reduce capacity of IECs to control the inflammatory signals (A. Kaser et al. 2008). 
Mice deficient for IRE1β, exhibit hypersensitivity to DSS-induced colitis. Finally, some 
polymorphisms affecting the XBP1 gene are associated with IBD susceptibility (Bertolotti 
2001). In UC patients, in both inflamed and non-inflamed colonic tissue, ER-stress is 
dysregulated leading to inflammation and cell dead in intestinal epithelium.  
Endogenous serine proteases in intestinal epithelium are required to create and maintain 
the barrier (Ronaghan et al. 2016). However, recent data demonstrated that high amounts 
of serine proteases such as trypsin, chymotrypsin or elastase in IBD tissues and 
stools(Nathalie Vergnolle 2016; Giuffrida, Biancheri, and MacDonald 2014; J. Motta et al. 
2011). Although the mechanism, the role and the source of serine proteases in the 
pathogenesis of IBD is not well understood, sustained increase of proteolytic activity drives 
decreased TEER and dysfunction on intestinal biology (Ronaghan et al. 2016).  
Protease-activated receptors (PARs) are activated by the cleavage of proteinases including 
thrombin or trypsin. They are expressed apically and basally in intestinal epithelium and 
thus they respond to luminal or mucosal proteases. Four different PARs (PAR1-4) have been 
cloned (Soreide 2008). These receptors are involved in many biological functions such as 
gut epithelial transport, proliferation, pain and inflammation. PAR-2, which is activated by 
trypsin, plays an important role in intestinal permeability (Cenac et al. 2003; Róka et al. 
2007; Hyun et al. 2008).  
 
Therefore, the aim of this project was to analyze whether aberrant ER-stress in IECs 
modifies the secretion of trypsin proteolytic activity, its implication in intestinal 
homeostasis and the aim was also to study the molecular mechanisms associated 
with ER stress-induced biological functions.    
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Abstract (<250 words) 
Colonic intestinal epithelial cells (IECs) from inflammatory bowel disease (IBD) patients 
exhibited an excessive induction of endoplasmic reticulum stress (ER-Stress) linked to an 
altered intestinal barrier function and inflammation. Colonic luminal content of IBD 
patients is also characterized by increased serine protease activity, known for its 
contribution to mouse gut inflammation. However, the interplay between ER-Stress and 
serine proteases in the destabilization of intestinal barrier function associated with 
inflammation is unknown. Colonic biopsies from Ulcerative colitis patients exhibited 
increased Trypsin-like activity and in particular Trypsin-3 expression is associated with 
elevated ER-Stress. Stimulation of ER-stress in human intestinal Caco-2 cell line cultured 
in a transwell displayed enhanced trypsin-like activity and enhanced Trypsin-3 expression 
in the apical compartment. Increased trypsin activity destabilized intestinal barrier 
function by increasing intestinal permeability and inducing inflammatory signs. The 
deleterious impact of ER stress-associated trypsin activity depends on the activation of 
Protease-Activated Receptors 2 and 4. In conclusion, excessive ER-Stress in IECs 
increased the release of trypsin activity which, in turn, alters intestinal barrier function 
then favoring the development of inflammatory process. Trypsin-3 could be responsible 
for this increased activity and ER stress-associated epithelial dysfunctions. 
 
Key words: Inflammatory Bowel Disease, Intestinal epithelial cells, Endoplasmic 
Reticulum Stress, Mesotrypsin/PRSS-3, Permeability. 
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Significance of this study: 
 
What is already known on this subject? 
-Excessive Trypsin activity is measured in the colon of IBD patients. 
-Colonic mucosa of IBD patients exhibited enhanced endoplasmic reticulum stress. 
-Endoplasmic reticulum stress is a component of colonic inflammation. 
What are the new findings? 
-IBD-associated excessive Trypsin activity in colonic tissues (both Crohn’s and UC 
patients) originates mostly from the epithelium. 
-Colonic epithelial cells released a large amount of Trypsin activity in the luminal 
compartment upon induction of ER stress. 
-ER stress-induced altered barrier function is mediated by Trypsin activity, PAR2 and 
PAR4 activation in human intestinal monolayers. 
-Colonic epithelial cells from UC patients but not CD patients exhibited an increased 
expression of Trypsin-3, concomitant to the presence of ER stress marker. 
-Activation of ER-stress induces a specific release of Trypsin-3 at apical side of human 
epithelial monolayers. 
-Trypsin activity secreted in response to ER-stress does not modify the induction ER-
stress. 
-Trypsin-3 is unable to induce ER-stress. 
How might it impact on clinical practice in the foreseeable future? 
-Trypsin activity in patient biopsies could be used as a marker of epithelial dysfunction. 
-Trypsin-3 protein level could be proposed as a marker associating epithelial ER stress 
and increased permeability in UC patients. 
-Specific inhibitors for Trypsin-3 could be developed as new therapeutic options for the 
treatment of UC. 
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Introduction. 
Inflammatory Bowel Diseases (IBD) include Crohn’s disease (CD) and ulcerative 
colitis (UC). Although considered as idiopathic pathologies, consensus for the 
mechanisms involved in IBD proposed that in genetically predisposed individuals, 
excessive immune response to luminal content leads to the development of chronic 
inflammatory disorders of the gut (1). Over the past ten years, genetic studies have 
identified more than 170 loci of susceptibility involved in the development of IBD. 
Among those genes, some are linked to the unfolded protein response (UPR), with genes 
coding for X-box binding protein 1 (XBP1)(2). 
Accumulation of unfolded or misfolded proteins in the lumen of the Endoplasmic 
Reticulum (ER) leads to cellular dysfunction termed ER stress (3, 4). ER stress triggers 
UPR gene expression in order for cells to adapt to harmful environment and to solve ER 
disturbances. Three ER-localized proteins, inositol-requiring kinase/endonuclease 1 
(IRE1), pancreatic ER kinase (PERK), and activating transcription factor 6 (ATF6) were 
defined as UPR main proteins. Under ER stress, activated IRE1 removes 26-bp nucleotide 
intron from mRNA encoding for XBP1 (5). XBP1 spliced form then regulates gene 
expression that boosts folding protein regulation, ER-accumulated protein degradation, 
protein quality control, and phospholipid synthesis (3, 5, 6).  
Previous studies have shown that ER-stress is linked to intestinal inflammation 
(7-11). Genetic deletion of Xbp1 in intestinal epithelial cells (IECs) caused spontaneous 
enteritis in mice (10). Besides, deletion of IRE1β led to higher susceptibility to dextran 
sulfate sodium (DSS)-induced colitis (7), particularly when the gene was specifically 
deleted in intestinal epithelial cells (12). A new mouse model of UC has been 
characterized by an abnormal induction of ER-stress in goblet cells leading to colitis (13, 
14). In human, recent studies have shown that colonic mucosa of IBD patients exhibited 
a dysregulation of ER stress (11, 12, 16). Glucose-regulated protein 78-kDa (GRP78) and 
XBP1 splicing genes were increased in inflamed gut of CD patients (10, 11, 15). 
Similarly, UC patients, have increased GRP78 expression in inflamed colon (9-11). 
Additional studies have reported that uninflamed colonic mucosa from UC patients 
displayed increased expression of spliced XBP1, GRP78, glucose-regulated protein 94-
kDa (GRP94) and ATF6 (16). While it is clear now that ER stress in intestinal epithelial 
cells is associated with an inflammatory phenotype and by in large with IBD, the 
mechanisms by which ER stress could contribute to inflammation is less clear. What 
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mediators released upon ER stress by intestinal epithelial cells participate to 
inflammatory signs? We have made the hypothesis that active epithelial proteases could 
be released upon ER stress induction and thereby participate to generate inflammatory 
features in the context of IBD.  
Genetic studies have evidenced an association between increased levels of 
proteases and IBD (17). Elevated metalloproteinase and trypsin activity in colonic tissues 
and stools from CD and UC patients have been demonstrated (18, 19). However, the 
cellular origin of this activity and the nature of proteases released are unclear. Recent 
studies have identified the colonic epithelium as an important source of proteolytic 
activity. Both elastolytic and trypsin-like activity were associated with human colon 
epithelium (20-22), where the activation of Protease-Activated Receptors (PARs) 
modulates a number of cellular signals, including ion transport, barrier function or 
inflammatory mediator release (23-27). Here, we identified that trypsin-like activity in 
tissues from IBD patients is associated with the epithelium. We investigated whether ER 
stress in human intestinal epithelial cells can induce the release of proteolytic activity and 
whether this could contribute to the inflammatory phenotype associated with ER stress in 
intestinal epithelium. We have further identified Trypsin-3 as an epithelial protease 
associated with ER stress and IBD.   
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Results 
 Trypsin activity in IBD colon tissues is associated with the epithelium 
As previously reported, trypsin-like activity was released by human colonic 
biopsies incubated for 1h in culture media (Figure 1A). This released activity was 
significantly increased in supernatants of biopsies harvested from IBD patients (both CD 
and UC) (Figure 1A). In situ zymography using substrate for trypsin-like activity was 
performed in human colonic tissues and confirmed a significant increase in trypsin-like 
activity in tissues from CD and UC, compared to controls (Figure 1B right panel). 
Photomicrographs of in situ zymography also revealed that most of the trypsin-like 
activity detected in colonic tissues from CD and UC patients was associated with the 
epithelium (Figure 1B left panel), suggesting that intestinal epithelial cells were a major 
source of trypsin-like activity.  
 ER stress in human intestinal epithelium provokes the apical release of 
trypsin-like activity 
 We investigated whether the induction of ER stress in human intestinal epithelial 
cells could provoke the release of trypsin-like activity. In monolayers of differentiated 
Caco-2 cells, Tunicamycin or Thapsigargin, two ER stress inducers, triggered the release 
of trypsin-like activity compared to controls (Figure 1C). This release of ER stress-
induced trypsin-like activity was specific of the apical compartment (Figure 1C), but was 
not observed in the basal compartment (Figure 1D). The ER stress-induced release of 
trypsin-like activity in the apical compartment was inhibited by AEBSF incubation (not 
shown) and was significant at 2, 4, and 6h post stimulation (Figure 1C), but was inhibited 
by a pre-treatment with the ER stress inhibitor 4-PBA, at 6h post thapsigargin exposure 
(Figure 1E). We monitored that Tunicamycin and Thapsigargin treatments duly induced 
ER stress, by observing a significant increase of the ER stress markers XBP1s, CHOP, 
ATF4 and ATF6, compared to unstimulated controls (Supplementary Figure 1A). We 
also demonstrated that Tunicamycin and Thapsigargin treatment did not induce cell death, 
as no change in lactate deshydrogenase (LDH) activity was observed in controls or 
stimulated cell cultures (Supplementary Figure 1B). The ER stress-associated apical 
release of trypsin-like activity was also observed in HT29-MTX cells, another human 
intestinal epithelial cell line, at 2, 4 and 6h after Thapsigargin exposure (Supplementary 
Figure 2). These data demonstrated a polarized secretion of trypsin activity by intestinal 
epithelial cells upon ER stress induction. 
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Identification of protease(s) responsible for ER stress-associated trypsin 
activity in intestinal epithelial cells 
Trypsin-specific activity-based probe (ABP) was used to further characterize the 
ER stress-induced trypsin activity released by intestinal epithelial cells. When incubated 
in the presence of the biotin-PK-DPP ABP, trypsin-like activity in apical supernatants 
from thapsigargin-treated cells was completely inhibited (Figure 2A). This demonstrates 
that the ABP employed was able to retain the protease(s) responsible for ER stress-related 
trypsin-like activity. The ABP was then used to establish the profile of active proteases 
present in intestinal epithelial cell supernatants upon stimulation or not with the ER stress 
inducer Thapsigargin. Bands corresponding to active proteases were discriminated from 
non-specific labelling by pre-incubation with the large spectrum protease inhibitor 
AEBSF. Supernatants from stressed cells showed a strong signal for a band at 33-kDa, 
compared to a very weak signal for the same band in control cells. The signal for this ER 
stress-associated 33-kDa band disappeared in the presence of AEBSF (Figure 2B), 
indicating that this band corresponds to an active protease. This 33-kDa band signal was 
increased by 10-fold, compared to unstimulated cells supernatant (Figure 2C).  
Unbiased mass spectrometry analysis revealed the presence of seven proteins 
corresponding to proteolytic enzymes in ABP-treated samples of cell supernatants from 
control or thapsigargin-treated cells (Table 1). Only one type of protease signal was 
significantly increased (ratio thapsigargin-treatment/control >2) in ER stress-treated cells 
compared to controls. This signal corresponded to putative Trypsin-6 precursor, encoded 
by the PRSS3 Pseudogene-2. As a pseudogene, the expression of its predicted protein has 
never been described. The results of the mass spectrometry analysis did not therefore 
permit the clear identification of a known protease. Among all forms of known trypsins, 
only the molecular weight of Trypsin-3 (encoded by PRSS3 gene) corresponded to the 
33-kDa band that was observed in the ABP profiling gel (Figure 2B). Because no specific 
antibodies exist to discriminate between Trypsin-1 and -2, only a specific anti-trypsin-3 
antibody was available, we decided to further study the expression of trypsin-3 in ER 
stress conditions. 
Trypsin-3 expression in ER stress conditions and in IBD patients 
The presence of Trypsin-3 in supernatants of ER stress-stimulated intestinal 
epithelial cells was investigated. At 6 and 24 hours after ER stress induction, western blot 
performed in culture supernatants from apical compartment showed a strong band at 33-
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kDa, corresponding to Trypsin-3, not present in control conditions (Figure 3A). The 
densitometry analysis revealed that Trypsin-3 expression was increased by 3-fold and 25-
fold at 6 and 24 hours respectively (Figure 3A). This increased Trypsin-3 protein 
expression was not observed in basal lateral compartment of ER stress-stimulated Caco2 
cells (not shown). In cell extracts, Trypsin-3 protein expression was not modified between 
control and ER stress-stimulated conditions both at 6 or 24 hours (Supplementary Figure 
3A). In Caco2 cells, ER stress did not induce changes in mRNA expression of PRSS-3 
(gene of Trypsin-3) at 6-h, but significantly increased this expression at 24-h 
(Supplementary Figure 3B). In HT29-MTX cells, increased PRSS-3 mRNA expression 
was observed as soon as 6h after ER stress induction (Supplementary Figure 3C). This 
increased expression of PRSS3 mRNA seemed to be inhibited in the presence of the ER 
stress inhibitor PBA (not shown). Taken together, these results strongly evidenced that 
ER-stress induced the specific release of Trypsin-3 by intestinal epithelial cells in the 
apical compartment, and successively induced the transcription of its gene. 
In human colonic tissues, the presence of Trypsin-3 was mostly associated with 
the epithelium as demonstrated by the co-staining with the epithelial cell marker Ep-CAM 
(Figure 3B left panel). Trypsin-3 expression was significantly stronger in tissues from 
UC patients, compared to controls or to CD patients (Figure 3B). ER stress marker XBP1 
was only up-regulated in tissues from UC patients compared to controls or CD patient 
tissues (Figure 3C). Taken together, these data reinforced the link between induction of 
ER-stress and increased release of Trypsin-3 by intestinal epithelial cells, this seems 
particularly relevant in UC patients. 
ER stress modifies intestinal barrier function by a mechanism involving the 
apical release of trypsin-like activity 
We investigated whether ER stress induction and its associated release of 
proteolytic activity were able to disrupt barrier function of differentiated Caco-2 
monolayers. Thapsigargin-induced ER stress altered paracellular permeability, mRNA 
expression of antimicrobial peptides and mucins as well as the secretion of CxCL8 
(Supplementary Figures 4 A-C and Figure 4). All these epithelial dysfunctions were 
clearly associated to the induction of ER stress, and they were all inhibited by the ER 
stress inhibitor PBA (Supplementary Figure 4). Apical addition of protease inhibitors 
(AEBSF or Leupeptin) inhibited ER stress-induced increased permeability in Caco2 cells 
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(Figure 4A), suggesting that proteolytic activity released apically by ER stress disrupted 
epithelial barrier integrity.  
ER-Stress did not affect mRNA expression of human β-defensin 1 (HB1), but 
increased mRNA expression of β-defensin2 (HBD2), Trefoil factor 3 (TFF3), mucin 2 
(MUC2) and CXCL8 (Figure 4B). Apical addition of the protease inhibitor AEBSF 
blocked ER stress-induced TFF3, CXCL8 and HBD2 increased mRNA levels, suggesting 
that ER stress-associated proteolytic activity controls secretory barrier function (Figure 
4B). 
CXCL8 protein release was increased in supernatants of thapsigargin-treated cells 
compared to non-stimulated cells (Figure 4C). The addition of AEBSF or Leupeptin to 
thapsigargin-treated cells exacerbated CXCL8 protein release (Figure 4C).  
In HT29-MTX cells, Thapsigargin-induced increased mRNA expression of 
MUC5 and HBD2 were inhibited by apical addition of AEBSF (Figure 5A). CXCL8 
protein was increased in supernatants of Thapsigargin-treated HT29-MTX cells 
compared to controls and this increase was exacerbated by AEBSF apical treatment 
(Figure 5B). These data demonstrate that many of the effects of ER stress on intestinal 
epithelial cells are mediated by the release of trypsin-like activity on the apical 
compartment.  
ER stress-associated trypsin activity alters barrier function of Caco-2 
monolayers by activating PAR2 and PAR4 receptors. 
The mechanisms by which trypsin-like activity was involved in ER stress-
associated epithelial changes were investigated by studying the involvement of the two 
trypsin receptors PAR2 and PAR4. Thapsigargin treatment of Caco-2 cells increased 
mRNA expression of PAR2 and PAR4 at 6 and 24 hours (Figure 6A). Pre-incubation of 
Caco-2 cells with PAR2 antagonist (GB83) and/or PAR4 antagonist (ML354) blocked 
ER stress-induced increased paracellular permeablility both at 6 and 24h (Figure 6B, only 
6h shown). ER stress induced the release of CXCL8 both in the apical and basal 
compartment of stimulated Caco2 cells (Figure 4C and 6C). Pre-incubation with PAR2 
and/or PAR4 antagonists further enhanced ER stress-induced CXCL8 release (Figure 
6C), similar to the effects of the trypsin inhibitor AEBSF (Figure 4C). 
Apical trypsin activity or trypsin-3 do not modify ER stress processes  
ER stress markers XBP1s, CHOP, ATF4 and ATF6 were increased by 
Thapsigargin treatment after 6h in Caco2 cells, and the apical addition of the protease 
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inhibitor AEBSF did not modify the expression of these markers (Supplementary Figure 
5A). Similar results were obtained in HT29-MTX cells (not shown). These results suggest 
that ER stress-associated proteolytic activity did not affect the induction of ER stress. 
Apical addition of Trypsin-3 to Caco-2 cells did not modify the expression of XBP1s, 
CHOP, ATF4 and ATF6 (Supplementary Figure 5B), and did not induce the release of 
CXCL8 (Supplementary Figure 5C).  
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Discussion 
Abnormal induction of ER stress and increased serine proteases activity in colonic 
tissues have been established in IBD patients (16, 19), as well as in mouse colitis models 
(7, 9, 13, 20, 21). Here, we confirmed that excessive trypsin protease activity was released 
by colonic tissues from IBD patients, compared to healthy controls (19). We also 
evidenced that the IBD patient tissue-associated trypsin activity was detected mostly in 
intestinal epithelial cells. The induction of ER stress enhanced apically-released trypsin 
activity by intestinal epithelial cells. We showed that this trypsin activity was responsible 
for many of the ER stress-induced alterations of epithelial homeostasis, through a 
mechanism involving the activation of PAR2 and PAR4. Finally, we identified that 
Trypsin-3 could be an enzyme responsible for ER-stress induced epithelial disturbances. 
Indeed, Trypsin-3 has been detected in apical supernatants of ER stress-stimulated 
epithelium. Trypsin-3 is known to activate both PAR2 and PAR4 (28) and to induce 
increased epithelial permeability (22). Finally, Trypsin-3 expression was increased in 
tissues from UC patients, concomitantly to an increased expression of ER stress markers, 
while both expression were unchanged in tissues from CD patients.   
Experimental and clinical studies have reported that colonic tissues and luminal 
contents in inflammatory mouse models and IBD patients displayed excessive serine 
protease activity (19, 21, 24). While the cellular source of this activity has been discussed, 
no study had yet identified where this activity could come from. The role of proteases 
from infiltrated immune cells has been suggested, as well as a possible pancreatic source 
or even a microbiota source. In this study, we demonstrate that colonic mucosa from IBD 
patients releases higher trypsin proteolytic activity than colonic mucosa of healthy 
controls, and this activity in colonic tissues is associated with the epithelium. 
Interestingly, in a recent study, similar increased trypsin-like activity was detected in 
human intestinal epithelial cells from irritable bowel syndrome patients (22). In that 
study, this increased trypsin-like activity was associated with an increased Trypsin-3 
expression and secretion, and could be up-regulated by stress hormones or bacterial 
motifs, such as epinephrine and LPS respectively (22). From our results, it appears that 
ER stress is another regulator of Trypsin-3 expression and release by human intestinal 
epithelial cells. Further, our results suggest that Trypsin-3 up-regulation in IBD is specific 
of UC, as it was not observed in CD. While Trypsin-3 appears as a good candidate 
responsible of increased proteolytic activity in UC patient tissues, it seems that other 
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proteases could be responsible for trypsin-like activity in colonic tissues from CD 
patients.  
Mass spectrometry analysis definitively pointed towards members of the trypsin 
family as epithelial enzymes responsible for ER stress-induced proteolytic activity. 
However, with this approach, we were not able to clearly identify a known protease. 
Indeed, mass spectrometry identified peptides related to the putative trypsin-6 protein. 
No study has yet reported the existence of this protein, coded by the PRSS3 Pseudogene-
2. Putative Trypsin-6 has peptides in common with Trypsin-1 and Trypsin-2, which could 
then also be considered as possible enzymes responsible for ER stress-induced trypsin-
like activity. No selective inhibitor has been reported to discriminate between the activity 
of the 3 known forms of trypsin: Trypsin-1, Trypsin-2 and Trypsin-3. Likewise, no 
specific antibody discriminates between Trypsin-1 and Trypsin-2 proteins. Only a 
Trypsin-3 antibody has been described that does not cross-react with Trypsin-1 or 
Trypsin-2. This lack of specific tools has hampered our ability to determine which 
enzyme is specifically responsible for ER stress-induced proteolytic activity. We have 
tried to apply an shRNA approach targeting Ttrypsin-3 expression in Caco-2 cells, but all 
PRSS gene expression (PRSS1, PRSS2 and PRSS3) were affected by this approach, 
preventing a selective inhibition. Although Trypsin-3 expression reflects ER stress-
induced trypsin activity, we cannot rule out that Trypsin-1, Trypsin-2 or even the possible 
existence of Trypsin-6 might be responsible, at least in part, for the ER stress-induced 
proteolytic activity.  
Abnormal induction of ER stress in intestinal epithelial cells is also associated 
with IBD pathophysiology(16). Previous studies have linked aberrant induction of ER 
stress in colonic mucosa of UC patients (9, 10). Likewise, our results reported that colonic 
biopsies of UC, but not CD, carry an abnormal induction of ER-stress by upregulation of 
XBP1s. Our data correlate atypical ER stress induction and excessive secretion of 
Trypsin-3 in colonic mucosa of UC patients, pointing out Trypsin-3 as an interesting 
molecular motif to target ER stress pathways, and potentially for UC treatments. We 
verified that the induction of ER stress was not modified by the presence of proteolytic 
activity, and that Trypsin-3 did not induce ER stress. We revealed that the release of 
trypsin activity by intestinal epithelial cells is truly a consequence and not a cause of ER 
stress. Indeed, our results clearly demonstrated that most of the disruptive effects of ER 
stress on intestinal epithelial cell barrier were mediated by the apical release of trypsin 
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activity. This constitutes a breakthrough in understanding ER stress pathways and 
effectors. We demonstrated that the up-regulation of β-defensin-2, Trefoil factor 3, 
Mucin-2, and CXCL8 mRNA expression, as well as the increased permeability induced 
by ER stress are all caused by the apical release of trypsin-like activity.  
Interestingly, inhibition of trypsin-like proteolytic activity induced by ER stress 
further enhanced the detection of CXCL-8 protein in both apical and basolateral 
compartments of enterocytes and muco-secreting monolayers, while CXCL8 mRNA 
transcripts were inhibited by protease inhibitors. These results point to a differential role 
for proteases at the transcriptional level and the protein levels. It could be hypothesized 
that ER stress-released proteases cleave the CXCL8 proform thereby releasing more 
proteins. However, the fact that PAR2 antagonist further enhanced this CXCL8 protein 
release points to a receptor-mediated effect rather than a maturation process. Interestingly, 
our data suggest that ER stress-associated trypsin-like activity inhibits the acute release 
of CXCL8, but favors the subsequent chronic CXCL8 mRNA up-regulation. This is also 
in favor of a disruptive role for trypsin-like proteolytic activity in epithelial biology, and 
a potential benefic role for the inhibition of trypsin activity.  
Proteases use different regulatory mechanisms of action for cell signaling, 
including proteolytic cleavage of molecules or receptors to induce a large spectrum of 
intracellular signals. Proteolytic processing by proteases is required to mature 
antimicrobial peptides like the human defensin-5 or to increase the chemotactic activity 
of CXCL-8 (proteinase-3) or CXCL-5 (cathepsin G)(29, 30). In contrast, proteases like 
cathepsin G, proteinase-3 or elastase 2 can also degrade other cytokines including IL-6 
or TNF-α as well as some proteins involved in cellular contacts (31-34). In addition to 
these roles, proteases are also able to activate, by proteolytic cleavage of their 
extracellular N-terminal domain, the PARs (35, 36). PARs cleavage activates a broad 
range of cellular effects in the intestine, including ion exchange, motility, nociception, 
permeability, secretion (22, 25, 37-39). In agreement with PARs involvement in epithelial 
physiology, our data demonstrated that pre-treatment with PAR2 and/or PAR4 
antagonists inhibited the effects of ER stress on altered epithelial monolayer. Previous 
studies have demonstrated that PAR2 and PAR4 are both activated by trypsin-like 
enzymes (40), including Trypsin-3 (28). In addition, PAR2 activation is known to induce 
increased epithelial permeability (38). Trypsin-3 also induces increased permeability 
through a PAR2-dependent mechanism (22). Taken together, these studies are in 
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agreement with our finding reporting the involvement of PARs in increased permeability. 
Our study though brings to knowledge the fact that ER stress induction might be among 
the triggers to induce increased epithelial permeability in IBD, and in UC in particular, 
through a protease and PAR-dependent mechanism. Indeed, the involvement of PARs 
and PAR2 in particular in the development of colitis in animal models has been well 
documented (41).  
Overall, this study deciphers the mechanisms by which ER stress participates to 
epithelial dysfunction in intestinal epithelial cells. This study points out the role of 
trypsin-like activity, and to Trypsin-3 as a potential molecular target for the treatment of 
intestinal inflammation. These results appear to be particularly relevant in a UC context, 
where both ER stress and trypsin-3 are induced.   
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Material and Methods 
Patients. Human colonic tissues were obtained from individuals treated at the 
Centre Hospitalier de Toulouse (France) (Table S1). Biopsies were collected during 
colonoscopy procedures aimed at clinically evaluating the disease of established and 
well-characterized CD and UC patients or done in individuals undergoing colon cancer 
screening who were otherwise healthy (healthy controls). Written and verbal informed 
consent was obtained before enrollment in the study, and the Ethics Committee approved 
the human research protocol (Comité d’Ethique sur les Recherches Non 
Interventionnelles) (Identifier: NCT01990716). Isolated biopsy specimens were 
embedded in optimal cutting temperature (OCT) compound (Dako) at −186°C and stored 
for in situ trypsin activity. 
Cell culture and reagents. Caco-2 cells were purchased from the DSMZ 
collection (Braunschweig, Germany). Caco-2 cells were routinely grown at 37°C in a 5% 
CO2 water-saturated atmosphere in GlutaMAX DMEM (Gibco, Saint Aubin, France) 
supplemented with 10% of heat inactivated fetal bovine serum (Biowest, Nuaillé, France), 
1% nonessential amino acids, and 1% antibiotics (100 U/mL penicillin, 100 mg/mL 
streptomycin (Gibco) as previously described (42). Cultured medium was changed three 
times per week and cells passed once a week. Cells were grown to confluence as a 
monolayer in Transwell inserts, 12-well plate of 12-mm, polyester membrane, 0.3-µm 
pore size, (Costar, Paris, France) for 20 days. Endoplasmic reticulum stress (ER Stress) 
was induced by adding Thapsigargin or Tunicamycin (10µg/mL, sigma) in the culture 
medium as previously described (13). Before stimulation, cells were washed 2 times with 
Ca2+ /Mg2+- free PBS (Sigma, Saint Quentin Fallavier, France). Trypsin-like activity 
was inhibited by adding in the culture medium, AEBSF (200µM) or Leupeptin (50µM), 
two serine inhibitors. Caco-2 cells were pre-treated 45 minutes with PARs antagonists, 
PAR2, (ML354; 10µM) and PAR-4 (0.5µM) Tocris, (Bioscience, Lille, France), before 
thapsigargin stimulation.  
In situ zymography of colonic biopsies. Frozen OCT sections of colonic tissues 
from patients (8-μm thickness) were permeabilized with PBS2% Tween-20, rinsed with 
washing solution (PBS) and incubated at 37°C overnight with N-p-Tosyl-GPR-amino-4-
methylcoumarin hydrolchloride (50µg/mL, Sigma, Saint Quentin Fallavier, France) 
together with 0.3% low melting agarose as previously described (22). All sections were 
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visualized with the LSM710 microscope (Carl Zeiss France) and analyzed by observers 
blinded of patients subgroup, with Zen 2009 software (Carl Zeiss) 
Trypsin like activity. Trypsin-like activity was measured in basal and apical 
supernatants as previously described (43) with the substrate N-p-Tosyl-GPR-amino-4-
methylcoumarin hydrolchloride (0.1mM, sigma) in 50 mM Tris, 10mM CaCl2 buffer (pH 
8). Hydrolysis rate was measured by the change in fluorescence (360/460 nm 
excitation/emission wavelengths) every 30 seconds for 15 minutes at 37ºC on a 
microplate reader 96-well plate NOVOstar. Activity was standardized to the rate 
generated by trypsin of known concentration from porcine pancreas (Sigma).  Control 
and IBD patients biopsies with OCT were cryostat sectioned (8 μm thickness) and washed 
with PBS, 2% Tween-20. Samples treated with the substrate N-p-Tosyl-GPR-amino-4-
methylcoumarin hydrochloride (0.1 mM, Sigma) in 0.3% low melting agarose were 
incubated overnight at 37°C as previously described (22). Nuclei were stained with 
Topro3 (Invitrogen). Images were analyzed with ImageJ software. 
Activity-based probe. The Biotin-PK-DPP serine protease activity-based probe 
was obtained from the laboratory of Dr. Nigel W. Bunnett (Columbia University, USA), 
with the participation of Dr. Laura Edgington-Mitchell (Monash University, Australia) 
and synthetized as previously described (44). Supernatant were treated with Pefabloc SC 
plus kit (Roche. Mannhein, Germany) with or without AEBSF (4 mM for 15 min at 37ºC 
under stirring (1000 rpm). Then, the ABP biotin-PK-DPP was added to each reaction to 
a final concentration of 1 M, and samples were incubated for 60 min at 37ºC under 
stirring (1000 rpm). Next, protein from supernatant was precipitated with 15% 
trichloroacetic acid/acetone and separated by SDS–polyacrylamide gel electrophoresis 
(4-15%). Membrane was block with 1% BSA and incubated for 1 hour at room 
temperature with 1/1000 streptavidin-HRP (LifeTechnologies). Immunoblots were 
visualized with chemiluminescence. (Chemidoc XRS Bio-Rad) 
Western blot. Caco-2 cells proteins were extracted with the kit Nucleospin 
RNA/Protein Kit (Macherey-Nagel) as per manufacturer’s instructions. Proteins from 
supernatant were concentrated with trichloroacetic acid/acetone, separated by SDS–
polyacrylamide gel electrophoresis (4-15%) and transferred onto a nitrocellulose 
membrane (Life Science). Membranes were blocked with 1% milk, 1% BSA, incubated 
with anti-PRSS3 antibody (ab107430-Abcam) (1/100) overnight at 4ºC and with 
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secondary antibody conjugated with HRP (1/3000, w4018-Promega).  Immunoblots were 
visualized with chemiluminescence (Chemidoc XRS Bio-Rad). 
Immunofluorescence in biopsies. Colonic samples were cut (5-μm thickness) 
with cryostat (Leica Microsystems, GmbH) as previously described (22). Sections were 
incubated with antibodies against trypsin-3 (1/500 #ab107430-Abcam) and the epithelial 
cell maker EpCAM/CD326 (1/500, #2929, Cell Signalling) followed by secondary 
antibody conjugated to AlexaFluor 488 donkey anti-rabbit IgG (1/500, #A21206, 
Molecular Probes) and 568 donkey anti-mouse IgG (1/500, #A10037, Molecular Probes). 
Slides were mounted with Prolong Gold Antifading Reagent with 4’,6’-diamidino-2-
phenylindole (DAPI) (#P36935, Molecular Probes), to counterstain cell nuclei. The 
fluorescence intensity mean corresponds to trypsin-3-immunoreactivity in epithelial cells, 
as determined by EpCAM co-staining, and it was quantified with ImageJ software.  
Real-time PCR analysis. Total RNA was extracted with the NucleoSpin 
RNA/Protein Kit (Macherey-Nagel, Hoerdt, France) and converted to complementary 
DNA using the Maxima First Strand cDNA Synthesis Kit for reverse transcription-
quantitative PCR (RT-qPCR) (Thermo Scientific). Polymerase chain reaction was 
performed using SYBR Green Master I Kit (Roche), sense and antisense specific primers 
(see Table 2) in a LightCycler 480 Instrument (Roche). After amplification, the relative 
expression of mRNA was determined with methode 2-DDCt by using hGAPDH as 
reference gene. 
Measures of paracellular Permeability. Paracellular permeability of 
differentiated Caco-2 monolayer cells was monitored as previously described (45). 
Briefly, dextran-Fluorescein IsoThioCyanate (FITC) (4000 kDa, Sigma) was added into 
the apical compartment of a transwell, together with the corresponding reagent. 
Paracellular permeability was monitored by the passage of dextran from the apical to the 
basolateral medium, as previously described(42).  
Measure of CXCL8 protein expression. Supernatant from cells were stocked at 
-80°C. Concentration of CXCL8 was measured by enzyme-linked immunosorbent assay 
(BD Biosciences, Heidelberg, Germany) according to the manufacturer’s instructions 
(46). 
Measurement of cell cytotoxicity with Lactate dehydrogenase (LDH). 
Supernatant from treated cells or not treated cells were collected at 2, 4 and 6 hours. Cell 
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cytotoxicity was measured following the protocol of Pierce™ LDH Cytotoxicity Assay 
Kit. 
Statistical Analysis. Results are expressed as mean± SEM except for, 
immunostaining and in situ zymography quantification of patient biopsies, where each 
dot represents one patient. Statistical analyses were performed using GraphPad Prism 
5.00 (GraphPad software, San Diego, CA) software package for PC. Multigroup 
comparisons were performed using a 1-way analysis of variance followed by a Bonferroni 
correction for multiple tests. Two-group comparisons were performed using an unpaired 
t test don’t assuming the Gaussian distribution. The Gaussian distribution was tested by 
Kolmogorov-Smirnov test. A value of P <0.05 was considered statistically significant. 
All P values were 2-sided. 
 
  
Results 
110 | 
 
Table 1. Main active trypsin proteases secreted from Caco-2 cells. This list shows the 
active ABP-labelled proteases identified by LC-MS/MS analysis of pooled supernatant 
from caco-2 cells control and stimulated with thapsigargin. The table shows the respective 
gene symbol, protein name, predicted molecular weight and the ratio 
thapsigargin/control. 
Gene Symbol Protein Name Predicted MW 
(in kDa) 
Ratio 
Thaps/Control 
PRSS3P2 Putative Trypsin-6 26 17.73 
PSA Kallikrein- Q8NHM43 103.3 1.83 
UB2N Ubiquitin-Conjugating Enzyme E2N 17.1 1.22 
BLMH Bleomycin Hydrolase 52.6 0.89 
CTSD Cathepsin D 44.6 0.81 
PSMA5 Proteasome Subunit Alpha 5 26.4 0.53 
CASP14 Caspase 14 27.7 0.29 
 
 
 
Table S1. Characteristics and outcomes of patients from which biopsies were collected. 
N, number. F, female. M, male.  
 CTR CD UC 
Number (F/M) 14 (4/10) 28 (14/14) 10 (6/4) 
Age : median (years, range) 50.2 (18-77) 38.7 (23- 69) 42.2 (26-62) 
Without treatment  8 2 
 
 
 
Table S2. Sequence of oligonucleotides used for RT-qPCR experiments. GAPDH, 
Glyceraldehyde-3-Phosphate Dehydrogenase;  PRSS3, protease serine 3 (mesotrypsin); 
PAR-2, Protease-activated receptor 2; PAR-4, Protease-activated receptor 4; HD1, human 
beta-defensin 1; HD2, human beta-defensin 2; MUC2, Mucin 2; TFF3, Trefoil Factor 3; 
CHOP, CCAAT-enhancer-binding protein homologous protein; XBP1s, X-Box Binding 
Protein 1 spliced; ATF4, Activating Transcription Factor 4; ATF6, Activating 
Transcription Factor 6, CXCL8, C-X-C Motif Chemokine Ligand 8. 
Gene Sense 5’ – 3’ Antisense  3’- 5’ 
GAPDH GAGAAGGCTGGGGCTCAT TGCTGATGATCTTGAGGCTG 
PRSS-3 ACCCTAAATACAACAGGGAC AGCCAAAAAGCTCAGAGT 
PAR-2 CAGTGGCACCATCCAAGGA TGTGCCATCAACCTTACCAATAA 
PAR-4 TGCGTGGATCCCTTCATCTAC CCTGCCCGCACCTTGTC 
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HD1 TCCTGAAATCCTGGGTGTTG TTTGGTAAAGATCGGGCAGG 
HD2 CCATGAGGGTCTTGTATCTCC AGGGCAAAAGACTGGATGAC 
MUC2 ACTCCAACATCTCCGTGTCC AGCCACACTTGTCTGCAGTG 
TFF3 GCTCTGCTGAGGAGTACGTG GGG ATC CTG GAG TCA AAG CA 
CHOP CCTCAGTCAGCCAAGCCAGAGA CACCTCCTGGAAATGAAGAGGAA 
XBP1s ATGGATGCCCTGGTTGCTGAA CCTGCACCTGCTGCTGCGGACT 
ATF4 TGGCATGGTTTCCAGGTCATCT CCAACAACAGCAAGGAGGATGC 
ATF6 AGGGCAGAACTCCAGGTGCT TGCACCCACTAAAGGCCAGAC 
CXCL8 GCCTTCCTGATTTCTGCAGCT TGCACTGACATCTAAGTTCTTTAGCAC 
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Figures legend. 
 
Figure 1. Trypsin-like activity in ER stress-stimulated intestinal epithelial cells and 
in the intestinal mucosa of IBD patients. 
Biopsies from Healthy control (HC, n=14), Crohn’s Disease (CD, n=28) and Ucerative 
colitis (UC, n=10) were incubated for 1 hour in HBSS medium and Trypsin activity 
released by biopsies in culture supernatants was monitored. Data are expressed as mean 
±SEM and were compared using Student's t-test. *P<0.05 vs. Healthy control group (A). 
Human colonic tissues were obtained from individuals treated at the Centre Hospitalier 
de Toulouse (France) (Table S1). Biopsies from Healthy control (HC, n=14), Crohn 
Disease (CD, n=28 and Ucerative colitis (UC, n=10) were embedded in optimal cutting 
temperature (OCT) for in situ trypsin activity measures. Representative confocal 
photomicrographs of in situ zymography assays performed in colonic tissue slices (scale 
bar: 50μm). Graph representation of mean fluorescence intensity quantified from 6 to 12 
patients per group. Data are expressed as mean±SEM and were compared using Student's 
t-test. *P<0.05 vs. Healthy control group. (B) Monolayers of differentiated Caco-2 cells 
cultured on Transwell system were stimulated with Tunicamycin (10µg/mL) or 
Thapsigargin (10µg/mL), two classic ER-Stress inducers and/or pre-treated with 1mM 
4PBA, a chemical chaperon that inhibits ER-stress activation. (C-E) Trypsin-like activity 
was measured in (C) apical and (D) basal supernatants recovered from control or ER 
stress-treated Caco-2 cells and in (E) apical supernatant of ER stress-treated Caco-2 cells 
incubated with PBA for 6 hours. Assembled data from at least four independent 
experiments with 5 wells per set. Data are expressed as mean±SEM and were compared 
using Student's t-test. *p<0.05 and **p<0.01 and ***p<0.001 vs. control group. 
 
Figure 2. Inhibition and activity profile of active proteases present in supernatants 
from intestinal epithelial cells in response to ER-Stress. 
(A-C) Monolayers of differentiated Caco-2 cells cultured on Transwell system were 
stimulated with Thapsigargin (10µg/mL). (A, B) Incubation of apical supernatant of 6 
hours ER-Stressed and control Caco-2 cells, with a Trypsin-specific activity-based probe 
(ABP), biotin-PK-DPP. (A) Trypsin-like activity was measured in supernatants after ABP 
binding. (B) Gel electrophoresis was performed to detect the molecular weight of active 
trypsin-like proteases. Samples from each condition were pre-incubated with serine 
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proteases inhibitor (AEBSF) to confirm the specificity of the serine protease band. (C) 
Relative ABP-33kDa protein quantification (D) Mass spectroscopy analysis by Student’s 
t-test. *p<0.05, **p<0.01 and***p<0.001 vs. control group. 
 
Figure 3. Trypsin-3 expression in ER stress-stimulated intestinal epithelial cell 
supernatants and in colonic mucosa of UC and CD patients.  
Monolayers of differentiated Caco-2 cells cultured on Transwell system were stimulated 
with Thapsigargin (10µg/mL). Relative Trypsin-3 protein quantification by Western blot 
analysis from apical supernatant protein extracts of control and ER-stressed at 6 (left) and 
24 hours (right) (A) Human colonic tissues were obtained from individuals treated at the 
Centre Hospitalier de Toulouse (France) (B) Biopsies from Healthy control (Ctrl), n=19), 
Crohn Disease (CD, n=16) and Ulcerative colitis (UC, n=11) were embedded in optimal 
cutting temperature (OCT) for immunostaining with anti-Trypsin-3 antibody and an 
epithelial cell maker EpCAM/CD326. Representative confocal photomicrographs of 
immunostaining performed in colonic tissue slices (scale bar: 50μm). Graph 
representation of mean fluorescence intensity quantified from 6 to 12 patients per group. 
Data are expressed as mean±SEM and were compared using Student's t-test. *P<0.05 vs. 
Healthy control group. (D) Relative mRNA expressions of XBP1-spliced form in colonic 
biopsies from healthy control (Ctrl), Crohn’s disease (CD) and Ulcerative colitis patients. 
Data are expressed as mean±SEM and were analysis by Student’s t-test. *p<0.05, 
**p<0.01 and ***p<0.001 vs control/healthy control group. 
 
Figure 4. Effects of protease inhibitors on ER stress-induced epithelial dysfunction 
in enterocytes 
(A-C) Monolayers of differentiated Caco-2 cells were cultivated in Transwell system, 
and were stimulated with Thapsigargin (10µg/mL) for 6 hours in presence or not of 
Trypsin inhibitors (AEBSF (200µM) or Leupeptin (50µM)). (A) Paracellular 
permeability was monitored by measuring the apical-to-basolateral flux of dextran 4kDa–
FITC. (B) Relative mRNA expressions of β-Defensin-1, β-Defensin-2, Trefoiled factor-
3, mucin-2 and CXCL8 after 6 hours of ER-Stress stimulation. (C) Levels of CxCL-8 
monitored by Elisa, and released by Caco-2 cells in the apical and basolateral 
compartments of Transwell system. Data expressed as mean±SEM were compared using 
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one way non-parametric anova (Bonferroni test). *p<0.05, **p<0.01, ***p<0.001, 
***p<0.0001vs control group; ϕp<0.05, ϕϕp<0.01, ϕϕϕp<0.001 vs. thapsigargin group. 
 
Figure 5. Effects of protease inhibitors on ER stress-induced epithelial dysfunction 
in muco-secreting epithelial cells 
(A, B) Monolayers of HT29MTX cells were cultivated in Transwell system, and were 
stimulated with Thapsigargin (10µg/mL) for 6 hours in presence or not with Trypsin 
inhibitor (AEBSF (200µM)). (A) Relative mRNA expressions of β-Defensin-2, mucin-5 
and mucin-2 after 6 hours of ER-Stress stimulation. (B) Levels of CxCL-8 monitored by 
Elisa, released by HT29MTX cells in the apical and basolateral compartments of 
Transwell system. Data expressed as mean±SEM were compared using one way non-
parametric anova (Bonferroni test). **p<0.01 and ***p<0.001 vs control group; 
ϕϕp<0.01 vs. thapsigargin group. 
 
Figure 6. Protease-Activated Receptor -2 and -4 expression and function in caco-2 
cells treated or not with ER-stress inducer.  
Differentiated Caco-2 cells cultured in a transwell system were stimulated with 
Thapsigargin (10µg/mL) (A) Relative gene expression of PAR2 and -4 was quantified at 
6 and 24 hours after stimulation. (B, C) Caco-2 cell monolayers were stimulated with 
Thapsigargin (10µg/mL) and pre-treated with antagonist PAR2 (GB83, 10µM) and/or 
PAR4 (ML354, 0.5µM). (B) paracellular permeability was measured at 6 and 24 hours 
and (C) CXCL8 was quantified in the apical and basal supernatant at 24 hours. Data 
expressed as mean±SEM were compared using one way non-parametric anova 
(Bonferroni test). *p<0.05, **p<0.01, ***p<0.001 vs control group; ϕϕp<0.01, 
ϕϕϕp<0.001, ϕϕϕϕp<0.0001 vs. thapsigargin group 
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Supplementary figures 
Figure S1. Thapsigargin- and Tunicamycin-induced ER Stress markers and cell 
death. 
(A, B) Monolayers of differentiated Caco-2 cells cultured in a transwell system were 
stimulated with Tunicamycin (10µg/mL) or Thapsigargin (10µg/mL) for 6 hours. (A) 
Relative gene expression of ER-stress markers, (XBP1s, ATF6, ATF4, CHOP) were 
measured. (B) Percentage of LDH (Lactate dehydrogenase) activity was measured in the 
culture media, 2, 4 and 6 hours after exposure to Tunicamycin or Thapsigargin. Data are 
expressed as mean±SEMand were analysis by Student’s t-test. **p<0.01 and ***p<0.001 
vs. control group. 
 
Figure S2. Trypsin-like activity in supernatants of human ER stress-stimulated 
muco-secreting cells. 
(A) Monolayers of HT29MTX cells cultured in a Transwell system were stimulated with 
Thapsigargin (10µg/mL). (A) Trypsin-like activity was measured in apical and basal 
supernatants recovered from control or ER stress-treated HT29MTX cells for 2, 4 and 6 
hours. Data are expressed as mean±SEM were compared using one way non-parametric 
anova (Bonferroni test). *p<0.05 vs control group. 
 
Figure S3. Trypsin-3 levels cellular expression upon ER-stress stimulation. 
(A, B) Caco-2 cell cultured in transwells were stimulated with thapsigargin (10µg/mL). 
(A) Protein levels of trypsin-3 were measured by Western Blot at 6 and 24 hours. B-actin 
was used as a control. (B) Gene expression of PRSS-3, trypsin-3 precursor, was quantified 
at 6 hours and 24 hours after stimulation. (C) Monolayers of HT29MTX cells cultured in 
a Transwell system were stimulated with Thapsigargin (10µg/mL). Relative gene 
expression of PRSS3 was measured at 6 hours after ER-stress induction. Data are 
expressed as mean±SEM were compared using one way non-parametric anova 
(Bonferroni test). *p<0.05, **p<0.01 vs control group. 
 
Figure S4. Effects of ER stress inhibitor PBA on ER-stress-induced epithelial 
dysfunctions   
(A-C) Monolayer of differentiated Caco-2 cells cultured in a transwell system were pre-
treated with PBA (1mM) and followed by Thapsigargin (10µg/mL) stimulation. (A) 
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Paracellular permeability was measured after 6 hours stimulation. (B) Relative gene 
expression of Human β-Defensin-2, Trefoiled factor-3, mucin-2 and CXCL8 was 
analyzed after 6 hours stimulation (C) CXCL8 from 6-wells supernatants was quantified 
by Elisa.  Data are expressed as mean±SEM were compared using one way non-
parametric anova (Bonferroni test). **p<0.01, ***p<0.001 vs control group; ϕp<0.05, 
ϕϕp<0.01 vs. thapsigargin group. 
 
Figure S5. Effects of protease inhibitor and of Trypsin-3 on ER-Stress induction. 
(A) Caco-2 cells were stimulated with Thapsigargin in the presence or not of AEBSF. ER-
stress markers including XBP1s, CHOP, ATF4 and ATF6 were measured. (B-C) Caco-2 cells 
were stimulated with Thapsigargin and with Trypsin-3 (1nM and 10 nM). (B) ER-stress 
markers (XBP1s, CHOP, ATF4 and ATF6) were measured. (C) CXCL8 from 6-wells 
supernatants was quantified by Elisa. Data are expressed as mean±SEM and were analysis 
by Student’s t-test. *p<0.05, **p<0.01, ***p<0.001 vs. control group. ϕϕp<0.01 vs. 
thapsigargin group. 
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  Supplementary Figure S1. 
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Caco-2 cells results not included in the paper 
 
 
Methodology 
Cell culture and reagents. Described in the paper. Before ER-stress induction, cells were pre-
stimulated with antagonist PAR1 10µM (SCH79797, Tocris) or ML-7 20µg/mL (SIGMA) for 45 
minutes.  
Real-time PCR analysis. Described above on the paper. Primer sequence Table 1. 
Measures of paracellular Permeability. Described in the paper 
Measure of CXCL8 protein expression. Described in the paper 
Measurement of cell cytotoxicity with Lactate dehydrogenase (LDH). Described in the paper 
Measurement of PAR2 cleavage. CHO cells co-expressing luciferase PAR2 were obtained by 
Morley Hollenberg and Rithwick Ramachandran, Calgary, Canada). CHO-lucPAR2 cells were 
routinely grown at 37°C in a 5% CO2 water-saturated atmosphere in Ham F12 GlutaMAX (Gibco) 
supplemented with 10% of heat inactivated fetal bovine serum (Biowest, Nuaillé). Cultured 
medium was changed three times per week and cells passed once a week. 15000 cells were seed 
in 96 well-plates (Thermos Fisher) for 2 days. Before stimulation cells were washed 2 times with 
ca2+ /Mg2+- free PBS (Sigma). Then, cells were incubated with 100µL of cell supernatant from 
non-stimulated cells or thapsigargin-stimulated caco-2, followed by 15 min of incubation at RT. 
Supernatant was collected and transferred to a new 96 well plate (sigma). The plate was 
centrifuged 5 min at 1200rtm. Next, 80 µL of supernatant was transfer to a white 96 well plate 
(Corning). Luciferase substrate was added (nanoglo luciferase assay promega #N1110) and the 
plate was imminently read in the dark on a microplate reader 96-well plate NOVOstar at  Several 
dilutions of trypsin from porcine pancreas (sigma) (1U/mL) were used as a positive control and 
thrombin from human plasma (sigma) (1U/mL) as a negative control.   
 
 
Results 
mRNA expression of PRSS-1 and -2 increased after 6 hours of ER-stress induction  
As shown previously, ER-stress induces increased trypsin-like activity in the apical compartment 
of intestinal epithelial cells. Trypsin-like substrate is cleaved by the three main trypsin forms 
including trypsin-1, trypsin-2 and trypsin-3, (PRSS-1, -2 and -3 trypsinogen genes respectively), 
and also by tryptase. Previous data from the laboratory have demonstrated that intestinal 
epithelial cells did not express tryptase (Rolland-Fourcade et al. Gut 2017). Thus, 6 hours after 
ER-stress induction, mRNA expression of these three main trypsinogen genes present in intestinal 
epithelial cells, PRSS-1, PRSS-2 and PRSS-3 were quantified (Figure 7A). At this time-point, only 
PRSS1 and PRSS2 but not PRSS3 mRNA expression were significantly up-regulated. In addition, 
mRNA levels of matriptase I, elastase-2A and elafin (an elastase inhibitor) were analyzed, showing 
that Elastase-2A was strongly up-regulated, while its inhibitor Elafin was significantly down-
regulated (Figure 7B). The expression of Matryptase-1 was not modified by exposure to ER stress 
inducers (Figure 7B). 
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Trypsin activity alters barrier function of Caco-2 monolayers by activating PAR2 and -4 
receptors but not PAR1  
ER stress-associated increased paracellular permeability was due to trypsin proteolytic activity 
and was blocked by pre-treating caco-2 cells with PAR2 antagonist (GB83) and PAR4 antagonist 
(ML354). Pre-treatment with the PAR1antagonist (SCH79797) aggravated the increase in 
paracellular permeability associated with ER stress (Figure 8). Combination of PAR1 and PAR2 
antagonist and combination of PAR1 and PAR4 antagonist pre-treatments have no additional 
effect, both normalized permeability. Similar results were observed at 6 (Figure 8A) and at 24 
hours (Figure 8B).  
 
PAR1 antagonist decreased ER stress-associated CXCL8 secretion 
The release of CXCL8 in apical and basal compartment of ER stress-stimulated cells was 
normalized to control levels by pre-incubation with PAR1 antagonist.  The addition of PAR2 and -
4 antagonists on the contrary enhanced the release of CXCL8 both in the apical and basal 
compartments (Figure 9). These data suggest that each PAR signaling pathway play a different 
role protecting or harming CXCL8 release.  
 
Trypsin proteolytic activity from stressed caco-2 cells cleave PAR2 
Next, we have examined the ability of supernatants from ER stress-stimulated cells to cleave PAR2 
receptors. Stable cell line carrying the firefly luciferase PAR2 was exposed to supernatants of ER-
stress-induced cells and control. Supernatants from stressed cells strongly cleaved PAR2 
compared to non-stimulated cell supernatant (Figure 10) 
 
Increased permeability is MLCK-dependent 
Activation of PAR2 leads to phosphorylation of MLC via myosin light chain kinase which, in turn, 
induces cytoskeleton contraction. To study whether PAR2-MLCK was the mechanism used to 
increase permeability, ML-7, a MLCK inhibitor, was used. 6 and 24 hours after ML7 pre-treatment, 
stressed cells exhibited normalized paracellular permeability (Figure 11). 
 
Discussion and conclusions 
See below in General discussion and conclusions.  
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Figure 7. mRNA expression of other serine proteases or inhibitors. (A-B) Monolayers of Caco-
2 cells were stimulated with thapsigargin for 6 hours. Relative mRNA expressions of PRSS-1, PRSS-
2 and PRSS-3 (A), matriptase 2, Elafin and Elastase 2a (B) were quantified. At least n=8 
well/condition. Data expressed as mean±SEM were compared using one way non-parametric 
anova (Bonferroni test). *p<0.05, **p<0.01 vs control group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The impact of PAR1 antagonist on intestinal barrier homeostasis. (A-B) Monolayer 
of caco-2 cells cultured in a transwell stimulated with thapsigargin and were pre-treated with 
antagonist PAR1, -2 and -4. (A) Paracellular permeability was monitored by measuring the apical-
to-basolateral flux of dextran 4kDa–FITC after 6 hours stimulation (A) and 24 hours (B). Data 
expressed as mean±SEM were compared using one way non-parametric anova (Bonferroni test). 
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***p<0.001 vs control group; ϕp<0.05, ϕϕp<0.01, ϕϕϕp<0.001, ϕϕϕϕp<0.0001 vs. thapsigargin 
group. 
 
 
 
Figure 9. PAR1 antagonist decrease CXCL8 release. Monolayer of caco-2 cells cultured in a 
transwell stimulated with thapsigargin and were pre-treated with antagonist PAR1, -2 and -4. 
Levels of CXCL8 were monitored by Elisa in apical and basal supernatant of the transwell system. 
Data expressed as mean±SEM were compared using one way non-parametric anova (Bonferroni 
test). ***p<0.001 vs control group; ϕp<0.05, ϕϕp<0.01, ϕϕϕp<0.001, ϕϕϕϕ p<0.0001 vs. 
thapsigargin group. 
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Figure 10. PAR2 cleavage. Monolayer of caco-2 cells cultured in a transwell were stimulated with 
thapsigargin for 6 hours. Supernatant was collected. Stable cell line carrying the firefly luciferase 
PAR2 were incubated with supernatant of stressed cells. PAR2 cleavage was measured. *p<0.05 
vs control group 
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Figure 11. The impact of MLCK on permeability. Monolayer of caco-2 cells cultured in a 
transwell stimulated with thapsigargin were pre-treated with ML-7, a MLCK inhibitor. 
Paracellular permeability was monitored by measuring the apical-to-basolateral flux of dextran 
4kDa–FITC after 6 and 24 after thapsigargin and ML-7 treatment. Data expressed as mean±SEM 
were compared using one-way non-parametric anova (Bonferroni test). ****p<0.0001 vs control 
group. ϕϕp<0.01, ϕϕp<0.001  vs. Thapsigargin group. 
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HT29-mtx results 
 
 
Methodology 
Cell culture and reagents. Described in the paper.  
Real-time PCR analysis. Described in the paper. Primer sequence Table 1. 
Measure of CXCL8 protein expression. Described in the paper 
 
Results 
ER-stress increased the three trypsinogen genes in HT29mtx cells 
Similar to what was observed in caco-2 cells, stressed HT29-mtx cells showed upregulation of 
PRSS-1, PRSS-2 after 6 hours of induction. However, stressed mucus-secreting cells also showed 
upregulated mRNA levels of PRSS-3 mRNA (Figure 12). This result, together with trypsin like 
activity, confirmed that ER-stress induces trypsin-like proteolytic activity at the apical side of IECs, 
and an increased expression of trypsin-3. 
 
Trypsin activity alters barrier homeostasis  
Stressed HT29mtx with or without serine protease inhibitors displayed upregulated mRNA levels 
of HBD2 and MUC2 (Figure 13A). Moreover, apical release of CXCL8 quantified by ELISA increased 
after 24 hours stimulation in stressed cells. A small increase of CXCL8 was observed in the 
presence of serine proteases inhibitors (Figure 13B). Although more experiments should be done 
to confirm mRNA results (n=3 samples/condition), these data showed, like in Caco2, that ER-
stress activation strongly alters intestinal barrier function, but in contrast to Caco2, HT29-MTX 
did not seem to use the release of trypsin-like activity to control HBD2 expression. Like in Caco2 
cells however, trypsin activity released by thapsigargin-treated HT29-MTX was not responsible 
for the increased release of CXCL8 in the basal or apical compartment of monolayers, nor for the 
overexpression of MUC2 mRNA. 
 
mRNA levels of PAR2 and -4 increased under ER-stress  
Stressed HT29-mtx cells showed upregulation of mRNA levels of PAR2 and -4, while inhibition of 
trypsin proteolytic activity, by AEBSF, normalized PAR4 mRNA levels (Figure 14). These data 
together with Caco-2 results presented in the article, evidenced an association between ER-stress 
and the up-regulation of PARs expression. However, the number of samples should be increased 
to confirm these results. 
 
 
Discussion and conclusion  
 
Taken together, these data suggest that mucus-secreting cell line mostly behaves like enterocytes 
under ER-stress induction. Both cell lines increased trypsin proteolytic activity at the apical side 
of the monolayers, and several biological changes associated with ER stress induction are 
mediated by this increased trypsin-like activity. In HT29-MTX, PRSS-3 mRNA expression was 
increased as early as 6 hours after ER stress stimulation, suggesting that trypsin-3 could also be 
the main candidate to explain the increased trypsin-like activity in monolayer supernatants. PAR2 
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and -4, are also upregulated in HT29MTX cells under ER-stress. Although the effects of PAR 
antagonists were not tested in HT29MTX cells, the fact that PAR2 and PAR4 are up-regulated could 
suggest a similar mechanisms as in Caco2, involving these two receptors.  In conclusion, these data 
suggest that ER-stress on mucus secreting cells increases trypsin proteolysis and induces 
inflammatory signs disrupting intestinal barrier likewise stressed caco-2.  
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Figure 12. mRNA relative expression of the three trypsinogen genes. Monolayers of HT29MTX 
cells were stimulated with Thapsigargin for 6 hour. mRNA levels of PRSS-1, PRSS-2 and PRSS-3 
were quantified. At least n=8 wells/ condition. Data expressed as mean±SEM were compared 
using one-way non-parametric anova (Bonferroni test). *p<0.05, **p<0.01 vs control group. 
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Figure 13. ER-stress alters intestinal homeostasis. Monolayers of HT29MTX cells cultivated in 
Transwells, were stimulated with Thapsigargin for 6 hours in presence or not of serine protease 
inhibitor. (A) Relative mRNA expressions of β-Defensin-2 and mucin-2 were quantified. (B) Levels 
of CXCL8 monitored by Elisa, at the apical and basolateral compartments of a Transwell system. 
Data expressed as mean±SEM were compared using one way non-parametric anova (Bonferroni 
test). *p<0.05, **p<0.01 and ***p<0.001 vs control group. ϕp<0.05 vs. thapsigargin group. 
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Figure 14. Up-regulation of PAR2 and -4 in HT29-mtx cells treated with ER-stress inducer. 
Differentiated Caco-2 cells cultured in a transwell system were stimulated with Thapsigargin 
(10µg/mL) in the presence or not of AEBSF (200µM). Relative gene expression of PAR2 and -4 
was quantified at 6 hours after stimulation. At least 3 samples/ condition. Data expressed as 
mean±SEM were compared using one-way non-parametric anova (Bonferroni test). *p<0.05, 
**p<0.01 vs control group. 
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Discussion  
 
In our study, we demonstrated that epithelial colonic mucosa constitutes for a large part the origin 
of increased trypsin proteolytic activity in the lumen of CD and UC patients compared to healthy 
controls. Most of earlier studies have focused on infiltrated immune cells and microbiota to 
explain the origin of upregulated expression of proteinases (Nathalie Vergnolle 2016). However, 
N. Vergnolle’s team suggested in 2012 that intestinal epithelial cells could be a potential source of 
proteases during gastrointestinal pathologies (J. P. Motta et al. 2012). Affected and unaffected 
tissue of UC and CD showed increased elastolytic and trypsin activity detected on mucosal tissue 
(J. P. Motta et al. 2012). Moreover, patients with IBS exhibited increased levels of a set of serine 
proteases including tryptase, elastase, trypsin or cathepsin G in the stools compared to healthy 
controls (Nathalie Vergnolle 2016; Schmid et al. 2007; J. P. Motta et al. 2012). Our result reinforces 
the previous data, strengthening the concept that intestinal epithelial cells are major producers of 
proteases in gastrointestinal pathologies.  
Autophagy stimulation increased cysteine protease activity but decreased trypsin-like 
proteolytic activity. Moreover, mRNA expression of specific serine proteases such as PRSS1, -2, -
3, matriptase-1 and the serine protease inhibitor, elafin, were downregulated. Autophagy alters 
intestinal homeostasis as evidenced by increased paracellular permeability or mRNA levels of 
TFF3. Increased permeability was normalized when cysteine proteases inhibitor was added to the 
culture.  These data demonstrate that active autophagy downregulates trypsin proteases 
expression, while it induces a strong release of cysteine proteolytic activity which, in turn, alters 
intestinal barrier. Increased permeability is associated with the mRNA downregulation of 
matriptase-1, which is a membrane proteases known to keep TJ homeostasis.  On the contrary, 
upregulation of TFF3 suggest that the cell is working to repair the causes of damage. Two different 
papers have demonstrated the association between TFF3 and cell-cell adhesion. TFF3 up-
regulates the expression of claudin-1 and ZO-1, two crucial TJ, while decreased claudin-2 
expression. Moreover, TFF3 facilitates cell migration in damage mucosa (Meyer zum 
Büschenfelde, Tauber, and Huber 2006; Xu et al. 2012). Necrosis is associated with increased 
levels of caspases, a group of cysteine proteases (Negroni, Cucchiara, and Stronati 2015). Since 
our results showed increased levels of cysteine protease activity, it was important to assess cell 
death in our experimental conditions. LDH activity was quantified as a marker of cell death by 
necrosis, which releases freely into the medium intracellular enzymes such as LDH. Indeed, LDH 
activity was not increased suggesting that necrosis is not associated with the experimental 
induction of autophagy. However, other forms of cell death such as apoptosis could occur, LDH 
being trapped within granules during apoptosis is not increased in cell supernatants. Therefore, 
we cannot exclude the occurrence of apoptosis in our experimental conditions. To eliminate the 
possibility that NS model induce apoptosis, further experiments should analyse the mRNA levels 
of caspases and apoptosis assays such as Tunel or Annexin V assay.  
As a protective mechanism upon autophagy induction, intestinal cells might reduce their activity 
to be able to keep essential mechanisms for cell maintenance. Thus, we confirmed here that 
although autophagy induction is not responsible for trypsin activity increase, it does modulate 
cysteine proteases balance. Indeed, cysteine protease activity has also been found upregulated 
in IBD patients (Menzel et al. 2006; Flood et al. 2015). In further experiments, we could use Caco-
2 cells bearing the ATG16L1 mutation, and investigate proteolytic activity (both trypsin-like and 
cysteine activities) released by those cells, compared to wild-type controls. These cells carry the 
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same ATG16L1 polymorphism associated with CD, and constitute therefore a very useful tool to 
study the cellular mechanisms associating potentially epithelial cell proteases and CD 
pathogenesis.  
Although ER-stress is active at basal levels, prolonged stress might contribute to IBD 
pathogenesis by compromising protein secretion, mediating intestinal epithelial cell apoptosis, 
mucosal barrier dysfunction and induction of inflammatory response in the gut (Cao 2016, 2015). 
Polarized Caco-2 cell line stimulated with Tunicamycin or Thapsigargin, two well-known ER-
stress inducers, increased the release of trypsin-like activity at the apical side. Similar results are 
observed in HT-29mtx mucus-secreting cell line. ER-stress induction was confirmed by mRNA 
expression of XBP1s, CHOP, ATF6 and -4. These results demonstrate that aberrant ER-stress 
modulates trypsin proteolytic activity. Moreover, our results showed upregulation of PRSS-1, -2 
and elastase 2 after 6 hours of ER-stress stimulation. mRNA levels of PRSS-3 and matriptase-1 
remained unchanged in Caco2 cells at this time-point, while elafin expression was downregulated. 
However, mRNA levels of PRSS-3 increased 24 hours after induction in Caco2 cells, and was 
significantly up-regulated as soon as 6h after ER stress induction in HT29MTX cells. Together 
these results showed that ER stress profoundly altered proteolytic homeostasis in intestinal 
epithelial cells, not only at the granule secretion level, but also at the transcriptional level. 
 
The impact of ER-stress on intestinal barrier homeostasis 
In the present study, we better analyzed the impact of ER-stress on epithelial biology. IBD are 
characterized by impaired intestinal barrier including altered intestinal permeability, activated 
inflammatory response and disruption of the gut shield along with decreased AMPs and thinner 
mucus layer. In both cell lines and animal models, deletion of UPR factors lead to spontaneous 
inflammation and exacerbated colitis. Knockdown of XBP1 in ileal epithelium causes hyperactivity 
of IRE1a increasing inflammatory response in the gut and activating JNK and NF-κB (A. Kaser et 
al. 2008). Monolayers of polarized Caco-2 cells treated with Thapsigargin increased permeability 
compared to control. It has been demonstrated that proteases can increase intestinal permeability 
either directly by degradation of tight junctions or by receptor-mediated signaling pathway. In 
colonic biopsies of IBS patients, permeability was found increased pointing out to cysteine 
proteases from microbiota as the main responsible for TJ degradation (Piche et al. 2009; Z. Zhang 
et al. 2000; Wan et al. 1999). Other studies have shown the ability of PAR2 activation to increase 
intestinal permeability via MLC phosphorylation (Cenac et al. 2004). Thus, both hypothesis 
highlight the lumen as possible main location for proteases responsible for the increased 
intestinal permeability either by TJ degradation (Annaházi et al. 2013) or by PAR2 via MLCK 
involvement. Our data showed that stressed Caco-2 cell monolayers pre-treated with ML-7, a 
MLCK inhibitor, normalized permeability compared to control conditions. These results suggest 
that trypsin activity alters permeability via MLCK rather than degrading TJ, and are in favor of a 
receptor-mediated mechanism to explain the permeability effects of ER stress-associated trypsin 
activity. Indeed, our other results confirmed the implication of both PAR2 and PAR4 in ER stress-
associated increased permeability, while previous studies have clearly demonstrated that PAR2 
activation is linked to MLC phosphorylation (Cenac et al. 2004) 
Importantly, our work reports for the first time that ER-stress is associated to increased 
permeability, and provides mechanisms associating the release of trypsin-like activity and the 
activation of PAR2 and PAR4. 
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Intestinal epithelia produce and release specific weapon peptides against pathogens, in the mucus 
of the gut. Although, Paneth cells are specialized for the storage and secretion of AMPs and goblet 
cells are responsible for mucus and AMPs secretion, enterocytes are also able to produce and 
secrete a variety of them. As previously mentioned, several publications have shown that aberrant 
UPR in IEC causes accumulation of MUC2 precursor on goblet cells (Tsuru et al. 2013). Epithelial 
cells constitutively express HBD1, while HBD2 is induced under inflammation (O’Neil et al. 1999). 
Rat model of DSS-induced colitis displayed increased expression of TFF3, a bioactive peptide 
responsible for maintaining intestinal epithelial homeostasis, in inflamed colonic mucosa (Renes 
et al. 2002). Moreover in vitro experiments demonstrated that TFF3 regulates permeability by 
upregulating claudin-1 and ZO-1, two crucial TJ for intestinal integrity and downregulating 
claudin-2, known to increase TEER (Meyer zum Büschenfelde, Tauber, and Huber 2006; Xu et al. 
2012). Therefore, we investigated whether ER-stress induction modified AMPs or mucus gene 
expression. Stressed caco-2 cells displayed upregulated mRNA levels of HBD2, MUC2 and TFF3 
while HBD1 remained unchanged. These results demonstrated that ER-stress is involved in the 
alteration of intestinal function.  
We further analyzed whether ER-stress had an impact on the inflammatory response. CXCL8, a 
neutrophil chemoattractant factor, is involved in the initialization of inflammation, released from 
different cell subtypes in response to inflammatory stimulus. Besides pro-inflammatory effects, it 
has been suggested that CXCL8 is involved in immature intestinal development including 
intestinal maturation, differentiation, migration and prevention from injury and cell death 
(Nguyen et al. 2014; Maheshwari et al. 2004, 2002). High quantities of CXCL8, also named as IL-8, 
are found in inflammatory mucosa of IBD patients. Our in vitro results showed increased CXCL8 
in the apical and basal supernatant of ER-stress cells. Both pro-inflammatory factors are induced 
by the transcription factor NF-κB, which activation induces further ER-stress and PAR 
downstream pathways (Mahdi, Rizvi, and Parveen 2016). We confirmed that ER-stress induction 
promotes inflammatory signs. We, thus, suggest that increased release of CXCL8 at the basal side 
of polarized IECs could attract inflammatory cells to fight possible bacteria infiltration, while 
apical CXCL8 release might be involved in restauration of intestinal homeostasis and repair.  
 
Trypsin-3 a protease increased in UC and stressed caco-2 cells 
A major aim of our studies was to determine the type of serine protease increased in supernatants 
of stressed epithelial cells of IBD patients.  
As mentioned before, colonic biopsies of UC and CD patients displayed increased trypsin activity 
in IECs. By immunohistochemistry, our results showed trypsin-3 detected in epithelial cells of UC 
but not in CD biopsies. Moreover, relative mRNA expression of PRSS-3 is downregulated in 
patients with UC compared to control or CD (data from Dr. A. Denadai Souza, post-doctoral fellow 
in the laboratory, data not shown). These results suggested that abnormal ER-stress is associated 
with increased trypsin-3 protein in epithelial cells and outside epithelial cells, and that it could be 
used as a marker to discriminate between UC and CD. Although little is known about trypsin-3, it 
has been found involved in several pathologies such as IBS or breast, lung, prostate, and pancreatic 
cancer. mRNA isoform of trypsin-3, PRSS-3, plays an important role in progression, 
transendothelial migration, metastasis and prognosis of human cancer besides neuronal sensing, 
visceral hypersensitivity and intestinal permeability (Hockla et al. 2012; Rolland-Fourcade et al. 
2017; Cottrell et al. 2004; Takeuchi, Shuman, and Craik 1999; Diederichs et al. 2004; Jiang et al. 
2010). Our data reported increased ER-stress signalling pathway, confirmed by XBP1s expression, 
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in UC but not CD. These data suggest that the correlation between tryspin-3 release and abnormal 
ER-stress response is a feature of UC but not CD.   
Moreover, our in vitro model also exhibited trypsin-3 as a trypsin type increased in stressed cells 
supernatant. By activity-based prove approach, supernatant from stressed cells showed a unique 
and specific band at molecular weight of 33 kDa compared to control or stressed samples treated 
with AEBSF, a serine protease inhibitor used as negative control to verify the specificity of active 
trypsin proteases. 33 kDa corresponds to the known molecular weight of trypsin-3. In addition, 
trypsin activity was lost in stressed supernatants treated with ABP, confirming that ABP binds 
effectively to the active protease site detected in trypsin activity assays. ABP result was confirmed 
by western blot, detecting trypsin-3 levels increased compared to non-stressed supernatants. In 
addition, just like ER stress-associated trypsin activity, the release of trypsin-3 was polarized on 
the apical compartment. Intracellular levels of trypsin-3 remained unchanged in stressed and 
non-stressed conditions, indicating that the first level of regulation is the release of trypsin-3 
intracellular stocks rather than the level of intracellular protein expression. Although trypsin-3 
appears as a serious candidate to explain the increased proteolytic activity associated with ER 
stress, one cannot rule out the possible involvement of other proteases. In particular, mRNA levels 
of PRSS1 and -2 were upregulated upon ER stress induction. We could not assess specifically the 
expression of these proteases as no specific antibodies are available to discriminate between 
trypsin-1, trypsin-2 and the trypsin common precursors. It is therefore not known whether PRSS1 
and PRSS2 are translated into proteins. 
Our results point to a polarized release of trypsin-3 at the apical compartment of enterocyte 
monolayers under ER stress conditions. The next step would be to identify whether specific 
inhibition of trypsin-3 in intestinal epithelial cells submitted to ER stress would completely inhibit 
the released trypsin-like activity and the ER-associated effects. However, no specific inhibitors 
have been reported so far for trypsin-3 and the antibody we used was not able to block trypsin-3 
activity (in enzyme assays performed with pure trypsin-3). We have tried to use a shRNA 
approach in Caco2 cells, in order to down-regulate the expression of Trypsin-3, but the expression 
of PRSS1 and PRSS2 were also down-regulated by this approach. Selective inhibition of trypsin-3 
activity could also be useful in in situ zymography of UC patients, in order to determine whether 
or not trypsin-3 is the protease responsible for increased activity in intestinal epithelial cells from 
those patients. Therefore, although strong presumptions point out trypsin-3 as the molecular 
target to inhibit ER stress disruptive effects associated with UC, we still need better tools to fully 
confirm this hypothesis. 
 
The association between ER stress-induced increased trypsin proteolytic activity and 
intestinal biology 
We aimed at determining whether dys-regulation of intestinal barrier was due to ER-stress itself 
or due to the large amount of trypsin released at the apical side of polarized enterocytes. Stressed 
caco-2 cells cultured in a transwell co-treated with AEBSF or Leupeptin, two serine proteases 
inhibitors, had a restored paracellular permeability, compared to un-stressed cells. These results 
confirm that disruption of intestinal barrier is due to increased serine proteases. However, 
surprisingly, inhibition of serine proteolytic activity aggravates the secretion of CXCL8, both in the 
apical and basal compartments of stressed supernatants. Previous studies have shown that 
specific components, such as LPS or transforming growth factor-β act as anti-inflammatory 
mediator attenuating the production of IL-1β and CXCL8 in response to inflammation (Rautava et 
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al. 2012, 2011; Fujihara et al. 2003). By proteolytic processing, some proteases are required to 
mature some antimicrobial peptides such as the human defensin-5 or to increase the chemotactic 
activity of CXCL8 (proteinase-3) or CXCL5 (cathepsin G)(Manna and Ramesh 2005; Nufer, Corbett, 
and Walz 1999). In contrast, proteases like cathepsin G, proteinase-3 or elastase 2 can also 
degrade cytokines including IL-6 or TNFα as well as some proteins involved in cellular contacts 
(Bank et al. 1999; Chin et al. 2008). We thus, could hypothesise that active proteases degrade 
CXCL8, mediating anti-inflammatory effects. The results generated with the PAR2 and PAR4 
antagonists contradicted this hypothesis since PAR blockade also increased the release of CXCL8 
in cell culture media after ER stress, suggesting that a PAR-mediated effect is responsible for the 
enhanced CXCL8 release.  
 
Activation of PARs by trypsin might be the molecular mechanism to disrupt intestinal 
homeostasis 
Protease mechanism of action is transmitted through the cleavage of protein substrates or 
receptors which modulates irreversibly their function. Beside molecular maturation or 
degradation as mentioned above, protease-mediated signalling can be established through the 
proteolytic cleavage of the Protease-activated receptor (PAR). PARs are widely expressed along 
the GI on several cell types including enterocytes, endothelial cells, neurons and inflammatory 
cells among others. The activation of the receptor is involved in GI physiological processes as 
visceral sensitivity, secretion, motility, intestinal permeability and gut immune response (Coelho 
et al. 2002; Nathalie Vergnolle and Chignard 2006). Our cell culture studies evidenced that 
induction of ER-stress increased the gene transcription of PAR2 and -4 and moreover, inhibition 
of serine proteases normalized their mRNA expression at 24 and 6 hours, respectively. Likewise 
observed in previous data, our results have shown a reduced permeability when stressed cells 
were pre-treated with antagonists of PAR2 and -4. Surprisingly, pre-treatment with antagonist 
PAR1 aggravated paracellular permeability compared to stressed-cells. A recent study from the 
lab demonstrated that trypsin-3 cleaves and activates PAR2, leading to visceral hypersensitivity 
(Rolland-Fourcade et al. 2017). We confirm that in our model, trypsin-3 also regulates 
permeability through PAR2 and -4.  
As mentioned above, stressed Caco-2 cells treated with ML-7 normalized permeability, suggesting 
that PAR-2 and -4 activated by the trypsin activity, can  activate MLCK signaling pathway 
disrupting TJ (Cenac et al. 2004). Although PAR-1-mediated mechanism is poorly understood, 
PAR-1 activation induces apoptosis leading to intestinal barrier dysfunction (Chin et al. 2003). 
Thus, it is surprising that blockade of PAR1 in caco-2 cells monolayers increased intestinal 
permeability since our data suggest a protective role. However, we hypothesized that inhibition 
of PAR1 let the other two receptors PAR2 and -4 more available for trypsin, thus, due to over-
activation of PAR2 and -4, permeability could be increased. Nonetheless, the use of PAR1 
antagonist in this study had some limitations, since we notably suspected a detrimental effect of 
this PAR1 antagonist. My team have used the same antagonist to treat organoids for 72 hours, 
detecting cell death caused by this PAR1 antagonist. Although in this project the time course used 
was 6 hours, cells could start undergoing apoptosis, therefore altering the results. Thus, 
permeability is increased and CXCL8 decreased when cells are pre-treated with PAR1 antagonist. 
CHO cells carrying the firefly luciferase PAR2 evidenced that ER-stress supernatant was able to 
cleave the receptor compared to control supernatants. Firefly luciferase PAR4 were not available 
in the lab, thus we cannot conclude on whether ER-stress supernatant can cleaves it. Taken 
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together, these analyses demonstrated that PAR2 and PAR4 might be activated by trypsin-3, 
released due to ER-stress induction, which in turn, enhanced permeability by a MLCK-dependent 
mechanism. 
 
Interaction between ER-stress and trypsin proteases. 
Finally, we investigated whether excessive release of active trypsin was able to modulate the 
induction of ER-stress. First, we have shown that serine protease inhibitor do not modulate ER-
stress markers in stressed cells. Second, caco-2 cells treated with trypsin-3 failed to induce any 
signs of ER-stress. Moreover, levels of CXCL8 remained stable in cells treated with trypsin-3. Thus, 
we demonstrated that ER-stress is able to trigger the release or Trypsin-3 while trypsin-3 is 
unable to induce ER-stress and that trypsin-3 alone, without an inflammatory context, is not able 
to induce CXCL8.  
 
Trypsin-3 inhibitor as a possible treatment for UC patients 
Patients with abnormal activity of ER-stress display increased trypsin-3 in intestinal epithelial 
cells. Increased trypsin proteolytic activity is responsible for intestinal barrier alteration while 
ER-stress induces inflammation. Our results suggest that Trypsin-3 inhibition could be beneficial 
in the course of IBD, and specifically for UC patients. However, one has to wonder which patients 
might benefit the most from such treatment, and when would be the best time and in which 
combination with potential other treatments this approach could be used?  Pentasa (Mesalamine) 
is used to induce remission in mild to moderate active UC. Ingested orally, pentasa is slowly 
released into the body, acting locally in the colon instead of systemically.  The mechanisms of 
action of Mesalamine include the inhibition of lipoxygenase and cyclooxygenase pathways, 
cytokine inhibition (interleukin-1, interleukin-2, TNF). It also acts as a potent antioxidant and a 
free-radical scavenger, as well as a Peroxisome proliferator-activated receptor (PPAR)-gamma. 
Through all these mechanisms, Mesalamine treatment usually achieve a good inhibition of cell 
recruitment and a fair repair of damaged tissues. However, the effects that Mesalamine treatments 
have on epithelial homeostasis are most likely indirect. No direct effect for this treatment on 
epithelial repair or on reinforcement of epithelial barrier have ever been demonstrated. 
Therefore, there might be some space for a combinatory treatment in mild and moderate UC 
patients that would target a fast repair of epithelial functions and integrity. Anti-trypsin-3 
treatment might well fit within that space.  While classical anti-inflammatory drugs such as 
Mesalamine would suppress the inflammation and inflammatory cell recruitment, trypsin-3 
inhibition would repair and reconstruct rapidly the damaged mucosa.  
ER-stress inhibition though would not be a good strategy since ER stress is an essential cellular 
mechanism, especially for secreting cells like Paneth and Goblet cells.  Anti-inflammatory drugs 
have to be taken during active phases, until remission is achieved. But one can imagine that low 
doses of trypsin-3 inhibitors could be taken even in remission phases. Since ER-stress is 
constitutively active in these patients, trypsin-3 inhibition would lower the pro-inflammatory 
effects of constitutive up-regulation of ER stress associated with UC and might maintain 
remissions for a longer period. 
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Conclusion 
 
Among the three main cellular pathways associated with IBD (NOD2, Autophagy and ER stress), 
we demonstrated that only ER stress is associated with increased trypsin-like activity. Most 
importantly, we have identified here the downstream mechanisms of ER stress in intestinal 
epithelial cells. Our results point to trypsin activity, and in particular trypsin-3 release, as possible 
new therapeutic targets in the context of intestinal inflammation that involves ER stress.   
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Figure 15.  The three main IBD pathways and trypsin activity. Under physiological conditions, 
basal levels of trypsin-like are released. Nod2 activation does not modify trypsin activity 
secretion. Autophagy reduces trypsin proteolytic activity released by IECs and their genetic 
expression. ER-stress induces the secretion of trypsin activity in the apical compartment of 
polarized IECs together with mRNA upregulation of PRSS1,-2, elastase 2A, downregulation of 
elafin and no changes of PRSS3. 
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Figure 16. The impact of ER-stress on intestinal biology. ER-stress increased paracellular 
permeability which was normalized blocking MLCK with ML-7. ER-stress also enhanced the 
secretion of CXCL8 apically and basally and upregulated TFF3, HBD2 and MUC2. 
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Figure 17. Impact of proteases on intestinal biology. Trypsin-3 increases permeability by 
activating PAR-2 and -4, which in turn, phosphorylates MLCK. By inhibiting serine proteases 
(AEBSF), PAR-2 (GB83) or PAR-4 (ML354) permeability is normalized to basal levels. Inhibition 
of proteases restore mRNA of TFF3 but not HB2 or MUC2. Inhibition of serine proteases or PAR-2 
and PAR-4 increases CxLC-8 secretion at the apical and basal side of IEC. 
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Figure 18. Impact of ER-stress on trypsin activity secretion. ER-stress induces trypsin-3 
release but trypsin-3 is not able to induce ER-stress. 
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Abstract 
 
While proteases are essential in gastrointestinal physiology, accumulating evidence 
indicates that dysregulated proteolysis plays a pivotal role in the pathophysiology of 
inflammatory bowel disease (IBD). Nonetheless, the identity of overactive proteases released 
by human colonic mucosa remains largely unknown. Studies of protease abundance have 
primarily investigated expression profiles, not taking into account their enzymatic activity. 
Herein we have used serine protease-targeted activity-based probes (ABPs) coupled with 
mass spectral analysis to identify active forms of proteases secreted by the colonic mucosa of 
healthy controls and IBD patients. Profiling of (Pro-Lys)-APB bound proteases revealed that 
most of hyperactive proteases from IBD secretome are clustered at 28-kDa. We identified 
seven active serine proteases: cathepsin G, plasma kallikrein, plasmin, tryptase, 
chymotrypsin-like elastase 3A, aminopeptidase B, and thrombin. Only cathepsin G and 
thrombin were overactive in supernatants from IBD patient tissues compared to healthy 
controls. Gene expression analysis highlighted the transcription of genes encoding these 
proteases into intestinal mucosae. The functional ABP-targeted proteomic approach that we 
have used to identify active proteases in human colonic samples bears directly on the 
understanding of the role these enzymes may play in the pathophysiology of IBD. 
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Introduction 
 
The degradome represents almost 2% of protein coding genes in the human genome, 
with at least 588 genes coding for proteases. Among them, one of the largest classes is 
represented by 184 genes encoding serine proteases, which are characterized by the presence 
of a nucleophilic serine in their reactive site
1
. Since the hydrolysis of peptide bonds is an 
irreversible process, the expression and activity of proteases are tightly regulated. For 
instance, these enzymes often exist as inactive zymogens (pro-forms), which must be 
activated by proteolytic cleavage. A large array of endogenous protease inhibitors also exists 
that can control cell and tissue proteolysis. 
 
Proteases are essential mediators in gastrointestinal physiology, being produced and 
released by the pancreas, in order to be activated in the intestinal lumen for digestive 
purposes. Proteolytic activity is also detected within mucosal tissues in healthy conditions 
and is thought to play a role in mucus consistency and mucosal antigen processing
2
. 
Otherwise, in intestinal pathophysiological contexts such as inflammatory bowel disease 
(IBD), proteolytic homeostasis can be disrupted in tissues
2
. Increased serine protease activity 
has been demonstrated in colonic tissues from Crohn’s disease (CD) or Ulcerative Colitis 
(UC) patients
3-5
. Some of these studies also demonstrated that the reestablishment of the 
proteolytic homeostasis by the local delivery of recombinant protease inhibitors reduces the 
severity of experimentally-induced colitis
3,6
, thus highlighting the importance of these 
enzymes both as central mediators of IBD pathophysiology, and as potential therapeutic 
targets. 
 
The identity of overactive serine proteases in intestinal tissues remains elusive. In situ 
zymography assays demonstrated that the increased IBD-associated elastolytic activity was 
mostly present within the epithelium
3
. This is an interesting finding, given that most studies 
aimed at identifying upregulated proteases in inflammatory diseases have focused on 
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enzymes highly expressed by infiltrating immune cells. Thus, gene and protein expressions 
of several proteases released primarily by leukocytes (including neutrophil elastase, 
proteinase-3, cathepsin G, tryptase, chymase or granzymes) have been found to be 
upregulated in IBD
2
. Additionally, genetic studies have supported an association of protease 
genes with IBD risk
7,8
. Nevertheless, the major limitations of such studies based on 
expression analysis are due to the fact that mRNA or protein levels for proteases do not 
necessarily reflect their activity status. Indeed, variations of zymogen activation or local 
availability of endogenous inhibitors can drastically modify biological activity. 
 
Therefore, the identity and implication of proteases in health and diseases, including IBD, 
have to come from studies investigating the in situ net activity of these enzymes
9
. The 
development of functional proteomic assays based on Activity-Based Probes (ABPs) now allows 
such approaches, monitoring the availability of enzyme active sites in biological samples
10-13
. 
The ABP structure possesses a reactive group that mimics enzymatic substrate and 
covalently binds to active proteases. Additionally, the ABP reactive group is associated to a 
biotin motif via a spacer, in such a way that bound active enzymes thus become biotinylated 
and can be visualized and/or immobilized by avidin-based affinity chromatography. Further 
mass spectral analysis could then determine the enzyme sequence. Obviously, detection of 
active proteases is dependent to their affinity towards the ABP that is used. We have 
previously used this approach successfully to identify active serine proteases upregulated in 
the setting of a murine model of infectious colitis
14
 and to determine the sequences of serine 
proteases present in complex allergenic cockroach extracts
15
. Here, we performed a study to 
profile and identify active serine proteases secreted by the colonic mucosa of control and IBD 
patients by using ABPs. 
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Results 
 
Validation of the sensitivity for detecting Trypsin-like activity using a Biotin-PK-DPP 
activity-based serine protease probe: signal intensity correlates with trypsin activity 
level  
The ABP biotin-PK-DPP synthesized for the present study
16
 was of sufficient reactivity to 
detect a level of 2.5 mU of trypsin from bovine pancreatic trypsin. The ABP signal intensity 
was proportional to increasing concentrations of trypsin, and was eliminated by the serine 
protease irreversible inhibitor AEBSF (Figure 1A, 1B and supplementary figure 1). 
 
 
Secreted serine protease activity is upregulated in IBD colonic mucosa 
Colonic tissue supernatants from control patients exhibited a baseline proteolytic activity, 
which was increased in samples from CD and UC patients (Figure 2). To characterize the serine 
proteases underlying this increase of proteolytic activity, we initially performed ABP proteomic 
profiling assays with these samples. Since ABPs react only with active enzymes, the bands 
corresponding to proteases were discriminated from non-specific labelling by pre-incubating the 
samples in parallel with the serine protease inhibitor, AEBSF. Therefore, the signal intensity of 
protease bands from AEBSF-treated samples was reduced or absent in comparison to the sample 
not treated with this irreversible serine protease inhibitor. As a whole, bands representing putative 
serine proteases ranged from 12 to 250 kDa (Figure 3A). A distribution analysis of putative 
proteases according to their molecular weight regrouped them in 10 main clusters, with mean 
molecular weights of 15, 24, 28, 32, 36, 68, 100, 126, 140 and 250 kDa. The majority of serine 
proteases were grouped into the 28, 32 and 36 kDa clusters (Figure 3B). Once these clusters were 
analysed in individual groups of patients, some differences became evident. Likewise, the cluster 
1 (15 kDa) was only detected in IBD samples. The cluster 6 (68 kDa) was more prominent in UC 
samples, while cluster 9 (140 kDa) was only detected in CD samples. 
Annex 
159 | 
 
Next, we focused on the number of AEBSF-sensitive bands, which were diminished in 
the presence of the protease inhibitor, as opposed to the labelled bands which were not 
affected by AEBSF incubation. In all samples there were biotin-labelled constituents in the 
50 and 65 kD range which appeared to yield a comparable streptavadin-biotin reactivity, for 
which the signal was not diminished by AEBSF treatment (Figure 3A). Relative to those 
AEBSF-resistant signals present in all samples, quite distinct AEBSF-sensitive ABP labelling 
profiles were observed for samples obtained from the CD and UC individuals either compared 
between diseases or compared to controls (Figure 3A). In particular, the CD-derived samples 
contained a unique ABP-labelled constituent in the 15 kDa range comparable to a labelled 
component found in the trypsin preparation, that might represent a cleaved, catalytically 
active fragment of trypsin (supplementary figure 1). Other higher molecular mass AEBSF-
sensitive ABP-labelled bands also distinguished the CD samples from the UC and control 
samples. This distinction was quantified further by analysing the AEBSF-sensitivity of 
labelled bands for constituents clustered in the mass regions of 28 (cluster 3), 32 (cluster 4), 
68 (cluster 6) and 140 (cluster 9) kDa. According to this analysis, differences in the 
percentage of AEBSF-sensitive bands present in control versus CD samples were observed 
for clusters 3 (28 kDa: 63% reduction in Controls vs. 100% inhibition by AEBSF, in CD) and 
9 (140 kDa: 8% reduction in Controls vs. 25%, in CD). Changes in the percentage of AEBSF-
sensitive bands between controls and UC were observed for cluster 6 (68 kDa; 13% reduction 
caused by AEBSF in Controls vs. 42% reduction in UC) (Figure 3C). 
 
We then defined the activity index of each cluster bands by considering the intensity in the 
absence versus in the presence of AEBSF (Figure 3C). In control samples, the most active cluster 
was at 32 kDa (Figure 3A and C, cluster 4). The comparison of the activity index between control 
and IBD samples revealed an increased proteolytic activity index associated with some clusters. 
For instance, the activity index for clusters 3 and 9 (28 and 140 kDa, respectively) increased in 
CD samples. That said, although for bands in the 32 and 68 kDa (clusters 4 and 6) a number 
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of AEBSF-sensitive labelled bands appeared to differ between the CD and UC-derived 
samples, the difference in the activity index did not quite reach statistical significance (Figure 
3C). 
 
 
ABP-reactive enzymes identified by LC-MS/MS analysis 
Unbiased mass spectrometric analysis identified 6 proteases from S1 family in samples 
from colonic biopsy supernatants. These proteases were considered active according to the ability 
of AEBSF to block labelling, with an activity index >2 and P<0.05 (Table 1). Here, the activity 
index was defined by the ratio -/+ AEBSF of the quantity of positive peptides identified by LC-
MS-MS analysis. This group of identified active proteases includes thrombin, cathepsin G, 
kallikrein-1 (also named plasma kallikrein), plasmin, chymotrypsin-like elastase family member 
3A and tryptase. Additionally, aminopeptidase B (also called arginyl aminopeptidase), a lysine-
cleaving protease from the M01 family was also identified as active. Overall, thrombin was the 
most active protease identified, and its activity was particularly prominent in CD. Similarly, 
aminopeptidase B was highly active specifically in association with UC (Table 1). 
 
 
Active secreted proteases identified by ABP labelling are expressed by the intestinal 
mucosae 
Gene expression experiments were carried out to investigate whether or not the 
proteases identified as active were expressed in the human colonic mucosa. RT-PCR products 
were detected for the 7 proteases, wherein amplicons with expected base pair numbers were 
amplified from colonic mucosa. 
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Discussion 
 
Mass spectrometry proteomic approaches have been applied to IBD tissues, identifying 
global changes in proteome for these pathologies
17-20
. Using such approaches, only few proteases 
were identified. Their relative abundance seems to be secondary to immune cell infiltration as 
they are major components of innate immune cells. As a matter of course, the major drawback of 
classical proteomic approaches remains the lack of information about protease activity. As a 
consequence, the implication of these enzymes in the pathophysiology of human diseases has 
been only marginally characterized to date. Herein, we used a biotinylated ABP capable of 
interacting with lysine-cleaving proteases (biotin-PK-DPP), a catalytic feature of most serine 
proteases and some proteases from other classes
21
. Furthermore, experiments performed with 
increasing amounts of active trypsin clearly demonstrated that the signal intensity generated by 
this ABP augmented accordingly, thus highlighting that this probe can unveil varying activity 
levels of lysine-cleaving proteases. The ABP proteomic gel profiles revealed the presence ofbands 
with a broad molecular weight distribution, either sensitive or not to AEBSF inhibition. Because 
streptavidin which is used to reveal biotinylated bands, can bind non-specifically to proteins
22,23
, 
and because we cannot fully exclude that ABP might bind non-specifically to some proteins in a 
complex mixture, the use of inhibitory AEBSF pre-treatment in counterpart samples was 
instrumental at discriminating active protease bands. 
 
In previous work using activity-based probes to identify active serine proteases associated 
with intestinal inflammation in an infectious model of rodent colitis, we established a role for host 
serine proteases and their signalling target, protease-activated receptor-2 (PAR2), in driving the 
inflammatory response
14
. The results we report here establish proof of principle, that a 
comparable approach can be used to evaluate patient-derived tissue samples. Our work 
considerably extends our previous observations which showed that explants from individuals with 
IBD secrete increased lysine-targeted protease activity. Our main finding is that compared with 
non-diseased tissues, serine protease-targeted activity-based probes reveal a distinct set of 
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active serine proteases secreted by colonic tissues derived from individuals with either 
Crohn’s disease or ulcerative colitis. These data amplify in molecular terms, the initial finding 
that the secretome of tissues derived from IBD patients contained increased trypsin-like 
activity, relative to controls. Our data also complement observations by others reporting the 
increased presence of cathepsin-G in faeces of patients with ulcerative colitis
5
. 
 
Several studies have documented high levels of tryptase in IBD mucosae 
24-26
. 
However, increased level of tryptase in IBD mucosae was reported based on immunoassays 
24,26
. Active tryptase was not detected in the secretome from UC biopsies in this study. Our 
results suggest that concomitantly with exocytosis of tryptase, endogenous inhibitors could 
also be present in the granules or in the vicinity of activated mast cells, leading to a quick 
neutralization of enzymatic activity. While from protein or mRNA expression studies, 
tryptase could appear as a potential molecular target for IBD, our results suggest on the 
contrary that active tryptase is not present in patient’s tissues. 
 
The ABP-tagged enzymes that were distinct in the secretome from the Crohn’s disease 
and ulcerative colitis-derived tissues, compared with disease-free tissues, fell into four 
clusters. One cluster represented by a protease in the 10 kDa range was found only in tissues 
from CD individuals (Figure 3A) and three others, two of which (clusters 3 and 9, in the range 
of 28 and 140 kDa) were associated with Crohn’s disease and a fourth (cluster 6, in the range 
of 68 kDa), which was associated with samples from ulcerative colitis individuals. In 
addition, within these clusters, the scatter-plots, with groups of points well above baseline, 
suggest that a subset of individuals may be present within each cluster. It will be of 
importance to follow the clinical outcomes of the individuals with high activation profiles 
within the clusters, compared with the others in each patient group. 
The expression of all serine proteases identified by ABP labelling, namely thrombin, 
cathepsin G, plasma kallikrein, plasmin, tryptase and chymotrypsin-like elastase family member 
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3A, were also found as mRNA transcripts in extracts of colon biopsy tissue (Table 1 and Figure 
4). Thus, all of the ABP-labelled enzymes can be both produced and secreted in situ by mucosal 
tissue. Most of these identified serine proteases are well-established activators of Protease-
Activated Receptors (PARs), which have been implicated in IBD pathophysiology
16,17
. Further, 
the enzymes like cathepsin G, in addition to regulating PAR activity, can play an inflammatory 
role via either the processing/activation of cytokines, chemokines and growth factors (e.g. the 
convertase action of cathepsin-G for generating alarmin-IL-33) or by the cleavage/inactivation of 
such mediators
27
. It will be important to validate whether or not the active proteases we have 
identified in the tissue secretome would also be found as active enzymes in fecal samples, so as 
to provide for a ‘biomarker’ to follow disease progression. 
 
A high level of active thrombin was particularly detected in the secretome from CD mucosal 
biopsies and to a lesser extent from the ulcerative colitis-derived tissues. Biopsies from IBD 
patients were collected in macroscopic inflamed areas, where ulceration or erythema is observed, 
which can be associated to blood vessel leakage. At the site of colitis, circulating pro-thrombin 
could be activated by tissue factor Xa expressed on cells like monocytes, dendritic cells, platelets, 
endothelial cells and vascular smooth muscle cells. Of particular note, thrombin was also 
identified at colonic tissue mRNA transcript level. This extrahepatic source of thrombin could 
therefore also participate to modulation of innate immunity, notably via PARs 1 and 4 receptor 
cleavage. Activation of these receptors could result in intestinal epithelial cell apoptosis and 
barrier disruption
18
 and might cause either an inflammatory or anti-inflammatory response in the 
tissues
19. The exact role that thrombin might play in Crohn’s disease and ulcerative colitis, 
diseases that have been associated with increased thrombosis
20,21
, remains to be clarified. 
 
Surprisingly, one protease from a class other than serine protease was identified as 
active in samples from UC patients: the metallopeptidase aminopeptidase B. This enzyme is 
known to display endopeptidase activity after an Arg or a Lys residue
28
and this could explain 
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the fact that it binds to the ABP we have used here. To the best of our knowledge, the role of 
aminopeptidase B in IBD pathophysiology has not been evaluated yet. 
In summary, the functional proteomic approach employed herein allowed for the 
identification of a consistent proteomic profile of active serine proteases secreted by the colonic 
mucosa of healthy and IBD patients. Additionally, the use of ABP labelling in conjunction with 
mass spectral proteomic analysis resulted in the identification of unique active proteases 
selectively secreted from the colitis-derived samples, compared with samples from disease-free 
individuals. This approach identified not only proteases previously established as putative 
candidates in IBD pathophysiology, but also enzymes not yet appreciated in this context. In this 
way, the results presented herein pave the way for future studies aimed at understanding the roles 
of these proteases in IBD pathophysiology. This study also revealed strong differences between 
CD patients and UC in terms of profiles of active proteases that could dictate distinct and specific 
therapies for these 2 sub-categories of IBD patients in the forthcoming targeted therapy strategies. 
The approach proposed here can be applied to other diseases and other tissues, in order to identify 
active secreted proteases that may play roles in other inflammatory diseases, so as to serve as 
potential new therapeutic targets. 
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Methods 
 
Patients and colonic samples 
This work and tissue collection received ethical approval. All methods were performed in 
accordance with guidelines and regulations from the French Ethics Committee (Comité d’Ethique 
sur les Recherches Non Interventionnelles) (Identifier: NCT01990716). Colonic tissue samples 
were obtained from well-characterized CD and UC patients undergoing colonoscopy or colonic 
resection procedures at the Toulouse Hospital Centre (France). Colonic tissue samples from 
individuals undergoing colon cancer screening who were otherwise healthy were used as controls. 
Written and verbal informed consent was obtained before enrolment in the study. Fresh colonic 
tissue samples were rinsed in isotonic sterile Hanks’ balanced salt solution pH 7.4 (HBSS) and 
were then immediately incubated in 2 ml of HBSS (containing Ca
2+
 and Mg
2+
) at 37°C for 60 
min. Freshly isolated colonic tissue specimens were quick-frozen in RP1 buffer (Macherey-
Nagel, GmbH) and stored at −80°C until use for RNA extraction. 
 
Measurement of protein concentration 
The concentration of protein in colonic tissue supernatants was determined by using the 
Pierce Protein BCA Assay Kit, according to instructions (Thermo Scientific). 
 
Measurement of proteolytic activity 
The proteolytic activity was measured in colonic tissue supernatant samples with 0.1 mM 
N-p-Tosyl-GPR-amino-4-methylcoumarin hydrochloride as substrate in 50 mM Tris, 10 mM 
CaCl2, pH=8 (Sigma-Aldrich)
29
. Substrate cleavage was calculated by the change in fluorescence 
(excitation: 355 nm, emission: 460 nm), measured over 30 min at 37°C on a Varioskan Flash 
microplate reader (Thermo Fisher Scientific). Sample values were interpolated into a linear 
regression generated with a standard curve of TPCK-treated trypsin from bovine pancreas (8-500 
mU/mL; Sigma-Aldrich). Data were expressed as mU of trypsin-like activity per mg of 
protein. 
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Activity-Based Probe reaction 
The Biotin-PK-DPP serine protease activity-based probe was obtained from the laboratory 
of Dr. Nigel W. Bunnett (Columbia University, USA), with the participation of Dr. Laura 
Edgington-Mitchell (Monash University, Australia) and synthetized as previously described 
30
. 
This probe presents a relative selectivity towards Enzyme Class 3.4.21.4 and EC 3.4.21.5 
16,30
. 
Colonic supernatants (40 µg of protein) were diluted in 100 mM Tris-HCl, 1 mM CaCl2, pH=8 to 
a final volume of 900 µL and then split into duplicates. Each duplicate (450 µL) was then pre-
treated or not with a final concentration of 4 mM AEBSF (SIGMA) during 15 min at 37ºC under 
stirring (1000 rpm). The pre-incubation with this irreversible broad-spectrum serine protease 
inhibitor allows the identification of active proteases, since enzyme inhibition abrogates their 
interaction with the ABP, impacting the intensity signal of bands in proteomic profiles and of 
peptides retrieved by mass spectrometry. Then, the ABP biotin-PK-DPP was added to each 
reaction to a final concentration of 1 μM, and each replicate sample, containing 20 ug of protein, 
was incubated for 60 min at 37ºC under stirring (1000 rpm). 
 
Functional proteomic profiling 
The reaction product was then precipitated in 15% trichloroacetic acid at 4ºC during 90 
min. The pellet was washed twice in cold acetone (-20ºC) and solubilized in 20 μL of protein 
solving buffer with tris-(2-carboxyethyl)-phosphine hydrochloride (PSB-TCEP; Macherey-
Nagel, GmbH). Samples were then heated at 95ºC for 5 min, clarified by centrifugation at 12000 
x g for 5 min and the solubilized sample was loaded into 4-20% Mini-Protean TGX precast gels 
(Bio-Rad, GmbH). After electrophoresis, the proteins were blotted onto nitrocellulose 
membranes by using the Trans-Blot Transfer Turbo System (Bio-Rad). Membranes were 
incubated with streptavidin-HRP (Life Technologies), and bands were visualized with ECL 
Prime Western Blot Detection Reagent (GE Healthcare Life Sciences) and quantified by 
chemiluminescence yield (Chemidoc XRS; Bio-Rad). The molecular weight and intensity of 
each band was determined with the Image Lab Software v5 (Bio-Rad). The bands 
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corresponding to active proteases were identified by their sensitivity to AEBSF. Additionally, 
the activity index of each protease-corresponding band was estimated by the calculation of a 
ratio between the volumetric densitometry of the fluorescent signal generated by untreated vs 
AEBSF-pretreated duplicates (-/+AEBSF). An activity index of 0 was given to cluster bands 
that were not detected in specific samples. 
 
Mass spectrometry analysis 
For mass spectrometry analysis, colonic supernatants from 3 representative patients per 
group were pooled and submitted to an ABP reaction in a final volume of 4.0 mL, as described 
above. In the following, 3.8 mL of the reaction product were incubated with 50 μL of pre-washed 
Dynabeads MyOne Streptavidin C1 (Invitrogen, USA) for 60 min at room temperature under 
stirring (1000 rpm). The beads were washed 5 times with 1 mL of phosphate buffered saline 
pH=7.2. As a control procedure for the ABP reaction and following steps, 200 μL of ABP-labelled 
secretome fluids (before incubation with beads), bead supernatant and buffer from the first wash 
were recovered, precipitated and analysed by proteomic profiling. The pellets containing the 
ABP-protease complexes adsorbed to the magnetic beads were washed twice with 50 mM 
ammonium bicarbonate buffer (Sigma-Aldrich, USA), and then suspended in 6 M urea and 25 
mM DTT (Sigma-Aldrich). After 60 min under stirring (850 rpm) at room temperature, the 
samples were alkylated by the incubation in 90 mM iodoacetamide (Sigma-Aldrich) during 30 
min in the dark. Bead-bound samples were then washed twice as described above and submitted 
to overnight proteolysis at 37°C in ammonium bicarbonate buffer (50 mM, pH=8.5) 
containing 1 μg of trypsin (Promega, USA) per sample. The supernatants were collected, 
dried under vacuum and solubilized in 2% acetonitrile and 0.05% trifluoroacetic acid (Sigma-
Aldrich), for further analysis. 
 
The resulting peptides were analysed with a NanoLC (Ultimate 3000 RSLCnano system 
Thermo Scientific) coupled to a LTQ Orbitrap Velos mass spectrometer (Thermo Fisher 
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Scientific, Bremen, Germany). Peptides extracts (5 μL) were loaded on a C18 precolumn (300 
μm inner diameter x 5 mm; Thermo Scientific) in a solvent made of 2% acetonitrile and 0.05% 
trifluoroacetic acid, at a flow rate of 20 μl/min. After 5 min of desalting, the precolumn was 
switched online with the analytical C-18 column (75 μm inner diameter x 50 cm; Reprosil) 
equilibrated in 95% of solvent A (0.2% formic acid) and 5% of solvent B (80% acetonitrile and 
0.2% formic acid). The peptides were eluted using a 5-50% gradient of solvent B over 105 min 
at a flow rate of 300 nL/min. The LTQ Orbitrap Velos was operated in a data-dependent 
acquisition mode with Xcalibur software. MS survey scans were acquired in the Orbitrap on the 
350–1800 m/z range, with the resolution set to 60,000. The 20 most intense ions per survey scan 
were selected for fragmentation by collision-induced fragmentation and MS/MS spectra were 
acquired in the linear ion trap. A 60s dynamic exclusion was used to prevent repetitive selection 
of the same peptide. Triplicate LC-MS measurements were performed for each sample. 
 
Protein identification and quantification 
Raw MS files were processed with MaxQuant software (version 1.5.2.8) for database 
search with the Andromeda search engine and for quantitative analysis. Data were searched 
against human entries in the Swissprot protein database (release UniProtKB/Swiss-Prot 2015-
12; 20200 entries). Carbamidomethylation of cysteine was set as a fixed modification, 
whereas oxidation of methionine, protein N-terminal acetylation were set as variable 
modifications. Specificity of trypsin digestion was set for cleavage after K or R, and two missed 
trypsin cleavage sites were allowed. The precursor mass tolerance was set to 20 ppm for the first 
search, 5 ppm for the main Andromeda database search and minimum peptide length was set to 
7 amino acids. Andromeda results were validated by the target-decoy approach using a reverse 
database at both a peptide and a protein false-discovery rates of 1%. For label-free relative 
quantification of the samples, the match between runs option of MaxQuant was enabled with a 
time window of 0.7 min, to allow cross-assignment of MS features detected in the different runs. 
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To perform relative quantification between proteins identified, we used the “Intensity” 
metric from the MaxQuant “protein group.txt” output (sum of peptide intensity values for 
each protein). Quantitative data were first normalized and missing protein intensity values 
were replaced by a constant noise value that was determined independently for each sample 
as the lowest value of the total protein population. Enrichment ratios between AEBSF not 
treated and AEBSF treated samples were calculated from the mean protein intensities derived 
from three technical replicate experiments. A potential active protease was selected based on 
an enrichment ratio > 2 (Intensity AEBSF not treated vs. treated) and a Student’s t-test P-
value < 0.05 over the triplicates. 
 
RT-PCR 
Total RNA was extracted from human colonic tissue samples with the Nucleospin 
RNA/Protein Kit (Macherey-Nagel, GmbH). DNAse-treated RNA was reverse transcribed 
using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). Resulting cDNA 
samples were amplified by conventional PCR with Taq DNA polymerase (Invitrogen, USA) 
and sequence-specific primer pairs (Supplementary Table 1). As a control procedure, RT 
reactions were performed without the addition of enzyme to the mix. 
 
Statistical analysis 
For the enzyme kinetics and proteomic profiles assays, each dot represents the data 
from an individual patient. All data were used to calculate the values expressed as 
mean±SEM. Statistical analysis was performed using One-Way Analysis of Variance 
(ANOVA) or Kruskal-Wallis, followed by multi comparison tests, as indicated in figure 
legends. Outliers were identified by the method of ROUT with Q settled at 1%. GraphPad 
Prism v.6 software was used for analysis. Statistical significance was accepted at p<0.05. 
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Figure legends 
 
 
Figure 1. Validation of biotin-PK-DPP sensitivity of detection of trypsin-like enzymes 
 
A. 1µM PK-ABP was incubated with an increasing concentration of trypsin and the biotinylated 
trypsin product was visualized by electrophoresis followed by detection using streptavidin-linked 
horseradish peroxidase and ECL. B. Trypsin was treated first with the broad-spectrum serine 
protease inhibitor AEBSF (4mM) prior to its reaction with ABP and ECL detection. 
 
 
Figure 2. Measurement of trypsin-like activity released by human colonic mucosa.  
Trypsin-like activity detected in supernatants from colonic tissue samples of control or IBD 
patients (n=11-16). Data were analysed by ANOVA followed by the multi comparison test 
of Holm-Sidak. *P<0.05 vs. control. 
 
 
Figure 3. Proteomic profiling of serine proteases released by the human colonic mucosa. A 
 
Representative ABP proteomic profile, showing the differential repertoire of ABP-labelled 
serine proteases secreted from control or IBD colonic tissue samples along with the positive 
trypsin control (20 mU of trypsin). The red arrowheads point to bands corresponding to active 
proteases, as verified by the inhibitory effects of pre-treatment of the samples with AEBSF 
(4mM). B. Clustering of ABP-labelled serine proteases according to size (kDa). C. Graphic 
representation of protease size clusters along with their activity index determined by the 
impact of enzyme inhibition (-/+AEBSF). The percentage of AEBSF-inhibited bands per 
patient is represented by the pie graphs. The empty circles represent patients wherein bands 
within the cluster were not detected (negative), a 0 value was given to these samples as per 
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their activity index. Activity index data were analysed by Kruskal-Wallis followed by the 
multi comparison test of Dunn. *P<0.05, **P<0.01, vs. control; #P<0.05 vs. CD. 
 
Table 1. Active ABP-labelled serine proteases secreted from the colonic mucosa of 
control and IBD patients. The list shows the active ABP-labelled proteases identified by 
LC-MS/MS analysis of pooled supernatant samples from control and IBD patients, showing 
the respective protease family, gene symbol, protein name, predicted molecular weight and 
the activity index reflecting the sensitivity of ABP labelling to protease inhibition (-/+AEBSF 
ratio). 
 
Figure 4. Colonic RNA expression for proteases identified as active. Analytical agarose-
gel electrophoresis of RT-PCR products amplified from cDNAs prepared from human 
colonic mucosa tissue samples are shown with arrows denoting the predicted size (base pairs: 
bp) of the PCR product. Negative controls (noted -) consisted of RT reactions performed in 
the absence of enzyme. Positive expression was confirmed using cDNAs prepared from 
human tissue sources known to express the target proteases. 
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Supplementary Table 1. 
 
Transcript Sequences (5’-3’) Amplicons 
(bp) 
Splice 
variant 
Accession 
number 
CTSG  TGAGAGTGCAGAGGGATAGG 
AAGCCATTGTCACCCCAG 
154  NM_001911 
CELA3A
  
CTTTGGCTGCAACTTCATCTG  
TCTTTATTCAGGATGTGGGATCG 
141  NM_005747 
F2 GAGGACGCCTCGAGATAAGC 
GTGACTTGATCCTGGCCACA 
297 
297 
1 
2 
NM_000506 
NM_001311
257 
KLKB1 TCTTGCGTTCTCAGATGTGG 
ATGGCAGGGTTCAGGTAAAG 
256 
256 
287 
1 
2 
3 
NM_000892 
NM_001318
394 
NM_001318
396 
PLG AAGAGTCCAATCCACCGAAC 
CATGCTAAATCCCTACCCACG 
290  NM_000301 
TPSAB1/TPSB2 CTGGCATCTACACCCGTG 
TGGGTAGGAAGCAGTGGT 
143  NM_003294 
NM_024164 
RNPEP AGAACCCTTGTCTGACCTTTG 
CTCTCCAGTGATGTCCATGTG 
263 
263 
263 
263 
1 
2 
3 
4 
NM_020216 
NM_001319
182 
NM_001319
183 
NM_001319
184 
 
Supplementary Table 1. Sequences of oligonucleotides used for RT-PCR experiments. The human 
gene symbols, oligonucleotide sequences, amplicon size in base pairs (bp), individual or multiple splice 
variants targeted by each primer pair and respective NCBI accession numbers are indicated. 
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 The involvement of the three main Inflammatory Bowel 
Disease pathways and the secretion of trypsin proteolytic 
activity on intestinal epithelial cells 
 
 
Crohn's disease (CD) and Ulcerative colitis (UC) are two forms of 
Inflammatory Bowel Disease (IBD), a chronic inflammatory 
pathology affecting the digestive tract. Patients suffer from 
relapsing flares, diarrhea, abdominal pain and bleeding. Although 
the molecular mechanisms of IBD are poorly understood, recent 
data suggest that IBD occurs in genetically predisposed individuals 
developing an abnormal immune response to intestinal microbes 
after, being exposed to specific environmental triggers. Genetic 
studies have reported more than 170 polymorphisms susceptible 
to be involved in IBD pathogenesis. The strongest associations have 
highlighted three main pathways altered in IBD including bacterial 
sensing (NOD2, CD), autophagy (ATG16L1 and IRGM, CD) and 
endoplasmic reticulum stress (ER-Stress) (XBP1, UC). The role of 
intestinal barrier function is also strongly implicated in IBD 
pathogenesis, and is modulated by factors present in the lumen 
derived from microbiota, food or at a molecular level, by factors 
such as proteases. In IBD pathophysiology, the inflammatory 
process is characterized by impaired intestinal biology including 
disruption of tight junctions and leaky gut, decreased amount of 
Paneth and Goblet cells, and translocation of luminal antigens 
triggering inflammation. Previous studies have demonstrated an 
increased level of active serine proteases in the stools and tissues 
of IBD patients, supposing that proteases originate from infiltrated 
immune cells, pancreatic secretion or microbiota. However, our 
team has reported that intestinal epithelial cells are a major source 
of serine proteases, in particular trypsin-like enzymes, are released 
by a stressed epithelium in pathogenic context such as irritable 
bowel syndrome. 
In this project, we aimed at better understanding whether the three 
main pathways involved in IBD (Nod2, autophagy, ER-stress) could 
be linked to an epithelial release of trypsin and reciprocally, if 
epithelial trypsin is able to induce or modulate these three IBD 
pathways.  
We confirmed that trypsin-like activity was significantly higher in 
biopsies from UC and CD patients compared to healthy controls. In 
Caco-2 monolayers cultured in transwells, secreted trypsin-like 
proteolytic activity remained stable upon NOD2 stimulation but 
decreased under autophagy induction. Thapsigargin (Tg) 
stimulation a well-known ER-stress inducer, enhanced the apical 
release of trypsin-like activity in Caco2 cells. Activity-based probe 
assay identified a unique band at 33-KDa in ER-Stress-induced 
Caco-2 supernatants. This band showed specificity for Trypsin-3 in 
western blot. In UC patients, immunochemistry of colonic biopsies 
showed that Trypsin-3 was detectable mainly in epithelial cells, 
and up-regulated compared to biopsies from healthy controls and 
CD. Similarly, only UC patients displayed altered ER-stress with 
increased XBP1s mRNA levels.  In Caco-2 cells, ER-Stress induction 
provoked increased paracellular permeability, CXCL8 release, 
antimicrobial peptides (AMP) (TFF-3 and HBD2), and mucins 
(MUC2) dysregulation. Serine protease inhibitor AEBSF inhibited 
Tg-induced increased permeability and AMP dysregulation, while 
CXCL8 increase was aggravated. In Caco-2, Tg-induced ER-Stress 
increased PAR-2 and -4 mRNA expression, PAR4 control levels 
were restored in the presence of AEBSF. ER-Stress-associated 
increased paracellular permeability was suppressed by PAR2 
and/or -4 antagonist treatment, while CXCL8 was aggravated. 
Trypsin-3 did not induce ER stress in Caco2.  
Our data showed that in intestinal epithelial cells, ER-Stress 
increased trypsin-3 expression and trypsin proteolytic activity, 
which is responsible for altered barrier function and dysregulated 
AMP and mucin expressions. We identified PAR-2 and -4 activation 
as possible mechanisms by which ER-Stress contributed to 
epithelial pathophysiology. Trypsin-3 appears as a candidate 
protease overexpressed upon ER-Stress and in UC patients 
epithelium. 
 
 Interactions entre les voies inflammatogènes impliquées 
dans les maladies inflammatoires chroniques de l’intestin 
et l’activité protéolytiques de la muqueuse intestinale 
 
 
Les maladies inflammatoires chroniques de l’intestin (MICI) se 
caractérisent par une inflammation sévère de l’intestin grêle et du 
côlon et comprennent la maladie de Crohn (MC) et la rectocolite 
hémorragique (RCH). Les MICI sont des maladies complexes faisant 
intervenir des facteurs génétiques : certains senseurs bactériens, 
l’autophagie et le stress du réticulum endoplasmique. Un défaut de 
barrière de l’épithélium digestif est également fortement impliqué 
dans la physiopathologie du processus inflammatoire. La fonction 
barrière de l’épithélium digestif est assurée par plusieurs types 
cellulaires, synthétisant entre autres, des peptides antimicrobiens 
(PAM) et des mucines. Dans les MICI, une augmentation de la 
perméabilité intestinale et une perte de muco-sécrétion ont été 
décrites. Les protéases jouent un rôle fondamental dans la 
digestion du bol alimentaire mais également dans le maintien de 
l’homéostasie intestinale en activant ou dégradant divers motifs 
moléculaires, ou in induisant des signaux spécifiques aux cellules 
par l’activation de quatre récepteurs : les PARs (Protease-Activated 
Receptor). Dans les MICI, un excès d’activité protéolytique de type 
trypsine est observé. L’origine de cette activité est théoriquement 
attribuée aux cellules immunitaires, à une surproduction 
pancréatique ou au microbiote, mais les cellules épithéliales 
intestinales semblent également être une source majeure de 
protéases. L’objectif de mon projet de thèse visait à étudier l’impact 
des principales voies impliquées dans les MICI sur l’homéostasie 
des protéases épithéliales et le rôle de celles-ci dans la 
déstabilisation de la fonction de barrière. 
Nos résultats ont confirmé un excès de protéases à sérine dans les 
cellules épithéliales de patients atteint de MC ou de RCH. In vitro, 
sur des monocouches de cellules Caco-2, l’induction de l’autophagie 
diminuait la libération apicale de protéase de type trypsine, alors 
que le senseur bactériens NOD2 n’avait aucun effet. A l’inverse, une 
stimulation du Stress du réticulum endoplasmique (SRE) par la 
Thapsigargin, induisait une libération accrue de protéases actives 
de type trypsine au pôle apical des cellules. L’utilisation d’ABP 
(Activity-based probe), emprisonnant les protéases actives de type 
trypsine dans des surnageants apicaux de Caco-2 stimulées par la 
Thapsigargin, a montré une importante sécrétion d’une protéase 
unique au poids moléculaire de 33-KDa. Par western blot, la 
présence augmentée de Trypsine-3 était identifiée dans ces 
surnageants, de même que dans les colonocytes de patients atteints 
de RCH comparé à des échantillons contrôles ou CD. Seul les 
colonocytes de patients RCH présentaient également une induction 
du SRE. Sur les monocouches de Caco-2, l'induction du SRE 
augmentait la perméabilité paracellulaire, la sécrétion de CXCL88 
et l’expression de PAM, de mucine et des récepteurs PAR2 et -4. Les 
inhibiteurs de protéases de type trypsine supprimaient 
l’augmentation de la perméabilité et l’expression des PAM, de la 
mucine 2 et des récepteurs PAR2 et -4 induite par le SRE, et 
aggravaient la sécrétion de CXCL8. Les antagonistes sélectifs des 
récepteurs PAR2 et/ou PAR4 inhibaient l’augmentation de la 
perméabilité et l’expression des PAM, de la mucine 2 et des 
récepteurs PAR2 et -4 induite par le SRE, mais aggravaient la 
sécrétion de CXCL8. Enfin, la Trypsine-3 ne modifiait pas les 
marqueurs de SRE.  
En conclusion, l’induction d’un SRE dans les cellules épithéliales 
déclenche une libération apicale de Trypsine-3 et d’activité 
trypsine, responsable de l’altération de la fonction de barrière de la 
monocouche cellulaire. Nous avons identifié l’implication des 
récepteurs PAR2 et -4 (tous deux activables par la Trypsine-3) dans 
la rupture de l’homéostasie de l’épithélium intestinal. La Trypsine-
3 semble être spécifiquement surexprimée dans les colonocytes de 
patients RCH, cette surexpression pourrait être liée à une induction 
anormale du SRE. 
 
